PHARMACEUTICAL COMPOSITIONS

专利摘要:
Pharmaceutical compositions and methods are provided for treating headache, headache-associated symptoms, or side effects associated with administration of triptan.
公开号:FR3025425A1
申请号:FR1558300
申请日:2015-09-08
公开日:2016-03-11
发明作者:Paul Bosse；John Ameling；William Kozarek；Bernard Schachtel
申请人:Charleston Laboratories Inc；
IPC主号:

专利说明:

[0001] 1 PHARMACEUTICAL COMPOSITIONS BACKGROUND The available analgesics are generally provided in individual doses. The therapeutic effect of these drugs can be improved by combining them with other drugs that can relieve pain. In addition, the available painkillers may have side effects, such as nausea and vomiting. Because of these side effects, many patients are not able to tolerate the recommended dosages necessary to effectively relieve pain. Therefore, combination therapies can also meet the needs of effective therapeutic products with reduced side effects.
[0002] SUMMARY In one aspect, a pharmaceutical composition is provided, the pharmaceutical composition comprising a plurality of first particles comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, and a plurality of second particles comprising an antiemetic or a pharmaceutically acceptable salt thereof. of it, characterized in that the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1. In some instances, the weight ratio of the 5H-11B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof ranges from about 1: 2 to about 15: 1. In some instances, the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof ranges from about 3: 2 to about 11: 1. In some instances, the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof is from about 3: 1 to about 7: 1. . In some instances, the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof is from about 9: 2 to about 11: 2. . In some cases, the report. The weight of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof on the antiemetic or a pharmaceutically acceptable salt thereof is about 5: 1. In some cases, the weight ratio of the plurality of first particles to the plurality of second particles is about 4: 1. In some instances, the weight ratio of the 5HT1B receptor agonist or pharmaceutically acceptable salt thereof to the total weight of the plurality of first particles is from about 2: 5 to about 7:10. In some instances, the weight ratio of the antiemetic or a pharmaceutically acceptable salt thereof to the total weight of the plurality of second particles is from about 2: 5 to about 3: 5. In some instances, the plurality of first particles comprises one or more first pharmaceutically acceptable excipients and the weight ratio of the total amount of the 5HTIB receptor agonist or a pharmaceutically acceptable salt thereof to the total amount of the first pharmaceutically acceptable excipients is about 3: 2. In some cases, the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, and the weight ratio of the total amount of the antiemetic or a pharmaceutically acceptable salt thereof to the total amount of the second or second excipients. pharmaceutically acceptable is about 1: 1. In some instances, the 5HT1B receptor agonist is present in an amount of from about 50% to about 70% by weight of the plurality of first particles. In some instances, the 5HT1B receptor agonist is present in an amount of about 61% by weight of the plurality of first particles. In some instances, the antiemetic or a pharmaceutically acceptable salt thereof is present in an amount of from about 40% to about 60% by weight of the plurality of second particles. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof is present in an amount of about 50% by weight of the plurality of second particles. In some instances, about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof is stable for at least 30 days as measured by HPLC. In some instances, about 90% to about 100% of the antiemetic or a pharmaceutically acceptable salt thereof is stable for at least 30 days as measured by HPLC. In some cases, at least about 80% of both the 5HT1r3 receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic are released in less than about 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 apparatus (Basket) rotating at 100 rpm. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof has a slower release rate than the release rate of the 5HT13 receptor agonist or a pharmaceutically acceptable salt thereof. . In some instances, the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof comprises a triptan or a pharmaceutically acceptable salt thereof. In some instances, triptan or a pharmaceutically acceptable salt thereof includes sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan, naratriptan, or mixtures thereof. In some cases, sumatriptan is present in an amount of about 25 mg to about 100 mg. In some cases, sumatriptan is present in an amount of about 90 mg. In some instances, the pharmaceutically acceptable salt of sumatriptan comprises sumatriptan succinate. In some instances, sumatriptan succinate is present in an amount ranging from about 35 mg to about 140 mg. In some cases, sumatriptan succinate is present in an amount of about 126 mg. In some cases, the pharmaceutically acceptable salt of sumatriptan is present in a therapeutically equivalent amount to about 90 mg of sumatriptan. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof includes promethazine, aprepitant, dronabinol, perphenazine, palonosetron, trimethylobenzamide, metoclopromide, domperidone, prochlorperazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetyleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, 20 diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, droperidol, haloperidol, prochloperazine, metoclopromide, diphenhydramine, cannabis, midazolam, lorazepam, hyoscine, dexamethasone, emetrol, propofol or their mixtures. In some cases, promethazine is present in an amount of about 12.5 mg to about 50 mg. In some cases, promethazine is present in an amount of about 22 mg. In some cases, the pharmaceutically acceptable salt of promethazine includes promethazine hydrochloride. In some cases, promethazine hydrochloride is present in an amount of 25 mg. In some instances, the pharmaceutically acceptable salt of promethazine is present in an amount therapeutically equivalent to about 22 mg of promethazine. In some cases, the total weight of the plurality of first particles is from about 175 mg to about 300 mg. In some cases, the plurality of first particles is from about 200 mg to about 220 mg. In some cases, the total weight of the plurality of first particles is from about 208 mg to about 212 mg. In some cases, the total weight of the plurality of second particles is from about 30 mg to about 100 mg. In some cases, the total weight of the plurality of second particles is from about 45 mg to about 55 mg. In some cases, the total weight of the plurality of second particles is about 50 mg or about 51 mg. In some cases, the plurality of first particles comprises one or more first pharmaceutically acceptable excipients, characterized in that the first pharmaceutically acceptable excipient (s) comprises a diluent, a binder, a disintegrant, a lubricant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the binder comprises polyvinylpyrrolidone.
[0003] In some cases, the disintegrant includes croscarmellose sodium. In some cases, the lubricant includes magnesium stearate or talc. In some cases, the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, characterized in that the second or second pharmaceutically acceptable excipients comprise a diluent, a disintegrant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the disintegrating agent includes croscarmellose sodium. In some cases, the plurality of first particles comprises about 50 mg to 150 mg of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 1 mg to 10 mg polyvinylpyrrolidone, about 50 mg to 100 mg microcrystalline cellulose, about 1 mg to 10 mg croscarmellose sodium, about 0.1 mg to 5 mg magnesium stearate and a coating material; and the plurality of second particles comprises about 10 mg to 50 mg of the antiemetic or a pharmaceutically acceptable salt thereof, about 10 mg to 50 mg of microcrystalline cellulose, about 0.1 mg to 5 mg of croscarmellose sodium and a coating material. In some cases, the plurality of first 25 particles comprises about 90 mg of sumatriptan or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof, about 4 mg of polyvinylpyrrolidone, about 69 mg of microcrystalline cellulose, about 4 mg of croscarmellose sodium, about 1 mg of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 22 mg of promethazine or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof, about 24 mg of microcrystalline cellulose, about 1 mg of croscarmellose sodium; and a coating material, characterized in that the coating material comprises a polyvinyl alcohol. In some instances, the plurality of first particles comprises from about 40% to about 80% by weight of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 0.5% to about 5%. % by weight of polyvinylpyrrolidone, about 20% to about 60% by weight of microcrystalline cellulose, about 0.5% to about 5% by weight of croscarmellose sodium, about 0.1% to about 5% by weight of magnesium stearate and a coating material; and the plurality of second particles comprises from about 30% to about 70% by weight of the antiemetic or a pharmaceutically acceptable salt thereof, about 20% to about 70% by weight of microcrystalline cellulose, about 0.5% about 5% by weight of croscarmellose sodium and a coating material. In some cases, the plurality of first particles comprises about 60.5% by weight of sumatriptan succinate, about 2% by weight of polyvinylpyrrolidone, about 35% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium, about 0.5% by weight of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 50% by weight of promethazine hydrochloride, about 48% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium and a coating material, characterized in that the material of coating comprises a polyvinyl alcohol. In some cases, the first particles comprise a coating material. In some cases, the coating material is applied to the plurality of first particles at a weight gain of about 2%. In some cases, the second particles comprise a coating material. In some cases, the coating material is applied to the plurality of second particles at a weight gain of about 2%. In some cases, the first particles and the second particles comprise the same coating material. In some cases, the coating material comprises a polyvinyl alcohol, a cellulose acetate phthalate, a polyvinyl acetate phthalate, a methacrylic acid copolymer, a cellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate succinate, shellac, sodium alginate, zein, or mixtures thereof. In some cases, the coating material comprises a polyvinyl alcohol. In some cases, the coating material is a polyvinyl alcohol. In some cases, the pharmaceutical composition is characterized in that the diameter of each of the first particles is from about 595 microns to about 1190 microns. In some cases, the pharmaceutical composition is characterized in that the diameter of each of the second particles ranges from about 595 micrometers to about 1190 micrometers. In some instances, the pharmaceutical composition is characterized in that the diameter of each of the first particles is from about 595 microns to about 1190 microns, and the diameter of each of the second particles ranges from about 595 microns to about 1190 microns. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 90 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 100 mg. In some cases, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 90 mg. In some cases, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 100 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the antiemetic comprises promethazine hydrochloride and the promethazine hydrochloride is present in an amount of about 25 mg. In some cases, the pharmaceutical composition is in an oral dosage form. In some cases, the oral dosage form comprises a capsule. In some cases, the pharmaceutical composition is housed in a container. In some cases, the container is a bottle or a package for pills. In some aspects, the pharmaceutical composition described herein is for use in treating a headache of a patient in need thereof. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of migraine. In some cases, the pharmaceutical composition is for use in the treatment of acute migraine. In some cases, the pharmaceutical composition is for use in the treatment of chronic migraine. In some cases, the pharmaceutical composition 30254257 is for use in the treatment of migraine with or without aura. In some cases, the pharmaceutical composition is for use in the treatment of a cluster headache. In some cases, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some cases, the pharmaceutical composition is for use in the treatment of nausea associated with headache or vomiting associated with headache. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In some aspects, the pharmaceutical composition described herein is intended to be used in the treatment of photophobia of a patient in need thereof. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of light sensitivity. In some cases, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some cases, the pharmaceutical composition is for use in the treatment of nausea associated with headache or vomiting associated with headache. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In one aspect, a pharmaceutical composition is provided, the pharmaceutical composition comprising a plurality of first particles comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, and a plurality of second particles comprising an antiemetic or a pharmaceutically acceptable salt of it, characterized in that at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic are released in less than about 15 minutes as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Cart) apparatus rotating at 100 rpm. In some cases, at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic or a pharmaceutically acceptable salt thereof are released in less than of about 30 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 3025425 rpm. In some instances, the antiemetic or a pharmaceutically acceptable salt thereof has about the same release rate as that of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof has about the same release rate as that of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof in less than 10% of the approximately 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 apparatus (Basket) rotating at 100 rpm. In some instances, the antiemetic or a pharmaceutically acceptable salt thereof has a slower release rate than the release rate of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof has a slower release rate than the release rate of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof in less than about 5 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm. In some instances, from about 60% to about 65% of the antiemetic or a pharmaceutically acceptable salt thereof are released in less than about 5 minutes and about 70% to about 75% of the 5H1 receptor agonist. 1B or a pharmaceutically acceptable salt thereof are released in less than about 5 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Cart) apparatus rotating at 100 rpm /minutes. In some cases, the pharmaceutical composition is a rapid release pharmaceutical composition. In some cases, the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1. In some instances, the weight ratio of the 5H1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof ranges from about 1: 2 to about 15. 1. In some instances, about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof is stable for at least 30 days as measured by HPLC. In some instances, about 90% to about 100% of the antiemetic or a pharmaceutically acceptable salt thereof is stable for at least 30 days as measured by HPLC. In some instances, the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof comprises a triptan or a pharmaceutically acceptable salt thereof. In some instances, triptan or a pharmaceutically acceptable salt thereof includes sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan, naratriptan, or mixtures thereof. In some cases, sumatriptan is present in an amount of about 25 mg to about 100 mg. In some cases, sumatriptan is present in an amount of about 90 mg.
[0004] In some cases, the pharmaceutically acceptable salt of sumatriptan comprises sumatriptan succinate. In some instances, sumatriptan succinate is present in an amount of from about 35 mg to about 140 mg. In some cases, sumatriptan succinate is present in an amount of about 126 mg. In some instances, the pharmaceutically acceptable salt of sumatriptan is present in a therapeutically equivalent amount to about 90 mg of sumatriptan. In some cases, the antiemetic or a pharmaceutically acceptable salt thereof includes promethazine, aprepitant, dronabinol, perphenazine, palonosetron, trimethylobenzamide, metoclopromide, domperidone, prochlorperazine, chlorpromazine, trimethobenzamide ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol , dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, droperidol, haloperidol, prochloperazine, metoclopramide, diphenhydramine, cannabis, midazolam, lorazepam, hyoscine, dexamethasone, emetrol, propofol or their mixtures. In some cases, promethazine is present in an amount of about 12.5 mg to about 50 mg. In some cases, promethazine is present in an amount of about 22 mg. In some instances, the pharmaceutically acceptable salt of promethazine includes promethazine hydrochloride. In some cases, promethazine hydrochloride is present in an amount of 25 mg. In some instances, the pharmaceutically acceptable salt of promethazine is present in an amount therapeutically equivalent to about 22 mg of promethazine. In some cases, the total weight of the plurality of first particles is from about 175 mg to about 300 mg. In some cases, the total weight of the plurality of first particles is from about 200 mg to about 220 mg. In some cases, the total weight of the plurality of first particles is from about 208 mg to about 212 mg. In some cases, the total weight of the plurality of second particles is from about 30 mg to about 100 mg. In some cases, the total weight of the plurality of second particles is from about 45 mg to about 55 mg. In some cases, the total weight of the plurality of second particles is about 50 mg or about 51 mg. In some instances, the plurality of first particles comprise one or more first pharmaceutically acceptable excipients, characterized in that the first pharmaceutically acceptable excipient (s) comprises a diluent, a binder, a disintegrant, a lubricant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the binder comprises polyvinylpyrrolidone. In some cases, the disintegrating agent includes croscarmellose sodium. In some cases, the lubricant includes magnesium stearate or talc. In some cases, the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, characterized in that the second or second pharmaceutically acceptable excipients comprise a diluent, a disintegrant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the disintegrating agent includes croscarmellose sodium. In some instances, the plurality of first particles comprises about 50 mg to 150 mg of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 1 mg to 10 mg polyvinylpyrrolidone, about 50 mg to 100 mg. mg microcrystalline cellulose, about 1 mg to 10 mg croscarmellose sodium, about 0.1 mg to 5 mg magnesium stearate and a coating material; and the plurality of second particles comprises about 10 mg to 50 mg of antiemetic or a pharmaceutically acceptable salt thereof, about 10 mg to 50 mg of microcrystalline cellulose, about 0.1 mg to 5 mg of croscarmellose sodium and a coating material. In some cases, the plurality of first particles comprises about 90 mg of sumatriptan or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof, about 4 mg of polyvinylpyrrolidone, about 69 mg of microcrystalline cellulose, about 4 mg of croscarmellose sodium, about 1 mg of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 22 mg of promethazine or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof, about 24 mg of microcrystalline cellulose, about 1 mg of croscarmellose sodium; and a coating material, characterized in that the coating material comprises a polyvinyl alcohol. In some instances, the plurality of first particles comprises from about 40% to about 80% by weight of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 0.5% to about 5% by weight of polyvinylpyrrolidone, about 20% to about 60% by weight of microcrystalline cellulose, about 0.5% to about 5% by weight of croscarmellose sodium, about 0.1% to about 5% by weight of magnesium stearate and a material coating; and the plurality of second particles comprises from about 30% to about 70% by weight of the antiemetic or a pharmaceutically acceptable salt thereof, about 20% to about 70% by weight of microcrystalline cellulose, about 0.5% by weight. % to about 5% by weight of croscarmellose sodium and a coating material. In some cases, the plurality of first particles comprises about 60.5% by weight of sumatriptan succinate, about 2% by weight of polyvinylpyrrolidone, about 35% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium, about 10% by weight. 0.5% by weight of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 50% by weight of promethazine hydrochloride, about 48% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium and a coating material, characterized in that the material of coating comprises a polyvinyl alcohol. In some cases, the first particles comprise a coating material. In some cases, the coating material is applied to the plurality of first particles at a weight gain of about 2%. In some cases, the second particles comprise a coating material. In some cases, the coating material is applied to the plurality of second particles at a weight gain of about 2%. In some cases, the first particles and the second particles comprise the same coating material. In some cases, the coating material comprises a polyvinyl alcohol, a cellulose acetate phthalate, a polyvinyl acetate phthalate, a methacrylic acid copolymer, a cellulose acetate trimellitate. hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate succinate, shellac, sodium alginate, zein, or mixtures thereof. In some cases, the coating material comprises a polyvinyl alcohol. In some cases, the coating material is a polyvinyl alcohol. In some instances, the pharmaceutical composition is characterized in that the diameter of each of the first particles is from about 595 microns to about 1190 microns. In some cases, the pharmaceutical composition is characterized in that the diameter of each of the second particles is from about 595 micrometers to about 1190 micrometers. In some instances, the pharmaceutical composition is characterized in that the diameter of each of the first particles is from about 595 microns to about 12 microns, and the diameter of each of the second particles ranges from about 595 microns to about 1190 microns. . In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 90 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 100 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 90 mg. In some cases, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 100 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the antiemetic comprises promethazine hydrochloride and the promethazine hydrochloride is present in an amount of about 25 mg. In some cases, the pharmaceutical composition is in an oral dosage form. In some cases, the oral dosage form comprises a capsule. In some cases, the pharmaceutical composition is housed in a container. In some cases, the container is a bottle or a package for pills. In some aspects, the pharmaceutical composition described herein is for use in treating a headache of a patient in need thereof. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of migraine. In some instances, the pharmaceutical composition is for use in the treatment of acute migraine. In some cases, the pharmaceutical composition is for use in the treatment of chronic migraine. In some cases, the pharmaceutical composition is for use in the treatment of migraine with or without aura. In some cases, the pharmaceutical composition is for use in the treatment of a cluster headache. In some instances, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some cases, the pharmaceutical composition is for use in the treatment of nausea associated with headache or vomiting associated with headache. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In some aspects, the pharmaceutical composition described herein is for use in treating photophobia of a patient in need thereof. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of light sensitivity. In some cases, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some instances, the pharmaceutical composition is for use in the treatment of nausea associated with headache or headache associated vomiting. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In one aspect, a long-term form of a pharmaceutical composition is provided, the pharmaceutical composition comprising a plurality of first particles comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, characterized in that about 90 % to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof are stable for at least 30 days, as measured by HPLC, and a plurality of second particles comprising an antiemetic or a salt pharmaceutically acceptable salt thereof, characterized in that about 90% to about 100% of the antiemetic or a pharmaceutically acceptable salt thereof is stable for at least 30 days as measured by HPLC. In some instances, about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof is stable for at least 90 days. In some instances, about 95% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof is stable for at least 30 days. In some instances, from about 90% to about 100% of the antiemetic or pharmaceutically acceptable salt thereof are stable for at least 90 days. In some instances, about 100% of the antiemetic or pharmaceutically acceptable salt thereof is stable for at least 30 days. In some instances, the 5H'I'1B receptor agonist or a pharmaceutically acceptable salt thereof comprises a triptan or a pharmaceutically acceptable salt thereof. In some instances, triptan or a pharmaceutically acceptable salt thereof includes sumatriptan almotriptan, frovatriptan, eletriptan, rizatriptan, naratriptan, or mixtures thereof. In some cases, sumatriptan is present in an amount of about 25 mg to about 100 mg. In some cases, sumatriptan is present in an amount of about 90 mg. In some instances, the pharmaceutically acceptable salt of sumatriptan comprises sumatriptan succinate. In some cases, sumatriptan succinate is present in an amount of from about 35 mg to about 140 mg. In some cases, sumatriptan succinate is present in an amount of about 126 mg. In some cases, the pharmaceutically acceptable salt of sumatriptan is present in a therapeutically equivalent amount to about 90 mg of sumatriptan. In some instances, the antiemetic or a pharmaceutically acceptable salt thereof includes promethazine, aprepitant, dronabinol, perphenazine, palonosetron, trimethylobenzamide, metoclopromide, domperidone, prochlorperazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetyleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, 20 diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, droperidol, haloperidol, prochloperazine, metoclopramide, diphenhydramine, cannabis, midazolam, lorazepam, hyoscine, dexamethasone, emetrol, propofol or their mixtures. In some cases, promethazine is present in an amount of about 12.5 mg to about 50 mg. In some cases, promethazine is present in an amount of about 22 mg. In some cases, the pharmaceutically acceptable salt of promethazine includes promethazine hydrochloride. In some cases, promethazine hydrochloride is present in an amount of 25 mg. In some instances, the pharmaceutically acceptable salt of promethazine is present in an amount therapeutically equivalent to about 22 mg of promethazine. In some cases, a total weight of the plurality of first particles is from about 175 mg to about 300 mg. In some cases, the total weight of the plurality of first particles is from about 200 mg to about 220 mg. In some cases, the total weight of the plurality of first particles is from about 208 mg to about 212 mg. In some cases, the total weight of the plurality of second particles is from about 30 mg to about 100 mg. In some cases, the total weight of the plurality of second particles is from about 45 mg to about 55 mg. In some cases, the total weight of the plurality of second particles is about 50 mg or about 51 mg. In some cases, the plurality of first particles comprises one or more first pharmaceutically acceptable excipients, characterized in that the first pharmaceutically acceptable excipient (s) comprises a diluent, a binder, a disintegrant, a lubricant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the binder comprises polyvinylpyrrolidone.
[0005] In some cases, the disintegrant includes croscarmellose sodium. In some cases, the lubricant includes magnesium stearate or talc. In some cases, the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, characterized in that the second or second pharmaceutically acceptable excipients comprise a diluent, a disintegrant, or mixtures thereof. In some cases, the diluent includes microcrystalline cellulose. In some cases, the disintegrating agent includes croscarmellose sodium. In some cases, the plurality of first particles comprises about 50 mg to 150 mg of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 1 mg to 10 mg polyvinylpyrrolidone, about 50 mg to 100 mg microcrystalline cellulose, about 1 mg to 10 mg croscarmellose sodium, about 0.1 mg to 5 mg magnesium stearate and a coating material; and the plurality of second particles comprises about 10 mg to 50 mg of an antiemetic or a pharmaceutically acceptable salt thereof, about 10 mg to 50 mg of microcrystalline cellulose, about 0.1 mg to 5 mg of croscarmellose sodium and a coating material. In some cases, the plurality of first 25 particles comprises about 90 mg of sumatriptan or a therapeutically equivalent amount of pharmaceutically acceptable salt thereof, about 4 mg of polyvinylpyrrolidone, about 69 mg of microcrystalline cellulose, about 4 mg of croscarmellose sodium, about 1 mg of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 22 mg of promethazine or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof, about 24 mg of microcrystalline cellulose, about 1 mg of croscarmellose sodium; and a coating material, characterized in that the coating material comprises a polyvinyl alcohol. In some instances, the plurality of first 25 particles comprises from about 40% to about 80% by weight of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof, about 0.5% to about 5%. % by weight of polyvinylpyrrolidone, about 20% to about 60% by weight of microcrystalline cellulose, about 0.5% to about 5% by weight of croscarmellose sodium, about 0.1% to about 5% by weight of magnesium stearate and a coating material; and the plurality of second particles comprises from about 30% to about 70% by weight of the antiemetic or a pharmaceutically acceptable salt thereof, about 20% to about 70% by weight of microcrystalline cellulose, about 0.5% about 5% by weight of croscarmellose sodium and a coating material. In some cases, the plurality of first particles comprises about 60.5% by weight of sumatriptan succinate, about 2% by weight of polyvinylpyrrolidone, about 35% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium, about 0.5% by weight of magnesium stearate and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises about 50% by weight of promethazine hydrochloride, about 48% by weight of microcrystalline cellulose, about 2% by weight of croscarmellose sodium and a coating material, characterized in that the material of coating comprises a polyvinyl alcohol. In some cases, the first particles comprise a coating material. In some cases, the coating material is applied to the plurality of first particles at a weight gain of about 2%. In some cases, the second particles comprise a coating material. In some cases, the coating material is applied to the plurality of second particles at a weight gain of about 2%. In some cases, the first particles and the second particles comprise the same coating material. In some cases, the coating material comprises a polyvinyl alcohol, a cellulose acetate phthalate, a polyvinyl acetate phthalate, a methacrylic acid copolymer, a cellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, shellac, sodium alginate, zein, or mixtures thereof. In some cases, the coating material comprises a polyvinyl alcohol. In some cases, the coating material is a polyvinyl alcohol. In some cases, the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1. In some instances, the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof ranges from about 1: 2 to about 15. 1. In some cases, at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic are released in less than about 15 minutes, as measured by contact of the pharmaceutical composition with a dissolution fluid in a USP 1 apparatus (Basket) rotating at 100 rpm. In some instances, the antiemetic or a pharmaceutically acceptable salt thereof has a slower release rate than the release rate of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof. In some instances, the pharmaceutical composition is characterized in that the diameter of each of the first 10 particles is from about 595 microns to about 1190 microns. In some cases, the pharmaceutical composition is characterized in that the diameter of each of the second particles is from about 595 micrometers to about 1190 micrometers. In some instances, the pharmaceutical composition is characterized in that the diameter of each of the first particles is from about 595 microns to about 1190 microns, and the diameter of each of the second particles ranges from about 595 microns to about 1190 microns. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 90 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises triptan succinate and the triptan base is present in an amount of about 100 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 90 mg. In some cases, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the 5HT1B receptor agonist comprises sumatriptan succinate and the sumatriptan base is present in an amount of about 100 mg. In some instances, the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of the antiemetic comprises promethazine hydrochloride and the promethazine hydrochloride is present in an amount of about 25 mg. In some cases, the pharmaceutical composition is in an oral dosage form. In some cases, the oral dosage form comprises a capsule. In some aspects, the pharmaceutical composition described herein is for use in treating a headache of a patient in need thereof. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in treating a headache, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of migraine. In some cases, the pharmaceutical composition is for use in the treatment of acute migraine. In some cases, the pharmaceutical composition is for use in the treatment of chronic migraine. In some instances, the pharmaceutical composition is for use in the treatment of migraine with or without aura. In some cases, the pharmaceutical composition is for use in the treatment of a cluster headache. In some cases, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some instances, the pharmaceutical composition is for use in the treatment of headache-associated nausea or headache-associated vomiting. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In some aspects, the pharmaceutical composition described herein is for use in treating photophobia of a patient in need thereof. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is acute. In some cases, the pharmaceutical composition is for use in the treatment of photophobia, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition is for use in the treatment of light sensitivity. In some cases, the pharmaceutical composition is for use in the treatment of nausea or vomiting. In some cases, the pharmaceutical composition is for use in the treatment of nausea associated with headache or vomiting associated with headache. In some instances, the pharmaceutical composition is for use in the treatment of headache and headache associated vomiting. In some cases, the pharmaceutical composition is housed in a container. In some cases, the container is a bottle or a package for pills. In some embodiments, the pharmaceutical composition defined herein is administered to a subject from about every 12 hours to about every 24 hours, about every 12 hours, or about every 24 hours. In some embodiments, the pharmaceutical composition defined herein is administered to a subject from about every 8 hours to about every 12 hours. In some embodiments, the pharmaceutical composition defined herein is administered once, twice, or three times daily. In some embodiments, the pharmaceutical composition defined herein is administered no more than twice a day. In some embodiments, a second dose of the pharmaceutical composition defined herein is administered only if some response to the first dose has been observed. In some embodiments, doses after a first dose of the pharmaceutical composition defined herein are spaced at least 2 hours apart. In certain embodiments, the maximum dose of the pharmaceutical composition defined herein over a period of 24 hours does not exceed 200 mg. In some embodiments, a maximum single dose of the pharmaceutical composition defined herein does not exceed 50 mg in patients with mild to moderate hepatic impairment. In some embodiments, the pharmaceutical composition herein defined comprising sumatriptan succinate and promethazine hydrochloride is administered to a subject from about every 12 hours to about every 24 hours, about every 12 hours, or about every 24 hours. In some embodiments, the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered to a subject from about every 8 hours to about every 12 hours. In certain embodiments, the pharmaceutical composition herein defined comprising sumatriptan succinate and promethazine hydrochloride is administered once, twice, or three times daily. In some embodiments, the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered no more than twice daily. In some embodiments, a second dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered only if some response to the first dose has been observed. In some embodiments, doses after a first dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride are spaced at least 2 hours apart. In some embodiments, the maximum dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride over a period of 24 hours does not exceed 200 mg. In certain embodiments, a maximum single dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride does not exceed 50 mg in patients with mild to moderate hepatic impairment. In some embodiments, the frequency of the assay is determined or evaluated by a professional assessing the subject, the severity of the condition to be treated, and the expected duration of the treatment. In some aspects, a capsule is provided, the capsule comprising a capsule layer; a plurality of first particles, wherein each of the first particles comprises a first active pharmaceutical ingredient, the plurality of first particles is surrounded by the capsule layer, and each of the first particles is in the form of a ball, a spherule or pellet; and a plurality of second particles, wherein each of the second particles comprises a second active pharmaceutical ingredient, the plurality of second particles is surrounded by the capsule layer, and each of the second particles is in the form of a ball, a spherule, or pellet, and the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1. In some cases, the weight ratio of the first active pharmaceutical ingredient to the second active pharmaceutical ingredient ranges from about 1: 2 to about 15: 1. In some cases, the weight ratio of the first active pharmaceutical ingredient to the second active pharmaceutical ingredient is about 5: 1, respectively. In some cases, the weight ratio of the plurality of first particles to the plurality of second particles is about 4: 1. In some cases, the weight ratio of the first active pharmaceutical ingredient to the total weight of the plurality of first particles is from about 2: 5 to about 7:10. In some cases, the weight ratio of the second active pharmaceutical ingredient to the total weight of the plurality of second particles is from about 2: 5 to about 3: 5. In some instances, the plurality of first particles comprise one or more first pharmaceutically acceptable excipients, and the weight ratio of the total amount of the first active pharmaceutical ingredient to the total amount of the first pharmaceutically acceptable excipient (s) is about 3: 2. In some instances, the first pharmaceutically acceptable excipient (s) comprises a diluent, a binder, a disintegrant, a lubricant, or mixtures thereof. In some cases, the diluent is present in an amount of about 35% by weight of the plurality of first particles. In some instances, the binder is present in an amount of from about 0.5% to about 5% by weight of the plurality of first particles. In some cases, the disintegrant is present in an amount of about 2% by weight of the plurality of first particles. In some cases, the lubricant is present in an amount of about 0.5% by weight of the plurality of first particles. In some cases, the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, and the weight ratio of the total amount of the second active pharmaceutical ingredient to the total amount of the second or more pharmaceutically acceptable excipients is about 1: 1 . In some cases, the second or pharmaceutically acceptable excipients comprise a diluent, a disintegrant, or mixtures thereof. In some instances, the diluent is present in an amount of from about 20% to about 90% by weight of the plurality of second particles. In some cases, the disintegrant is present in an amount of from about 0.5% to about 2% by weight of the plurality of second particles. In some cases, the diameter of each of the first particles ranges from about 595 microns to about 1190 microns. In some cases, the diameter of each of the first particles ranges from about 595 microns to about 707 microns, from about 707 microns to about 841 microns, from about 841 microns to about 1000 microns, or from about 1000 microns to about about 1190 micrometers. In some cases, the diameter of each of the second particles ranges from about 595 microns to about 1190 microns. In some cases, the diameter of each of the second particles ranges from about 595 microns to about 707 microns, from about 707 microns to about 841 microns, from about 841 microns to about 1000 microns, or from about 1000 microns to about 1190 micrometers. In some cases, each of the first and second particles has a diameter of about 595 microns to about 1190 microns. In some cases, the total weight of the plurality of first particles is from about 175 mg to about 300 mg. In some cases, the total weight of the plurality of first particles is from about 208 mg to about 212 mg. In some cases, the total weight of the plurality of second particles is from about 30 mg to about 100 mg. In some cases, the total weight of the plurality of second particles is from about 45 mg to about 55 mg. In some instances, the first active pharmaceutical ingredient is present in an amount of from about 25 mg to about 150 mg. In some cases, the first active pharmaceutical ingredient is present in an amount of about 90 mg or about 126 mg. In some instances, the total amount of the first active pharmaceutical ingredient is from about 50% to about 70% by weight of the plurality of first particles. In some cases, the total amount of the first active pharmaceutical ingredient is about 61% by weight of the plurality of first particles. In some instances, the first active pharmaceutical ingredient comprises sumatriptan or a pharmaceutically acceptable salt thereof. In some instances, the pharmaceutically acceptable salt of sumatriptan comprises sumatriptan succinate. In some cases, the pharmaceutically acceptable salt of sumatriptan is sumatriptan succinate. In some cases, the total amount of the pharmaceutically acceptable salt of sumatriptan is therapeutically equivalent to about 90 mg of sumatriptan. In some instances, the second active pharmaceutical ingredient is present in an amount of from about 40% to about 60% by weight of the plurality of second particles. In some instances, the second active pharmaceutical ingredient is present in an amount of about 50% by weight of the plurality of second particles. In some cases, the second active pharmaceutical ingredient is present in an amount of from about 12.5 mg to about 50 mg. In some cases, the second active pharmaceutical ingredient is present in an amount of about 22 mg or about 25 mg. In some instances, the second active pharmaceutical ingredient comprises promethazine or a pharmaceutically acceptable salt thereof. In some cases, the pharmaceutically acceptable salt of promethazine includes promethazine hydrochloride. In some cases, the pharmaceutically acceptable salt of promethazine is promethazine hydrochloride. In some cases, the total amount of the pharmaceutically acceptable salt of promethazine is therapeutically equivalent to about 22 mg of promethazine. In some cases, the capsule has a net weight of about 90 mg to about 102 mg. In some cases, the capsule has a net weight of about 96 mg. In some cases, the capsule has a volume of about 0.6 ml to about 0.8 ml. In some cases, the capsule has a volume of about 0.7 ml. In some cases, the body of the capsule is about 17 mm to about 20 mm long. In some cases, the body of the capsule is about 18 mm long. In some cases, the cap of the capsule is about 10 mm to 12 mm long. In some cases, the cap of the capsule is about 11 mm long. In some cases, the body of the capsule has an outer diameter of about 6 mm to about 8 mm. In some cases, the body of the capsule has an outer diameter of about 7 mm. In some cases, the cap of the capsule has an outer diameter of about 7 mm to about 9 mm. In some cases, the cap of the capsule has an outer diameter of about 8 mm. In some cases, the total closed length of the capsule is from about 20 mm to 24 mm. In some cases, the total closed length of the capsule is about 22 mm. In some cases, the capsule has a capacity of about 400 mg to 800 mg and a powder density of about 0.6 to about 1.2 g / ml. In some cases, each of the first and second particles has the same shape. In some cases, the first particles comprise a coating material. In some cases, the coating material is applied to the plurality of first particles at a weight gain of about 2%. In some cases, the 10 second particles comprise a coating material. In some cases, the coating material is applied to the plurality of second particles at a weight gain of about 2%. In some cases, the first particles and the second particles comprise the same coating material. In some cases, the coating material comprises a polyvinyl alcohol, a cellulose acetate phthalate, a polyvinyl acetate phthalate, a methacrylic acid copolymer, a cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, shellac, sodium alginate, zein, or mixtures thereof. In some cases, the coating material comprises a polyvinyl alcohol. In some cases, the coating material is a polyvinyl alcohol. In some cases, the capsule is housed in a container. In some cases, the container is a bottle or a package for pills. BRIEF DESCRIPTION OF THE FIGURES FIG. 1 depicts an HPLC chromatograph of a dissolution fluid described herein. Figures 2A and 2B show HPLC chromatographs of standards for sumatriptan and promethazine, presented in full view (Figure 2A) and in enlarged view (Figure 2B). FIGS. 3A and 3B show HPLC chromatographs of a test sample, showing dissolution measurements presented in complete view (FIG. 3A) and in enlarged view (FIG. 3B). Figure 4 is a line graph showing dissolution rates for sumatriptan and promethazine in Formulation I, after contact with a dissolution fluid.
[0006] Figure 5 is a line graph showing the dissolution rates for sumatriptan and promethazine in Formulation II, after contact with a dissolution fluid. Figure 6 illustrates an example of capsule, unfilled (left, side view 5 and bottom) or filled (right) with particles. Figure 7 illustrates another example of capsule, unfilled (left, top view, side view and bottom view) or filled (right) with particles. DETAILED DESCRIPTION The present disclosure generally relates to compositions comprising multiple pharmaceutically active agents for relieving, reducing or eliminating one or more conditions of a patient in need thereof, as described in detail below in the present document. The term "therapeutically effective amount", when used in connection with the pharmaceutical composition described herein, refers to an amount of one or more pharmaceutically active agents, sufficient to produce a therapeutic result in a patient. in need. For example, a therapeutic result includes, but is not limited to, treatment of pain, migraine, nausea, vomiting, photophobia, phonophobia, or osmophobia by a subject. The term "therapeutically equivalent", when used in connection with the pharmaceutical composition described herein, refers to an amount of a pharmaceutically acceptable salt of a pharmaceutically active agent that is equivalent to the therapeutically effective amount of The free base of the pharmaceutically active agent. In some embodiments, the therapeutic results produced herein include the reduction or elimination of one or more side effects associated with one or more pharmaceutically active agents described herein. In some embodiments, the reduced or eliminated side effects include, but are not limited to, nausea or vomiting. Except where specifically indicated or evident from context, as used in this document, the term "approximately", in reference to a number or a range of numbers, means the number indicated and the numbers +/- 10% thereof, or 3025425 the 10% number below the listed lower limit and the number 10% above the upper limit listed for the values listed in a range. In some aspects, the pharmaceutical composition described herein comprises a therapeutically effective amount of a first pharmaceutically active agent; a second pharmaceutically active agent capable of reducing or eliminating side effects associated with the first pharmaceutically active agent; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of a triptan; an antiemetic; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof; promethazine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of a triptan; an antiemetic; a polymer; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of a triptan; an antiemetic; a vinyl polymer; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof; promethazine or a pharmaceutically acceptable salt thereof; polyvinylpyrrolidone; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically effective amount of a triptan; an antiemetic; a vinyl copolymer; and a pharmaceutically acceptable carrier or vehicle. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of a first pharmaceutically active agent and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of a second pharmaceutically active agent and one or more second pharmaceutically acceptable excipients; the first pharmaceutically acceptable excipient or excipients comprising a polymer. The pharmaceutically active agents described herein are capable of use in the pharmaceutical composition as described herein. In some embodiments, the pharmaceutically active agent is a triptan, an antiemetic or a pharmaceutically acceptable salt thereof. Triptans In some embodiments, the pharmaceutical composition described herein comprises one or more 5HT1B receptor agonists. Examples of 5HT1B receptor agonists include, but are not limited to, ergotamine and triptan family compounds. Examples of triptans include, but are not limited to, sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan, naratriptan, and their pharmaceutically acceptable salts. In some embodiments, the pharmaceutical composition described herein comprises a triptan or triptan analog. Triptan analogs generally form a family of tryptamine-based drugs used for the treatment of migraines and headaches. Their action is attributed to their binding to serotonin receptors in nerve endings and cranial blood vessels (causing constriction) and subsequent inhibition of pro-inflammatory neuropeptide release. In some embodiments, the triptan used in the pharmaceutical composition described herein is in its free base form or in the form of a pharmaceutically acceptable salt thereof, for example in the form of a succinate. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some embodiments, triptan is a triptan or a pharmaceutically acceptable salt thereof shown in Table 16. In some embodiments, the pharmaceutical composition described herein includes one or more of the pharmaceutically active agents indicated in Table 16, or a pharmaceutically acceptable salt thereof.
[0007] Antiemetic In some embodiments, the pharmaceutical compositions described herein include one or more antiemetics. Examples of antiemetics include aprepitant, dronabinol, perphenazine, palonosetron, trimethylbenzamide, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, lebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal , metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, droperidol, haloperidol, prochloperazine, metoclopramide, diphenhydramine, cannabis , midazolam, lorazepam, hyoscine, dexamethasone, emetrol, propofol and their pharmaceutically acceptable salts. Antiemetics also include H1 agonists, H1 antagonists, H2 agonists, 112 antagonists, H3 agonists, H3 antagonists, H4 agonists, and H4 antagonists. Examples of such agonists and antagonists include, but are not limited to, 2- (mfluorophenyl) histamine, azelastine, buclizine, carbinoxamine, cetrizine, clemastine, cyproheptadine, desloratidine, dimenhydrinate. , diphenhydramine, emedastine, fexofenadine, hydroxyzine, cetotifen, levocabastine, olopatadine, phenindamine, promethazine, chlorpheniramine, scopolamine, mepyramine, terfenadine, astemizole, triprolidine, dimethylamine, impromidine, amthamine, cimetidine, ranitidine, nizatidine, famotidine, R-alpha-methylhistamine, imetit, immepip, thioperamide, iodophenpropit, clobenpropit, clozapine and a pharmaceutically acceptable salt thereof. In some embodiments, the second pharmaceutically active agent is an antiemetic. In some embodiments, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic is an antiemetic or a pharmaceutically acceptable salt thereof shown in Table 16. In some embodiments, the pharmaceutical composition described herein includes one or more pharmaceutically active agents. shown in Table 16, or a pharmaceutically acceptable salt thereof.
[0008] Pharmaceutically acceptable salts In certain embodiments, the pharmaceutically active agent (s) used in the composition described herein is (are) in the form of a free base, a pharmaceutically acceptable salt or a pharmaceutically acceptable salt. , a prodrug, an analogue or a complex. In some cases, the pharmaceutically active agent 3025425 28 comprises the form of a pharmaceutically acceptable salt. In various embodiments, with respect to a pharmaceutically active agent in a composition, pharmaceutically acceptable salts include, but are not limited to, metal salts, such as sodium salts, potassium salts, and salts thereof. lithium; alkaline earth metal salts, such as calcium salts, magnesium salts and the like; organic amine salts, such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N, N'-dibenzylethylenediamine salts and equivalents; inorganic acid salts, such as hydrochloride salts, hydrobromide salts, sulfate salts, phosphate salts and the like; salts of organic acids, such as formate salts, acetate salts, trifluoroacetate salts, maleate salts, tartrate salts and the like; sulfonate salts, such as methanesulfonate salts, benzenesulfonate salts, p-toluenesulfonate salts and the like; and amino acid salts, such as arginate salts, asparginate salts, glutamate salts and the like. In some embodiments, the pharmaceutically acceptable salts include a bitartrate, a hydrated bitartrate, a hydrochloride, a p-toluenesulfonate, a phosphate, a sulfate, a trifluoroacetate, a bitartrate hemipentahydrate, a pentafluoropropionate, a hydrobromide, a mucate, oleate, dibasic phosphate, monobasic phosphate, acetate trihydrate, bis (heptafluorobutyrate), bis (pentafluoropropionate), bis (pyridine carboxylate), bis (trifluoroacetate), hydrochloride and pentahydrate sulfate. In some embodiments, the pharmaceutically active agent is promethazine, a pharmaceutically acceptable salt or its thiosemicarbazone, p-nitrophenyl hydrazone, o-methyloxime, semicarbazone or bis (methylcarbamate). Other representative pharmaceutically acceptable salts include, for example, water-soluble and water-insoluble salts, such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzesulphonate, benzonate , bicarbonate, bisulfate, bitartrate, borate, butyrate, calcium edetate, camphorsulfonate, camsylate, carbonate, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-salts, methylglucamine ammonium, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, e-carbonate), pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succincte, sulfate, sulfosaliculate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. A hydrate is another example of a pharmaceutically acceptable salt. In some embodiments, the second pharmaceutically active agent is capable of reducing or eliminating a side effect of the first pharmaceutically active agent.
[0009] Pharmaceutically Acceptable Excipients In some aspects, the pharmaceutical composition described herein includes one or more pharmaceutically acceptable excipients. Examples of pharmaceutically acceptable excipients within the scope of the pharmaceutical compositions described herein include, but are not limited to, binders, disintegrants, disintegrators, lubricants, diluents, fillers, flavorings, slips, sorbents, solubilizers, chelants, emulsifiers, thickeners, dispersants, stabilizers, suspending agents, adsorbents, granulating agents, preservatives, buffers, coloring agents and sweeteners or combinations thereof. Examples of binders include microcrystalline cellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, polyvinylpyrrolidone, polyvinylpolypyrrolidone, calcium carboxymethylcellulose, sodium carboxymethylcellulose, ceratonia, chitosan, cottonseed oil, and the like. dextrates, dextrin, ethylcellulose, gelatin, glucose, glyceryl behenate, galactomannan polysaccharide, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, inulin, lactose aluminum silicate, magnesium silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene glycol, polyethylene oxide, polymethacrylates, sodium alginate, sorbitol starch, sucrose, sunflower oil, vegetable oil, tocofersolan, zein or combinations thereof. Examples of disintegrating agents include croscarmellose sodium, sodium starch glycolate, lactose, magnesium aluminum silicate, methylcellulose, potassium polacrilin, sodium alginate, starch or the like. 30 combinations. Examples of lubricants include stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, glycerine monostearate, glyceryl palmitostearate, magnesium lauryl sulfate, mineral oil, palmitic acid, myristic acid, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, sodium lauryl sulphate, talc, zinc stearate, potassium benzoate, magnesium stearate or combinations thereof. Examples of diluents include talc, ammonium alginate, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, cellulose, cellulose acetate cornstarch, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, microcrystalline cellulose, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, starch, Sucrose, sulfobutyl ether (3-cyclodextrin, gum tragacanth, trehalose, xylitol or combinations thereof.) In some embodiments, at least one of the pharmaceutically acceptable excipients is a polymer. described In this document, one or more pharmaceutically acceptable excipients comprising a polymer and one or more pharmaceutically acceptable excipients remain. In some embodiments, the polymer is a vinyl polymer or a vinyl copolymer. In some embodiments, the vinyl polymer is polyvinylpyrrolidone or polyvinylpolypyrrolidone. In some embodiments, the pharmaceutical composition described herein comprises a polyvinylpyrrolidone having an average molecular weight of from about 10,000 to about 1,000,000 daltons, from about 20,000 to about 200,000 daltons, of about 30,000. at about 100,000 daltons, from about 30,000 to about 50,000 daltons, from about 10,000 to about 20,000 daltons, from about 20,000 to about 30,000 daltons, from 30,000 to about 40,000 daltons, from 40,000 to about 50,000 daltons, from about 50,000 to about 60,000 daltons, from about 60,000 to about 70,000 daltons, from about 70,000 to about 80,000 daltons, from about 80,000 to about 90,000 daltons, from about 90,000 to about 100,000 daltons, from about 100,000 to about 200,000 daltons, from about 200,000 to about 400,000 daltons, from about 400,000 to about 750,000 daltons, from about 750,000 to about 1,000,000 daltons.
[0010] In some embodiments, the pharmaceutical composition described herein comprises a polyvinylpyrrolidone having a K value of about 12 to about 120, including, but not limited to, one or more of 12, 15, 17 , 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 60, 90 or 120. In some embodiments, the pharmaceutical compositions comprise a polyvinylpyrrolidone having a K value selected from the group from about 12 to about 120, about 12 to about 15, about 15 to about 17, about 17 to about 25, about 25 to about 35, about 25 to about 32, about 24 to about 30, about 29 to about 32 from about 30 to about 60, about 60 to about 90 or about 90 to about 120. In some embodiments, the polymer is a vinyl copolymer, such as a polyvinylpyrrolidone copolymer, comprising polyvinylpyrrolidone and a further polymer. In some embodiments, the additional polymer is selected from the group consisting of polyvinyl acetate, vinyl acetate, and polyethylene glycol. In some embodiments, the additional polymer is selected from the group consisting of dimethylaminoethyl methacrylate, styrene and 1-triacontene. In some embodiments, the vinyl copolymer is a copolymer of polyvinylpyrrolidone / vinyl acetate, polyvinylpyrrolidone / polyvinyl acetate, polyvinylpyrrolidone / polyethylene glycol or vinylpyrrolidone / vinyl acetate. In some embodiments, the vinyl copolymer is a copolymer of polyvinylpyrrolidone / dimethylaminoethyl methacrylate, polyvinylpyrrolidone / styrene or polyvinylpyrrolidone / 1-triacontene. In some embodiments, the pharmaceutical composition described herein comprises a vinyl copolymer containing a polyvinylpyrrolidone and an additional polymer, wherein the relative weight ratio of polyvinylpyrrolidone to the additional polymer is from about (1 to 7) : (2-9), such as about 1: 2, 2: 2, 2: 3, 2: 4, 2: 5, 2: 6, 2: 7, 2: 8, 2: 9, 3: 2, 3 : 4, 3: 5, 3: 7, 3: 8, 4: 2, 4: 3, 4: 5, 4: 6, 4: 7, 4: 9, 5: 2, 5: 3, 5: 4 , 5: 6, 5: 7, 5: 8, 5: 9, 6: 2, 6: 4, 6: 5, 6: 7, 6: 8, 6: 9, 7: 2, 7: 3, 7 : 4, 7: 5, 7: 6, 7: 8, 7: 9. In some embodiments, the pharmaceutical composition described herein comprises a vinyl copolymer containing a polyvinylpyrrolidone and an additional polymer, wherein the weight ratio of polyvinylpyrrolidone to the additional polymer is about (1 to 7) (2 to 9), such as about 2: 8 to about 7: 3, or about 4: 6 to about 7: 3. In some embodiments, the pharmaceutical composition described herein comprises a polyvinylpyrrolidone copolymer having a polyvinylpyrrolidone / vinyl acetate ratio of about 60:40. In some embodiments, the pharmaceutical composition described herein comprises a vinyl copolymer that is a vinylpyrrolidone copolymer. In some embodiments, the vinylpyrrolidone copolymer comprises vinylpyrrolidone and vinyl acetate. In some embodiments, the pharmaceutical composition described herein comprises a vinylpyrrolidone copolymer containing vinylpyrrolidone and vinyl acetate, wherein the relative weight ratio polyvinylpyrrolidone / vinyl acetate is from about 60 to 40.
[0011] Dosage In some aspects, the pharmaceutical composition described herein includes multiple pharmaceutically active agents at the same or different doses. In some embodiments, the dose of the first pharmaceutically active agent, such as a triptan, varies as described later in the document, and the dose of the second pharmaceutically active agent, such as an antiemetic, is adjusted according to the particular triptan used. In some embodiments, the pharmaceutical composition comprises a triptan or a pharmaceutically acceptable salt thereof which is present at a dose of from about 1.0 mg to about 200 mg, including, but not limited to, from about 25 mg to about 100 mg, from about 20 mg to about 140 mg, from about 70 mg to about 140 mg, from about 80 mg to about 135 mg, from about 1.0 mg to about 25 mg. mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 1.0 mg to about 35 mg, from about 35 mg to about 70 mg, from about 70 mg to about 105 mg, from about 105 mg to about 140 mg, from about 140 mg to about 175 mg, or from about 175 mg to about about 200 mg. In some embodiments, the pharmaceutical composition comprises a triptan or a pharmaceutically acceptable salt thereof which is present at a dose of about 1.0 mg to about 200 mg, including but not limited to approximately 1.0 mg, 1.5 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg , 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg , 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 3025425 33 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg , 38.5 ing, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 42.5 mg, 43 mg, 43.5 mg, 44 mg, , 5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100, 105 mg, 110 mg, 115 mg, 120 mg, 120.5 mg, 121 mg, 121.5 mg, 122 mg, 122.5 mg, 123 mg, 123.5 mg, 124 mg, 124.5 mg, 125 mg, 125.5 mg, 126 mg, 126.5 mg, 127 mg , 127.5 mg, 128 mg, 128.5 mg, 129 mg, 129.5 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, mg, 180 mg, 185 mg, 190 mg, 195 mg or 200 mg. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of triptan in an amount therapeutically equivalent to a triptan dose described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of sumatriptan in a therapeutically equivalent amount to 90 mg of sumatriptan. In some embodiments, the amount of sumatriptan or a pharmaceutically acceptable salt thereof (eg, sumatriptan succinate) present in the pharmaceutical composition described herein is equivalent to about: 4 mg, 6 mg , 10mg, 25mg, 50mg, 85mg, 90mg or 100mg of sumatriptan free base form. In some embodiments, the amount of sumatriptan succinate present in the pharmaceutical composition described herein is about 35 mg, 70 mg, 126 mg, or 140 mg. In some embodiments, the amount of sumatriptan free base present in the pharmaceutical composition described herein is about 25 mg to 50 mg, 50 mg to 100 mg, or 75 mg to 100 mg. In some embodiments, the weight ratio of the plurality of first particles to the plurality of second particles is from about 2: 1 to about 6: 1, or from about 3: 1 to about 5: 1, respectively, by example of about 4: 1. In some embodiments, the weight ratio of the first active pharmaceutical ingredient to the total amount of one or more first pharmaceutically acceptable excipients is from about 1: 1 to about 2: 1, respectively, for example about 3 2. In some embodiments, the weight ratio of the second active pharmaceutical ingredient to the total amount of one or more second pharmaceutically acceptable excipients is from about 2: 1 to about 1: 2, respectively, for example about 1: 1. In some embodiments, the weight ratio of the first active pharmaceutical ingredient (e.g., a triptan or a pharmaceutically acceptable salt thereof, such as sumatriptan succinate) to the second active pharmaceutical ingredient (e.g., an antiemetic such that promethazine or a pharmaceutically acceptable salt thereof, e.g., promethazine hydrochloride) is from about 1: 2 to about 15: 1, respectively, for example about: 5: 1, 1: 1 , 2: 1, 3: 1, 4: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11: 1, 12: 1, 13: 1, 14: 1, respectively . In some embodiments, the weight ratio of the first active pharmaceutical ingredient to the total weight of the plurality of first particles is about 40% to 80%, 45% to 75%, 50% to 70%, or 55% to 65%, for example about 60%. In some embodiments, the weight ratio of the second active pharmaceutical ingredient to the total weight of the plurality of second particles is from about 30% to 70%, 35% to 65%, 40% to 60% or 45% to 55%. %, for example about 50%.
[0012] In some embodiments, the pharmaceutical composition described herein includes an antiemetic or a pharmaceutically acceptable salt thereof which is present at a dose ranging from about 0.5 mg to about 100 mg, including but not limited to range from about 0.5 mg to about 12.5 mg, from about 12.5 mg to about 50 mg, from about 50 mg to about 75 mg, from about 75 mg to about 100 mg From about 0.5 mg to about 15 mg, from about 15 mg to about 35 mg, from about 35 mg to about 55 mg, from about 55 mg to about 75 mg, or from about 75 mg to about 75 mg. about 95 mg. In some embodiments, the pharmaceutical composition comprises an antiemetic or a pharmaceutically acceptable salt thereof which is present at a dose of about 0.5 mg to about 100 mg, including but not limited to about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg , 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg , 28.5 mg, 29 mg, 29.5 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 12 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg , 95 mg or 100 mg. In some embodiments, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic is provided at a dose to prevent or reduce sedation. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of an antiemetic in an amount therapeutically equivalent to the antiemetic doses described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of promethazine in an amount therapeutically equivalent to 22 mg of promethazine. In some embodiments, the pharmaceutical composition described herein includes triptan and antiemetic. In some embodiments, triptan is present at a dose of about 1.0 mg to about 200 mg including, but not limited to, about 1.0 mg, 1.5 mg, 2, 5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7, 5 mg, 8.0 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13, 5mg, 14.0mg, 14.5mg, 15.0mg, 15.5mg, 16mg, 16.5mg, 17mg, 17.5mg, 18mg, 18.5mg, 19mg, 19mg , 5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25, 5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg , 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 42.5 mg, 43 mg, 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg , 85 mg, 90 mg, 95 mg, 100, 105 mg, 110 mg, 115 mg, 1 20 mg, 120.5 mg, 121 mg, 121.5 mg, 122 mg, 122.5 mg, 123 mg, 123.5 mg, 124 mg, 124.5 mg, 125 mg, 125.5 mg, 126 mg , 126.5 mg, 127 mg, 127.5 mg, 128 mg, 128.5 mg, 129 mg, 129.5 mg, 130 mg, 135 mg, 140 mg, 145 mg, 1150 mg, 155 mg, 160 mg 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, or 200 mg. In addition, the antiemetic is present at a dose of about 0.5 mg to about 100 mg, including, but not limited to, 0.5 mg, 1.0 mg, 1.5 mg, 2, 0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7, 0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg , 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24, 5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 31 mg, 32 mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 12mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 3025425, 90mg, 95mg or 100mg. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof and the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of an antiemetic in an amount therapeutically equivalent to the antiemetic doses described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable salt of promethazine in an amount therapeutically equivalent to the doses of promethazine described herein.
[0013] In some embodiments, the pharmaceutical composition described herein includes sumatriptan, or a pharmaceutically acceptable salt thereof, which is present at a free base dosage of about 10 mg to about 200 mg, including, but not limited to, from about 25 mg to about 100 mg, from about 35 mg to about 140 mg, from about 70 mg to about 140 mg, from about 80 mg to about 135 mg, from about 10 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 10 mg to about 35 mg, from about 35 mg to about 70 mg, from about 70 mg to about 105 mg, from about 105 mg to about 140 mg, from about 140 mg to about 175 mg, or from about 175 mg to about 200 mg. In some embodiments, the pharmaceutical composition comprises sumatriptan, or a pharmaceutically acceptable salt thereof, which is present at a dose of about 10 mg to about 200 mg, including, but not limited to, approximately 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg , 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg , 36 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 42.5 mg, 43 mg, 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100, 105 mg, 110 mg, 115 mg, 120 mg, 120.5 mg, 121 mg, 121 , 5 mg, 122 mg, 122.5 mg, 123 mg, 123.5 mg, 124 mg, 124.5 mg, 125 mg, 125.5 mg, 126 mg, 126.5 mg, 127 mg, 127.5 mg, 128 mg, 128.5 mg, 129 mg, 129.5 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195 or 200 mg. In some embodiments, the pharmaceutically acceptable salt of sumatriptan is sumatriptan succinate. In some embodiments, the pharmaceutical composition described herein comprises almotriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 50 mg, including but not limited to, from about 1.0 mg to about 30 mg, from about 5.0 mg to about 25 mg, from about 5.0 mg to about 15 mg, about 1.0 mg at about 5.0 mg, from about 5.0 mg to about 10.0 mg, from about 10.0 mg to about 15 mg, from about 15 mg to about 20 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 35 mg to about 40 mg, from about 40 mg to about 45 mg, or from about 45 mg to about 50 mg. In some embodiments, the pharmaceutical composition comprises almotriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 50 mg, including but not limited to , about 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28, 5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg. mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 42.5 mg, 43 mg, 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 m g, 49 mg, 49.5 mg or 50 mg. In some embodiments, the pharmaceutically acceptable salt of almotriptan is almotriptan malate.
[0014] In some embodiments, the pharmaceutical composition described herein comprises eletriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 10.0 mg to about 100 mg, including but not limited to, from about 10.0 mg to about 75 mg, from about 10.0 mg to about 50 mg, from about 10 mg to about 30 mg, from about 30 mg to about 50 mg from about 50 mg to about 70 mg, from about 70 mg to about 90 mg, from about 10.0 mg to about 20 mg, from about 20 mg to about 30 mg, from about 30 mg to about about 40 mg, from about 40 mg to about 50 mg, from about 50 mg to about 60 mg, from about 60 mg to about 70 mg, from about 70 mg to about 80 mg, from about 80 mg to about 90 mg, or about 90 mg to about 100 mg. In some embodiments, the pharmaceutical composition 3025425 38 comprises eletriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 10.0 mg to about 100 mg, including but not limited to limit, approximately 10.0 mg, 10.5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg , 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41, 5 mg, 42 mg, 42.5 mg, 43 mg, 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg or 100 mg . In some embodiments, the pharmaceutically acceptable salt of eletriptan is eletriptan hydrobromide. In some embodiments, the pharmaceutical composition described herein comprises frovatriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 0.5 mg to about 10.0 mg, including but not limited to from about 0.5 mg to about 5.0 mg, from about 1.0 mg to about 3.0 mg, from about 0.5 mg to about 1.5 mg, from about 1.5 mg to about 3.0 mg, from about 3.0 mg to about 4.5 mg, from about 4.5 mg to about 6.0 mg, from about 6.0 mg to about 7.5 mg, from about 7.5 mg to about 9.0 mg, from about 9.0 mg to about 10.0 mg, from about 0.5 mg to about 1.0 mg of about 1.0 mg to about 2.0 mg, from about 2.0 mg to about 3.0 mg, from about 3.0 mg to about 4.0 mg, from about 4.0 mg to about 5, 0 mg, from about 5.0 mg to about 6.0 mg, from about 6.0 mg to about 7.0 mg, from about 7.0 mg to about 8.0 mg, or about 8 mg. 0 mg to about 9.0 mg. In some embodiments, the pharmaceutical composition comprises frovatriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 0.5 mg to about 10.0 mg, including but not limited to limit, approximately 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg or 10.0 mg. In some embodiments, the pharmaceutically acceptable salt of frovatriptan is frovatriptan succinate. In some embodiments, the pharmaceutical composition described herein comprises rizatriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 50 mg, including but not limited to therein, from about 1.0 mg to about 75 mg, from about 1.0 mg to about 50 mg, from about 1.0 mg to about 25 mg, from about 1.0 mg to about about 15 mg, from about 15 mg to about 30 mg, from about 30 mg to about 45 mg, from about 1.0 mg to about 5.0 mg, from about 5.0 mg to about 10.0 mg, from about 10.0 mg to about 15 mg, from about 15 mg to about 20 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 30 mg, to about 35 mg, from about 35 mg to about 40 mg, from about mg to about 45 mg or from about 45 mg to about 50 mg. In some embodiments, the pharmaceutical composition comprises rizatriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 50 mg, including, but not limited to, about 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5, 5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10, 5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 42.5 mg, 43 mg , 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg or 50 mg. In some embodiments, the pharmaceutically acceptable salt of rizatriptan is rizatriptan benzoate. In some embodiments, the pharmaceutical composition described herein includes zolmitriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 25 mg, including but not limited to therein, from about 1.0 mg to about 15 mg, from about 1.0 mg to about 10 mg, from about 1.0 mg to about 7.5 mg, about 1.0 mg at about 7.0 mg, about 7.0 mg to about 14 mg, about 14 mg to about 25 mg, about 1.0 mg to about 2.5 mg, about 2.5 mg at about 5.0 mg, about 5.0 mg to about 7.5 mg, about 7.5 mg to about 10 mg, about 10 mg to about 12.5 mg, about 12, 5 mg to about 15 mg, from about 15 mg to about 17.5 mg, from about 17.5 mg to about 20 mg or from about 20 mg to about 25 mg. In some embodiments, the pharmaceutical composition comprises zolmitriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 25 mg, including, but not limited to, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10 mg. , 5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg , 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22 , 5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg or 25 mg.
[0015] In some embodiments, the pharmaceutical composition described herein includes naratriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 0.5 mg to about 25 mg, including but not limited to limited thereto, from about 0.5 mg to about 10 mg, from about 0.5 mg to about 7.5 mg, from about 0.5 mg to about 5.0 mg, about 0, 5 mg to about 4.0 mg, from about 0.5 mg to about 3.0 mg, from about 3.0 mg to about 5.0 mg, from about 5.0 mg to about 10.0 mg, from about 10.0 mg to about 15 mg, from about 15 mg to about 20 mg, from about 20 mg to about 25 mg, from about 1.0 mg to about 4.0 mg, of about 4.0 mg to about 7.0 mg, or about 7.0 mg to about 10.0 mg. In some embodiments, the pharmaceutical composition comprises naratriptan or a pharmaceutically acceptable salt thereof, which is present at a dose of about 1.0 mg to about 25 mg, including but not limited to about 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3, 0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8, 0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg or 25 mg. In some embodiments, the pharmaceutically acceptable salt of naratriptan is naratriptan hydrochloride. In some embodiments, the pharmaceutical composition comprises sumatriptan or a pharmaceutically acceptable salt thereof and promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, sumatriptan or a pharmaceutically acceptable salt thereof is present at a dose of about 10 mg to about 200 mg, including, but not limited to, about 10.0 mg, , 5 mg, 11.0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg. mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28, 5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg , 37 mg, 37 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg, 40 mg, 40.5 mg, 41 mg, 41.5 mg, 42 mg, 3025425 41 42.5 mg , 43 mg, 43.5 mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100, 105 mg, 110 mg, 115 mg, 120 mg , 120.5 mg, 121 mg, 121.5 mg, 122 mg, 122.5 mg, 123 mg, 123.5 m g, 124 mg, 124.5 mg, 125 mg, 125.5 mg, 126 mg, 126.5 mg, 127 mg, 127.5 mg, 128 mg, 128.5 mg, 129 mg, 129.5 mg , 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, approximately 25 mg to about 100 mg, from about 35 mg to about 140 mg, from about 70 mg to about 140 mg, from about 80 mg to about 135 mg, from about 10 mg to about 25 mg, from about 25 mg to about mg to about 50 mg, about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 10 mg to about 35 mg, about mg to about 70 mg, from about 70 mg to about 105 mg, from about 105 mg to about 140 mg, from about 140 mg to about 175 mg or from about 175 mg to about 200 mg. In some instances, promethazine or a pharmaceutically acceptable salt thereof is present at a dose of about 0.5 mg to about 100 mg, including, but not limited to, about 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg , 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, mg, 29.5mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 12mg, 43mg, 44mg mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, from about 0.5 mg to about 12.5 mg, from about 12.5 mg to about 50 mg, from about 50 mg to about 7 mg. 5 mg, from about 75 mg to about 100 mg, from about 0.5 mg to about 15 mg, from about 15 mg to about 35 mg, from about 35 mg to about 55 mg, about 55 mg about 75 mg, or about 75 mg to about 95 mg. In some embodiments, sumatriptan or a pharmaceutically acceptable salt thereof is present in the plurality of first particles and promethazine or a pharmaceutically acceptable salt thereof is present in the plurality of second particles. In some embodiments, the pharmaceutical composition described herein includes sumatriptan succinate and promethazine hydrochloride. In some embodiments, sumatriptan succinate is present at a dose of about 10 mg to about 200 mg, including, but not limited to, about 10.0 mg, 10.5 mg, 11 , 0 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5 mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg , 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg , 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 36 mg, 36.5 mg, 37 mg, , 5mg, 38mg, 38.5mg, 39mg, 39.5mg, 40mg, 40.5mg, 41mg, 41.5mg, 42mg, 42.5mg, 43mg, 43.5mg mg, 44 mg, 44.5 mg, 45 mg, 45.5 mg, 46 mg, 46.5 mg, 47 mg, 47.5 mg, 48 mg, 48.5 mg, 49 mg, 49.5 mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 115mg, 120mg, 120.5mg, 121 mg, 121.5 mg, 122 mg, 122.5 mg, 123 mg, 123.5 mg, 124 mg, 124.5 mg, 125 mg, 125.5 mg , 126 mg, 126.5 mg, 127 mg, 127.5 mg, 128 mg, 128.5 mg, 129 mg, 129.5 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg , 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, from about 25 mg to about 100 mg, from about 35 mg to about 140 mg, from about 70 mg to about 140 mg, from about 80 mg to about 135 mg, from about 10 mg to about 25 mg, from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, about 100 mg to about 15 Ang, about 150 mg to about 200 mg, about 10 mg to about 35 mg, about 35 mg to about 70 mg, about 70 mg to about 105 mg, from about 105 mg to about 140 mg, from about 140 mg to about 175 mg or from about 175 mg to about 200 mg. In some instances, promethazine hydrochloride is present at a dose of about 0.5 mg to about 100 mg, including, but not limited to, about 0.5 mg to about 100 mg, including but not limited to be limited to approximately 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4, 5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9 , 5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg , 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, , 5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg , 40mg, 41mg, 12mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg mg, 85 mg, 90 mg, 95 mg, 100 mg, from about 0.5 mg to about 12.5 mg, from about 12.5 mg to about 50 mg from about 50 mg to about 75 mg, from about 75 mg to about 100 mg, from about 0.5 mg to about 15 mg, from about 15 mg to about 35 mg, from about 35 mg to about 55 mg, from about 55 mg to about 75 mg, or from about 75 mg to about 95 mg. In some embodiments, sumatriptan succinate is present in the plurality of first particles and promethazine hydrochloride is present in the plurality of second particles.
[0016] In some aspects, the pharmaceutical composition described herein comprises multiple pharmaceutically acceptable excipients contained in the plurality of first particles and the plurality of second particles. In some embodiments, the particles are beads, pellets or spherules. In some embodiments, the particles comprise a therapeutically effective amount of a triptan or a pharmaceutically acceptable salt thereof. In some embodiments, the particles comprise a therapeutically effective amount of an antiemetic or a pharmaceutically acceptable salt thereof. In some embodiments, the dose of triptan and the dose of antiemetic will vary as described herein and the pharmaceutically acceptable excipients are adjusted according to the doses of triptan and antiemetic. In some embodiments, the pharmaceutical composition described herein comprises a vinyl polymer that is present in a weight percent of the plurality of first particles which is from about 0.25% to about 6.0%, including but not limited to approximately 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0% %, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5 %, 4.75%, 5.0%, 5.25%, 5.5%, 5.75% or 6.0%. In some embodiments, the vinyl polymer is polyvinylpyrrolidone. In some embodiments, the pharmaceutical composition described herein comprises a vinyl copolymer that is present in a weight percent of the plurality of first particles which is from about 0.25% to about 30%, including but not limited to, approximately 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75%, 5.0%, 5.25%, 5.5%, 5.75%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 30 11% 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29% or 30%. In some embodiments, the vinyl copolymer is a polyvinylpyrrolidone / vinyl acetate copolymer or a polyvinylpyrrolidone / polyvinyl acetate copolymer. In some embodiments, the vinyl copolymer is a vinylpyrrolidone / vinyl acetate copolymer. In some embodiments, the pharmaceutical composition described herein comprises microcrystalline cellulose that is present in a weight percent of the plurality of first particles that is from about 20% to about 90%, including but not limited to 'to limit, approximately 20.0%, 20.5%, 21.0%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24.0%, 24, 5%, 25.0%, 25.5%, 26.0%, 26.5%, 27.0%, 27.5%, 28.0%, 28.5%, 29.0%, 29, 5%, 30.0%, 30.5%, 31.0%, 31.5%, 32.0%, 32.5%, 33.0%, 33.5%, 34.0%, 34, 5%, 35.0%, 35.5%, 36.0%, 36.5%, 37.0%, 37.5%, 38.0%, 38.5%, 39.0%, 39, 5%, 40.0%, 40.5%, 41.5%, 42.0%, 42.5%, 43.0%, 43.5%, 44.0%, 44.5%, 45, 0%, 45.5%, 46.5%, 47.0%, 47.5%, 48.0%, 48.5%, 49.0%, 49.5%, 50.0%, 55% , 60%, 65%, 70%, 75%, 80%, 85% or 90%. In some embodiments, the pharmaceutical composition described herein includes croscarmellose sodium that is present in a weight percent of the plurality of first particles that is from about 0.0% to about 5.0%, including, but not limited to, approximately more than 0.0%, 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1, 75%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4, 25%, 4.5%, 4.75% or 5.0%. In some embodiments, the pharmaceutical composition described herein comprises magnesium stearate which is present in a weight percent of the plurality of first particles which is from about 0.2% to about 5.0%, including The pharmaceutical composition described herein includes talc which is present in a weight percent of the plurality of first particles which is from about 0.1% to about 5.0%, including but not limited to , about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 , 0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2 , 0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4 , 5%, 4.75% or 5.0%.
[0017] In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising polyvinylpyrrolidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and talc; and a plurality of second particles comprising microcrystalline cellulose and croscarmellose sodium. In some, but not limited to, modes of about 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%. %, 0.55%, 0.6%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.25 %, 1.5%, 1.75%, 2.0%, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75 %, 4.0%, 4.25%, 4.5%, 4.75% or 5.0%. In some embodiments, the polyvinylpyrrolidone composition described herein is present in a weight percent of the plurality of first particles which is from about 0.25% to about 6.0%, especially, but but not limited to approximately 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, 2% , 25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75%, 5.0%, 5.25%, 5.5%, 5.75% or 6.0%. In some embodiments, the microcrystalline cellulose is present in a weight percent of the plurality of first particles which is from about 20% to about 90%, including, but not limited to, about 20.0% , 20.5%, 21.0%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24.0%, 24.5%, 25.0%, 25.5% %, 26.0%, 26.5%, 27.0%, 27.5%, 28.0%, 28.5%, 29.0%, 29.5%, 30.0%, 30%, 5%, 31.0%, 31.5%, 32.0%, 32.5%, 33.0%, 33.5%, 34.0%, 34.5%, 35.0%, 35, 5%, 36.0%, 36.5%, 37.0%, 37.5%, 38.0%, 38.5%, 39.0%, 39.5%, 40.0%, 40%, 5%, 41.5%, 42.0%, 42.5%, 43.0%, 43.5%, 44.0%, 44.5%, 45.0%, 45.5%, 46, 5%, 47.0%, 47.5%, 48.0%, 48.5%, 49.0%, 49.5%, 50.0%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 15 90%. In some embodiments, croscarmellose sodium is present in a weight percent of the plurality of first particles which is from about 0.0% to about 5.0%, including, but not limited to, about more than 0.0%, 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, 2.25 %, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75% % or 5.0%. In some embodiments, magnesium stearate is present in a weight percent of the plurality of first particles which is from about 0.2% to about 5.0%, including but not limited to about 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.7% %, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0% %, 2.25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4, 5%, 4.75% or 5.0%. In some embodiments, talc is present in a weight percent of the plurality of first particles which is from about 0.1% to about 5.0%, including, but not limited to, about 0%. , 1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1 , 1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2 , 25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4.75% or 5.0%. In some embodiments, the microcrystalline cellulose disclosed herein is present in a weight percent of the plurality of second particles that is from about 20% to about 90%, including, but not limited to, approximately 20.0%, 20.5%, 21.0%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24.0%, 24.5%, 3025425 46 5 90%. In some embodiments, croscarmellose sodium is present in a weight percent of the plurality of first particles which is from about 0.0% to about 5.0%, including, but not limited to, about more than 0.0%, 0.25%, 0.5%, 0.75%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, 2, 25%, 2.5%, 2.75%, 3.0%, 3.25%, 3.5%, 3.75%, 4.0%, 4.25%, 4.5%, 4, 75% or 5.0%. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first microcrystalline cellulose-containing particles and polyvinylpyrrolidone, wherein the relative ratio by weight percent of each in the microcrystalline cellulose: polyvinylpyrrolidone ratio is from about (3 to 120): 1, such as about 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11: 1, 12 : 1, 13: 1, 14: 1 15: 1, 16: 1, 17: 1, 18: 1, 19: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 70: 1, 80: 1, 90: 1, 100: 1, 110: 1 or 120: 1. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles containing a triptan or a pharmaceutically acceptable salt thereof and polyvinylpyrrolidone, wherein the relative ratio by weight percentage of each in the triptan ratio or pharmaceutically acceptable salt thereof: polyvinylpyrrolidone is from about (8 to 25). In some aspects, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of a first agent. and a plurality of second particles comprising a therapeutically effective amount of a second pharmaceutically active agent and one or more pharmaceutically acceptable second excipients. position 25.0%, 25.5%, 26.0%, 26.5%, 27.0%, 27.5%, 28.0%, 28.5%, 29.0%, 29.5% , 30.0%, 30.5%, 31.0%, 31.5%, 32.0%, 32.5%, 33.0%, 33.5%, 34.0%, 34.5% , 35.0%, 35.5%, 36.0%, 36.5%, 37.0%, 37.5%, 38.0%, 38.5%, 39.0%, 39.5% , 40.0%, 40.5%, 41.5%, 42.0%, 42.5%, 43.0%, 43.5%, 44.0%, 44.5%, 45.0% , 45.5%, 46.5%, 47.0%, 47.5%, 48.0%, 48.5%, 49.0%, 49.5%, 50.0%, 51%, 52 %, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 65%, 70%, 75%, 80%, 85% or 150): 1, as approximately 8: 1, 9: 1, 10: 1, 11: 1 12: 1, 13: 1 14: 1, 15: 1, 16: 1, 17: 1, 18: 1, 19: 1, 20: 1, 21: 1, 22: 1, 23: 1, 24: 1, 25: 1, 26: 1, 27: 1, 28: 1, 29: 1, 30: 1, 31: 1, 32: 1, 33: 1, 34: 1, 35: 1, 36: 1, 37: 1, 38: 1, 39: 1, 40: 1, 42: 1, 44: 1, 46: 1, 48: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 90: 1, 95: 1, 100: 1, 110: 1, 120: 1, 130: 1, 140: 1 or The pharmaceutical composition described herein includes a plurality of first particles comprising a therapeutically effective amount of a tr iptan and one or more first pharmaceutically acceptable excipients, and a plurality of second particles comprising a therapeutically effective amount of an antiemetic and one or more second pharmaceutically acceptable excipients, wherein the first pharmaceutically acceptable excipient (s) comprises a vinyl polymer or a vinyl copolymer. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of promethazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable second excipients, wherein the at least one pharmaceutically acceptable excipient comprises a vinyl polymer or a copolymer of vinyl. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of promethazine or a pharmaceutically acceptable salt thereof and one or more second pharmaceutically acceptable excipients; wherein the first pharmaceutically acceptable excipient (s) comprises polyvinylpyrrolidone. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof, polyvinylpyrrolidone, microcrystalline cellulose, croscarmellose sodium magnesium stearate and talc; and a plurality of second particles comprising a therapeutically effective amount of promethazine or a pharmaceutically acceptable salt thereof, microcrystalline cellulose and croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises: a plurality of first particles comprising about 10 mg to 300 mg, for example about 30 mg to 150 mg, 10 mg to 200 mg, 25 mg to 200 mg. mg, 50 mg to 200 mg, 60 mg to 120 mg, 70 mg to 110 mg, 80 mg to 100 mg or 85 mg to 95 mg of sumatriptan or a pharmaceutically acceptable salt thereof, approximately 0.1 mg 20 mg, for example about 1 mg to 10 mg, 0.1 mg to 10 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 5 mg, 1 mg to 7 mg, 2 mg to 6 mg, 3 mg to 5 mg or 3.5 mg to 4.5 mg of polyvinylpyrrolidone, approximately 10 mg to 300 mg, for example, about 50 mg to 150 mg, 10 mg to 200 mg, 25 mg to 200 mg, 50 mg to 200 mg, 50 mg to 100 mg, 60 mg to 80 mg, 65 mg to 75 mg or 70 mg to 80 mg. mg of microcrystalline cellulose, about 0.1 mg to 20 mg, for example about 1 mg to 10 mg, 0.1 mg to 10 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, , 1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 5 mg, 1 mg to 7 mg, 2 mg to 6 mg, 3 mg to 5 mg or 3.5 mg to 4.5 mg of croscarmellose sodium, about 0.1 mg to 10 mg, for example about 0.1 mg to 5 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg, 0.1 mg to 2 mg, 0.5 mg to 1.5 mg, or 0.8 mg to 1.2 mg of magnesium stearate, and about 0.1 mg to 10 mg, for example about 0.1 mg to 5 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg , 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg, 0.5 mg to 3 mg, 1 mg to 3 mg, 1.5 mg to 2.5 mg, or 1.8 mg to 2.4 mg of talc; and a plurality of second particles comprising about 1 mg to 100 mg, for example about 10 mg to 50 mg, 10 mg to 60 mg, 10 mg to 70 mg, 10 mg to 80 mg, 10 mg to 90 mg, 15 mg 50 mg, 15 mg to 45 mg, 15 mg to 40 mg, 15 mg to 35 mg, 10 mg to 40 mg, 10 mg to 30 mg, 20 mg to 40 mg, 20 mg to 30 mg, 22 mg to 28 mg, or 24 mg to 26 mg of promethazine or a pharmaceutically acceptable salt thereof, about 1 mg to 100 mg, for example about 10 mg to 50 mg, 10 mg to 60 mg, 10 mg to 70 mg. mg, 10 mg to 80 mg, 10 mg to 90 mg, 15 mg to 50 mg, 15 mg to 45 mg, 15 mg to 40 mg, 15 mg to 35 mg, 10 mg to 40 mg, 10 mg to 30 mg, 20 mg to 40 mg, 20 mg to 30 mg, 22 mg to 26 mg, or 23 mg to 25 mg of microcrystalline cellulose, and about 0.1 mg to 10 mg, for example about 0.1 mg to 5 mg , 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg, , 1 mg to 2 mg, 0.5 mg to 1.5 mg, or 0.8 mg to 1.2 mg croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises: a plurality of first particles comprising about: 90, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 ,,,,,,,,,,,, , 250, 260, 270, 280, 290 or 300 mg of sumatriptan or a pharmaceutically acceptable salt thereof, approximately: 4, 4.2, 0.1, 0.5, 1, 1.5, 2 , 2.5, 3, 3.5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14 16, 18 or 20 mg of polyvinylpyrrolidone, about 72, 72.45, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 mg of microcrystalline cellulose, approximately: 4.2, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14, 16, 18 or 20 mg of croscarmellose sodium, approximately: 1.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of stearate magnesium, and about: 2, 2.1, 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of talc; and a plurality of second particles comprising about: 25, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 24, 26, 27, 28, 39, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95 or 100 mg of promethazine or a pharmaceutically acceptable salt thereof, about 24, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 25, 26, 27, 28, 39, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95 or 100 micrograms of microcrystalline cellulose, and about: 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of croscarmellose sodium. In some aspects, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of sumatriptan succinate, polyvinylpyrrolidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and talc; and a plurality of second particles comprising a therapeutically effective amount of promethazine hydrochloride, microcrystalline cellulose, and croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises: a plurality of first particles comprising about 10 mg to 300 mg, for example about 50 mg to 150 mg, 10 mg to 200 mg, 25 mg to 200 mg. mg, 50 mg to 200 mg, 60 mg to 120, 70 mg to 110, 80 mg to 100, or 85 mg to 95 mg sumatriptan succinate, about 0.1 mg to 20 mg, for example about 1 mg to 10 mg, 0.1 mg to 10 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 5 mg , 1 mg to 7 mg, 2 mg to 6 mg, 3 mg to 5 mg or 3.5 mg to 4.5 mg polyvinylpyrrolidone, about 10 mg to 300 mg, for example about 50 mg to 150 mg, mg to 200 mg, 25 mg to 200 mg, 50 mg to 200 mg, 50 mg to 100 mg, 60 mg to 80 mg, 65 mg to 75 mg or 70 mg to 80 mg of microcrystalline cellulose, approximately 0.1 mg to 20 mg, for example about 1 mg to 10 mg, 0.1 mg to 10 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 5 mg, 1 mg to 7 mg, 2 mg to 6 mg, 3 mg to 5 mg or 3.5 mg to 4.5 mg croscarmellose sodium, about 0.1 mg to 10 mg, for example about 0.1 mg to 5 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg, 0, 1 mg to 2 mg, 0.5 mg to 1.5 mg or 0.8 mg to 1.2 mg of magnesium stearate, and about 0.1 mg to 10 mg, for example about 0.1 mg to 5 mg. mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg 0.5 mg to 3 mg, 1 mg to 3 mg, 1.5 mg to 2.5 mg or 1.8 mg to 2.4 mg of talc; and a plurality of second particles comprising about 1 mg to 100 mg, for example about 10 mg to 50 mg, 10 mg to 60 mg, 10 mg to 70 mg, 10 mg to 80 mg, 10 mg to 90 mg, 15 mg 50 mg, 15 mg to 45 mg, 15 mg to 40 mg, 15 mg to 35 mg, 10 mg to 40 mg, 10 mg to 30 mg, 20 mg to 40 mg, 20 mg to 30 mg, 22 mg to 28 mg mg or 24 mg to 26 mg of promethazine hydrochloride, about 1 mg to 100 mg, for example about 10 mg to 50 mg, 10 mg to 60 mg, 10 mg to 70 mg, 10 mg to 80 mg, 10 mg 90 mg, 15 mg to 50 mg, 15 mg to 45 mg, 15 mg to 40 mg, 15 mg to 35 mg, 10 mg to 40 mg, 10 mg to 30 mg, 20 mg to 40 mg, 20 mg to 30 mg mg, 22 mg to 26 mg or 23 mg to 25 mg microcrystalline cellulose, and about 0.1 mg to 10 mg, for example, about: 0.1 mg to 5 mg, 0.1 mg to 9 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 6 mg, 0.1 mg to 4 mg, 0.1 mg to 3 mg, 0.1 mg to 2 mg, 0.5 mg 1.5 mg or 0.8 mg to 1.2 mg croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises: a plurality of first particles comprising about: 90, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 , 250, 260, 270, 280, 290 or 300 mg of sumatriptan succinate, approximately: 4, 4.2, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3, 5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14, 16, 18 or 20 mg of polyvinylpyrrolidone , approximately: 72, 72, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110 , 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 mg of cellulose microcrystalline, approximately: 4, 4.2,, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6, 6 , 5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14, 16, 18 or 20 mg of croscarmellose sodium, approximately: 1.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of magnesium stearate, and approximately: 0.21, 0.1, 0, 2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 1.8, 2, 2.5, 3, 3.5, 4.5, 5.5, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of talc; and a plurality of second particles comprising about: 25, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 24, 26, 27, 28, 39, 30 , 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95 or 100 mg of promethazine hydrochloride, approximately: 24, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 25, 26, 27, 28, 39, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95 or 100 mg of microcrystalline cellulose, and about: 1, 0.1, 0.2, 0.4, 0.6, 0.8, 3025425, 51 1.2, 1.4, 1.6, 1.8, 2, 2 , 5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg of croscarmellose sodium . In some aspects, the pharmaceutical composition described herein comprises a plurality of first particles comprising about 40% to about 80% by weight of sumatriptan succinate, about 0.5% to about 5% by weight of polyvinylpyrrolidone, about 20% to about 80% by weight of % to about 60% by weight of microcrystalline cellulose, about 0.5% to about 5% by weight of croscarmellose sodium, about 0.1% to about 5% by weight of magnesium stearate, and about 0.1% to about 5% by weight % by weight of talc; and a plurality of second particles comprising about 30% to about 70% by weight of promethazine hydrochloride, about 20% to about 70% by weight of microcrystalline cellulose, and about 0.5% to about 5% by weight of croscarmellose sodium . In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising about: 60%, 80%, 75%, 70%, 65%, 55%, 50%, 45% or 40% by weight of sumatriptan succinate, approximately: 2%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2.2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% by weight of polyvinylpyrrolidone, approximately: 34.5% , 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% by weight of microcrystalline cellulose, approximately: 2%, 0.5%, 0.6%, 0, 7%, 0.8%, 0.9%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2.2%, 2.5%, 3%, 3% , 5%, 4%, 4.5% or 5% by weight of croscarmellose sodium, approximately: 0.5%, 0.1%, 0.2%, 0.3%, 0.4%, 0, 6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2 , 5%, 3%, 3.5%, 4%, 4.5% or 5% by weight of magnesium stearate, and approximately: 1%, 0.1%, 0.2%, 0.3%, 0.4%, 0.6%, 0.7%, 0.8%, 0.9%, 1.2%, 1.4%, 1.6%, 1.8% %, 2%, 2.2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% by weight of talc; and a plurality of second particles comprising about 50%, 30%, 35%, 40%, 45%, 55%, 60%, 65% or 70% by weight of promethazine hydrochloride, about 48%, 30% 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70% by weight of microcrystalline cellulose, and approximately: 2%, 0.5%, 0.6%, 0.7% , 0.8%, 0.9%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2.2%, 2.5%, 3%, 3.5% %, 4%, 4.5% or 5% by weight of croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein includes a plurality of first particles comprising about 84 mg to about 126 mg sumatriptan succinate, about 1.05 mg to about 10.5 mg polyvinylpyrrolidone, about 42 mg. mg to about 126 mg of microcrystalline cellulose, about 1.05 mg to about 10.5 mg of croscarmellose sodium, about 0.525 mg to about 10.5 mg of magnesium stearate and about 2.1 mg to about 10.5 mg. mg of talc; and a plurality of second particles comprising about 20 mg to about 30 mg of promethazine hydrochloride, about 10 mg to about 30 mg of microcrystalline cellulose and about 0.25 mg to about 2.5 mg of croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising about 126 mg of sumatriptan succinate, about 4.2 mg of polyvinylpyrrolidone, about 72.45 mg of microcrystalline cellulose, about 4, 2 mg croscarmellose sodium, about 1.05 mg magnesium stearate and about 2.1 mg talcum; and a plurality of second particles comprising about 25 mg of promethazine hydrochloride, about 24 mg of microcrystalline cellulose and about 1 mg of croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein is a rapid release pharmaceutical composition. In certain embodiments, the pharmaceutical composition described herein is characterized in that at least about 80% of both sumatriptan or a pharmaceutically acceptable salt thereof and promethazine or a pharmaceutically acceptable salt of these are released in less than about 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm. In some embodiments, the pharmaceutical composition described herein comprises: a plurality of first particles, characterized in that each of the first particles comprises sumatriptan or a pharmaceutically acceptable salt thereof; and a plurality of second particles, characterized in that each of the second particles comprises promethazine or a pharmaceutically acceptable salt thereof, characterized in that at least about 80% of both sumatriptan or a pharmaceutically acceptable salt thereof and promethazine or a pharmaceutically acceptable salt thereof are released in less than about 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a rotary USP 1 (Basket) apparatus. at 100 rpm.
[0018] In some embodiments, the pharmaceutical composition described herein is stable for at least about 30 days, 60 days, 90 days, 6 months, 1 year, 18 months, 2 years, 3 years, 4 years, or 5 years. for example, about 80% to 100%, as about 80%, 90%, 95% or 100% of each active pharmaceutical agent in the pharmaceutical composition are stable, for example, as measured by liquid chromatography. high performance (HPLC), such as the HPLC method of Example 5. In some embodiments, about 80% to 100% (e.g., about 90% to 100% or 95% to 100%) of a 5HTIB receptor agonist (e.g., a triptan such as sumatriptan) or a pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) in the pharmaceutical composition described herein are stable for at least about: 30, 60, 90, 180, 360, 540 or 720 days, for example more than 90 days, which can be measured by HPLC, as with the method of Example 5. In some embodiments, about 80%, 85%, 90%, 95% or 100% (e.g., about 95% ) of the 5HT1B receptor agonist (e.g., a triptan such as sumatriptan) or the pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) are stable for 30 days or more, which may be measured in HPLC, as with the method of Example 5. In some embodiments, about 80% to 100% (e.g., about 90% to 100% or 95% to 100%) of an antiemetic (by for example, promethazine or a pharmaceutically acceptable salt thereof, such as promethazine hydrochloride) in the pharmaceutical composition described herein are stable for at least about 30, 60, 90, 180, 360, 540 or 720 days, for example more than 90 days, which can be measured by HPLC, as with the process of ex Example 5. In some embodiments, about 80%, 85%, 90%, 95%, or 100% (e.g., about 100%) of the antiemetic (e.g., promethazine or a pharmaceutically acceptable salt of this, such as promethazine hydrochloride) is stable for 30 days or more, which can be measured by HPLC, as with the method of Example 5.
[0019] Dosage Forms In some aspects, the pharmaceutical composition as described herein includes one or more pluralities of particles. The amounts and weight ratios described herein for the particles and their components provide an advantageous characteristic for the treatment of headache (e.g. migraine or cluster headache). The amounts and weight ratios described herein for the particles and their components also provide an advantageous characteristic for the treatment of nausea associated with migraine and / or migraine-associated emesis. In some embodiments, the plurality (s) of particles are enclosed in a discrete unit. In some embodiments, the dikrete unit is a capsule. In some embodiments, the capsule is formed using materials that include, but are not limited to, natural or synthetic gelatin, pectin, casein, collagen, proteins, modified starch, polyvinylpyrrolidone, acrylic polymers, cellulosic derivatives or combinations thereof. In some embodiments, the capsule is formed using preservatives, coloring and opacifying agents, flavors and sweeteners, sugars, gastroresistant substances or combinations thereof. In some embodiments, the discrete unit is a packet. In some embodiments, the capsule is coated. In some embodiments, the coating covering the capsule includes, but is not limited to, immediate release coatings, protective coatings, enteric or delayed release coatings, sustained release coatings, barrier coatings, sealing coatings or combinations thereof. In some embodiments, a capsule is here hard or mole. In some embodiments, the capsule is seamless. In some embodiments, the capsule is broken so that the particles are sprinkled on soft foods and swallowed without chewing. In some embodiments, the shape and size of the capsule also vary. Examples of capsule shapes include, but are not limited to, round, oval, tubular, oblong, twisted, or non-standard. The size of the capsule 20 may vary depending on the volume of the particles. In some embodiments, the size of the capsule is adjusted based on the volume of the particles. The hard or soft gelatin capsules may be made by conventional methods in the form of a single-body unit comprising the standard capsule form. A single-body soft gelatin capsule may be provided generally, for example, having sizes of 3 to 22 minims (1 minims being 0.0616 ml) and in oval, oblong or other forms. The gelatin capsule may also be manufactured by conventional methods, for example, in the form of a sealed or unsealed two-part hard gelatin capsule, generally in standard form and in various standard sizes, conventionally designated by 000), (00), (0), (1), (2), (3) (4), and (5).
[0020] 30 The highest number is the smallest size. In some embodiments, the pharmaceutical composition described herein (e.g., a capsule) is swallowed in its entirety. In some embodiments, the pharmaceutical composition described herein (e.g., a capsule) does not fully disintegrate in the mouth in less than about 2, 3, 4, 5, 6, 7, 8, 9 , 10, 3025425 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 minutes. In some embodiments, the pharmaceutical composition described herein is not a film. In certain embodiments, the pharmaceutical composition described herein is not intended to be administered orally. In some embodiments, the pharmaceutical composition described herein (e.g., a capsule) dissolves in the stomach or intestine. In some embodiments, the capsule comprises a plurality of first particles having a total weight of about 200 mg to about 220 mg and a plurality of second particles having a total weight of about 45 mg to about 55 mg. The plurality of first particles comprises a first active pharmaceutical ingredient and one or more first pharmaceutically acceptable excipients. Examples of first active pharmaceutical ingredients include triptans, for example, sumatriptan. Examples of first active pharmaceutical ingredients include antiemetics, for example, promethazine. In some cases, the particles are sorted through # 16 and # 30 mesh screens to obtain particles having a diameter of between 595 micrometers and 1190 micrometers. In some instances, the particles have a diameter of from about 595 microns to about 707 microns, from about 707 microns to about 841 microns, from about 841 microns to about 1000 microns, or from about 1000 microns to about 1190 microns.
[0021] In some cases, the plurality of first particles is about 208 or about 212 mg. In some cases, the plurality of first particles is about 50 mg or 51 mg of promethazine. In some embodiments, the capsule for containing the plurality of first particles and the plurality of second particles has a net weight of 28 mg to 107 mg, for example, from about 90 mg to about 102 mg, about 100 mg to 114 mg, approximately 103 mg to 117 mg, approximately 76 mg to 86 mg, approximately 71 mg to 81 mg, approximately 61 mg to 71 mg, approximately 57 mg to 65 mg from about 45 mg to 51 mg, from about 37 mg to 43 mg, from about 35 mg to 41 mg or from about 26 mg to 30 mg. In some cases, the capsule has a net weight of about 96 mg, 107 mg, 110 mg, 81 mg, 76 mg, 66 mg, 61 mg, 48 mg, 40 mg, 38 mg or 28 mg. In some cases, the capsule for containing the plurality of first particles and the plurality of second particles has a volume of about 0.1 ml to 0.8 ml, for example, from about 0.6 ml to about 0, 8 ml, about 0.4 ml to 0.6 ml, about 0.3 ml to 0.5 ml, about 0.2 ml to 0.4 ml, about 0.1 ml to 0.3 ml or about 0.05 ml to 0.25 ml. In some cases, the capsule has a volume of about 0.7 ml, 0.8 ml, 0.5 ml, 0.4 ml, 0.35 ml, 0.3 ml, 0.25 ml, 0.2 ml, 0.15 ml or 0.1 ml. In some cases, the body of the capsule is about 9 mm to 20 mm long, for example, about 17 mm to about 20 mm long, about 17 mm to 19 mm long, about 16 mm to 20 mm long, about 15 mm to 19 mm long, about 14 mm to 18 mm long, about 13 mm to 17 mm long, about 12 mm to 16 mm long long, about 11 mm to 15 mm long, about 10 mm to 14 mm long, about 9 mm to 13 mm long, about 9 mm to 12 mm long, about 9 mm to 11 mm long or about 9 mm to 10 mm long. In some cases, the body of the capsule is approximately: 18 mm long, 17 mm long, 16 mm long, 15 mm long, 14 mm long, 13 mm long, 12 mm long, 11 mm long, 10 mm long or 9 mm long. In some cases, the cap of the capsule is about 6 mm to 12 mm long, for example, about 10 mm to 12 mm long, about 9 mm to 11 mm long, about 8 mm to 12 mm long, mm to 10 mm long, about 7 mm to 9 mm long or about 6 mm to 8 mm long. In some cases, the cap of the capsule is about 11 mm long, 10 mm long, 9 mm long, 8 mm long, 7 mm long or 6 mm long. In some cases, the body of the capsule has an outer diameter of about 4 mm to 9 mm, for example from about 6 mm to about 8 mm, from about 7 mm to 9 mm, from about 7 mm to 8 mm. mm, from about 5 mm to 7 mm or from about 4 mm to 6 mm In some cases, the body of the capsule has an outer diameter of about: 9 mm, 8 mm, 7 mm, 6 mm, 5 mm or 4 mm. In some cases, the cap of the capsule has an outer diameter of about 4 mm to 9 mm, for example about 7 mm to about 9 mm, about 6 mm to 9 mm, about 7 mm to 8 mm. mm, from about 5 mm to 7 mm or from about 4 mm to 6 mm. In some cases, the cap of the capsule has an outer diameter of about 8 mm, 9 mm, 7 mm, 6 mm, 5 mm or 4 mm. In some cases, the total closed length of the capsule is about 10 mm to 24 mm, for example, about 20 mm to 24 mm, or about 21 mm to 23 mm, 20 mm to 22 mm , 19 mm to 21 mm, 18 mm to 20 mm, 17 mm to 19 mm, 16 mm to 18 mm, 15 mm to 17 mm, 14 mm to 16 mm, 13 mm to 15 mm, 12 mm to 14 mm, 11 mm to 13 mm or 10 mm to 12 mm. In some cases, the total closed length of the capsule is approximately: 22 mm, 24 mm, 23 mm, 21 mm, 20 mm, 19 mm, 18 mm, 17 mm, 16 mm, 15 mm, 14 mm, 13 mm, 12 mm, 11 mm or 10 mm. In some cases, the capsule has a capacity of about 50 mg to 800 mg, for example about 400 mg to 800 mg, 350 mg to 450 mg, 300 mg to 500 mg, 300 mg to 400 mg, 250 mg 350 mg, 200 mg to 300 mg, 200 mg to 250 mg, 150 mg to 200 mg, 100 mg to 200 mg, 100 mg to 150 mg, 50 mg to 100 mg, 450 mg, 425 mg, 400 mg, 375 mg, 350 mg, 325 mg, 300 mg, 275 mg, 250 mg, 225 mg, 200 mg, 175 mg, 150 mg, 125 mg, 100 mg or 75 mg, and a powder density of about 0, 6 to about 1.2 g / ml, for example about 0.6 g / ml, 0.8 g / ml, 1 g / ml or 1.2 g / ml. In some cases, each of the first particles and / or second particles in the capsule is in the form of a ball or pellet or spherule. In some cases, the first particles and / or the second particles are off-white in color. In some cases, the capsule is oblong. In some cases, the capsule is orange. In some cases, the capsule is white. In some aspects, the pharmaceutical composition as described herein is in the form of a tablet, film or particles.
[0022] Particles In some aspects, the pharmaceutical composition described herein contains variously shaped particles. In some embodiments, the particles are beads, granules, powders, pastes, spherules or pellets (e.g., micropellets or minipellets). In some embodiments, the particles have different sizes. In some embodiments, the particle diameter is more than 0.1 mm to about 2.0 mm, including, but not limited to, about 0.05 mm, 0.06 mm, 0.07 mm. mm, 0.08mm, 0.09mm, 0.1mm, 0.15mm, 0.2mm, 0.25mm, 0.3mm, 0.35mm, 0.4mm, 0.45mm mm, 0.5 mm, 0.55 mm, 0.6 mm, 0.65 mm, 0.7 mm, 0.75 mm, 0.85 mm, 0.9 mm, 0.95 mm, 1, 0 mm, 1.05 mm, 1.1 mm, 1.15 mm, 1.2 mm, 1.25 mm, 1.3 mm, 1.35 mm, 1.4 mm, 1.45 mm, 1, 5 mm, 1.55 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm or 2.0 mm. In some embodiments, the particle diameter is from 0.1 mm to about 2.0 mm, including, but not limited to, about 0.5 mm to about 1.5 mm, about 0.595 mm. mm to about 1.19 mm. In some embodiments, the particle size is from 0.60 mm to 0.85 mm. In some embodiments, the particles are balls, spherules or pellets. In some embodiments, the particle size is up to 2.5 mm, up to a maximum size of 2.8 mm for drug products to be sprinkled.
[0023] In some aspects, the pharmaceutical composition described herein includes a plurality of first particles and a plurality of second particles. In some embodiments, the first and second particles have about the same diameter. In some embodiments, the first particles and the second particles are balls, spherules or pellets. In some embodiments, the pharmaceutical composition comprises a plurality of first particles and a plurality of second particles, the diameters of the first particles and second particles being from about 0.1 mm to about 2.0 mm, including but not limited to from about 0.5 mm to about 1.5 mm, from about 0.595 mm to about 1.19 mm, from about 0.1 mm to about 0.25 mm, about 0.25 mm to about 0.5 mm, from about 0.5 mm to about 0.75 mm, from about 0.75 mm to about 1.0 mm, from about 1.0 mm to about 1 mm , 25 mm, from about 1.25 mm to about 1.5 mm, from about 1.5 mm to about 1.75 mm or from about 1.75 mm to about 2.0 mm. In some embodiments, the diameters of the first and second particles are the same. In some embodiments, the diameters of the first and second particles are different. In some embodiments, the pharmaceutical composition comprises about 150 mg to about 400 mg of a plurality of first particles, including, but not limited to, about 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 15,220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg or 400 mg. In some embodiments, the pharmaceutical composition comprises about 150 mg to about 400 mg of a plurality of first particles, including, but not limited to, about 175 mg to about 300 mg, about 200 mg to about 250 mg, about 200 mg to about 220 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 200 mg to about 225 mg, about 225 mg to about 250 mg, about 250 mg to about 275 mg, about 275 mg. mg to about 300 mg, about 300 mg to about 325 mg, about 325 mg to about 350 mg, about 350 mg to about 375 mg, about 375 mg to about 400 mg, about 165 mg to about 195 mg, about 195 mg at about 225 mg, about 225 mg to about 255 mg, about 255 mg to about 285 mg, about 285 mg to about 315 mg, about 315 mg, about 345 mg or about 345 mg to about 375 mg. In some embodiments, the pharmaceutical composition comprises about 25 mg to about 200 mg of a plurality of second particles, including, but not limited to, about 25 mg, 27.5 mg, 30 mg, 32.5 mg. , 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, 52.5 mg, 55 mg, 57.5 mg, mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 120 mg. In some embodiments, the pharmaceutical composition comprises about 25 mg to about 200 mg of a plurality of second particles, including, but not limited to, about 30 mg to about 150 mg, about 30 mg to about 100 mg. mg, about 40 mg to about 100 mg, about 30 mg to about 70 mg, about 47.5 mg to about 52.5 mg, about 25 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 40 mg to about 70 mg, about 70 mg to about 100 mg, about 100 mg to about 130 mg, about 130 mg to about 160 mg or about 160 mg to about 190 mg. In some embodiments, the pharmaceutical composition described herein includes a plurality of first particles and a plurality of 10 second particles. In some embodiments, the plurality of first particles is present in an amount of about 150 mg to about 400 mg, including, but not limited to, about 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg , 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg or 400 mg. In addition, the plurality of second particles is present in an amount of about 25 mg to about 200 mg, including, but not limited to, about 25 mg, 27.5 mg, 30 mg, 32.5 mg. , 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, 52.5 mg, 55 mg, 57.5 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg or 120 mg. In some embodiments, the target and maximum particle size, including particle size distribution, is determined by USP <786> 5 analytical sieving or other appropriately validated methods. Examples of filters used to generate particle sizes include, but are not limited to, mesh screens having a size of # 16, # 20 and # 30 corresponding, respectively, to a diameter of 1190, 707 and 595 micrometers. In some instances, the particle diameter is from about 595 microns to about 707 microns, from about 707 microns to about 841 microns, from about 707 microns to about 1190 microns, from about 841 microns to about 1000 microns or from about 1000 micrometers to about 1190 micrometers. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising one or more first pharmaceutically acceptable excipients and a plurality of second particles comprising one or more second pharmaceutical excipients. In some embodiments, the pharmaceutically acceptable first excipients or excipients and the pharmaceutically acceptable second excipient (s) include microcrystalline cellulose, hydroxypropyl methylcellulose, croscarmellose sodium, sodium starch glycolate, acid, and the like. stearic acid, sodium stearyl fumarate, glyceryl behenate, magnesium stearate, talc or combinations thereof. In some embodiments, the first pharmaceutically acceptable excipient (s) comprises microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and talc. In some embodiments, the first pharmaceutically acceptable excipient (s) comprises one or more vinyl polymers and one or more first pharmaceutically acceptable excipients remaining. In some embodiments, the first pharmaceutically acceptable excipient (s) remaining is microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and talc. In some embodiments, the pharmaceutically acceptable second or excipients comprise microcrystalline cellulose and croscarmellose sodium. In some embodiments, the pharmaceutical composition described herein comprises a plurality of first particles comprising a therapeutically effective amount of a triptan and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of an antiemetic and one or more second pharmaceutically acceptable excipients; the first pharmaceutically acceptable excipient or excipients comprising a vinyl polymer or copolymer. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some embodiments, the triptan is sumatriptan succinate. In some embodiments, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic is promethazine hydrochloride. In some embodiments, the vinyl polymer is polyvinylpyrrolidone. In some embodiments, the pharmaceutical composition comprises a plurality of first particles comprising a therapeutically effective amount of sumatriptan succinate and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of promethazine hydrochloride and one or more second pharmaceutically acceptable excipients; the first pharmaceutically acceptable excipient or excipients comprising polyvinylpyrrolidone. In some embodiments, the first pharmaceutically acceptable excipient (s) include, but is not limited to, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and talc, and the pharmaceutically acceptable second excipient (s). includes, but is not limited to, microcrystalline cellulose and croscarmellose sodium. In some cases, the particles, e.g., beads or spherules, described herein are coated with a coating material, for example, a sealant. In some embodiments, the coating material is water soluble. In some embodiments, the coating material comprises a polymer, a plasticizer, a pigment, or any combination thereof. In some embodiments, the coating material is a form of film coating, for example an ice-cold film, a pH-independent film coating, an aqueous film coating, a dry powder film coating (for example, a complete dry powder film coating), or any combination thereof. In some embodiments, the coating material is highly adhesive. In some embodiments, the coating material provides a low level of water permeation. In some embodiments, the coating material provides protection against oxygen. In some embodiments, the coating material allows immediate disintegration to rapidly release active drug substances. In some embodiments, the coating material is pigmented, transparent or white. In some embodiments, the coating material is transparent. Examples of coating materials include, but are not limited to, polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), methacrylic acid copolymers, cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (acetate acetate succinate), hypromellose), shellac, sodium alginate and zein. In some embodiments, the coating material comprises or is a PVA. In some embodiments, the coating material comprises or is HPMC. An example of a PVA coating material includes OPADRY II. In some cases, the coating material is about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% of the weight of the particles, for example beads or spherules. In some cases, the coating material represents more than about 2% of the weight of the particles, for example beads or spherules.
[0024] In some aspects, the pharmaceutically active agent dissolves in whole or in less than its total amount. In some embodiments, the dissolution of 100% of the pharmaceutically active agent takes place at a predetermined time. In some embodiments, both the 5HT1B receptor agonist and the antiemetic have a dissolution rate of 80% or more in less than 15 minutes, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, such as 100 rpm. In some embodiments, the 5HT1B receptor agonist or antiemetic both have a dissolution rate of 80% or more in less than 30 minutes, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket) rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the 5HT1B receptor agonist or antiemetic has a dissolution rate of 80% or more in less than 15 minutes, as measured by contacting the pharmaceutical composition described herein with a dissolving in a USP 1 (Basket) apparatus rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, such as 100 rpm. In some embodiments, the 5HT1B receptor agonist or antiemetic has a dissolution rate of 80% or more in less than 30 minutes, as measured by contacting the pharmaceutical composition described herein with a dissolution in a USP 1 apparatus (basket) rotating at 100 rpm.
[0025] In some embodiments, both the 5HT1B receptor agonist and the antiemetic have a dissolution rate of 80% or more in less than 15 or 30 minutes, for example, as measured by contact of the pharmaceutical composition. described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm like 100 rpm. In some embodiments, the 5HT1B receptor agonist or antiemetic has a dissolution rate of 80% or more in less than 15 minutes or 30 minutes, for example, as measured by contacting the pharmaceutical composition described in US Pat. This document with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at approximately 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some embodiments, the dissolution of at least about 60%, 61%, 62%, 63%, 64% or 65% of the antiemetic occurs in about 5 minutes, for example as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some embodiments, the dissolution of at least about 80% of the antiemetic occurs in about 15 minutes, for example as measured by contacting the pharmaceutical composition described herein with a dissolution fluid. in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the dissolution of at least about 80% of the antiemetic occurs in about 30 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid. in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the dissolution of at least about 99% or 100% of the antiemetic occurs in about 20 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some cases, the promethazine salt is promethazine chloride. In some embodiments, the dissolution of at least about 55%, 60%, 65%, 68%, 69%, 70% or 71% of the triptan occurs in about 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some embodiments, the dissolution of at least about 80% of the triptan occurs in about 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in an apparatus. USP 1 (Basket), for example, rotating at approximately: 3025425 64 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the dissolution of at least about 80% of the triptan occurs in about 30 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the dissolution of at least about 99% or 100% of the antiemetic occurs in about 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a fluid. in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some cases, the pharmaceutically acceptable salt of sumatriptan is sumatriptan succinate.
[0026] In some embodiments, the pharmaceutical composition comprises an antiemetic and a 5HT1B receptor agonist. In some embodiments, the 5HT1B receptor agonist is a triptan. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some cases, the antiemetic has a dissolution rate which is about the same as or less than the dissolution rate of the 5HT1B receptor agonist in less than about 15 minutes, for example as measured by contact with the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at approximately 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than about 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein. with a dissolving fluid in a USP apparatus 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 turns /minute. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than about 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein. with a 3025425 dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 turns /minute. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm . In some cases, the antiemetic has about the same dissolution rate as the dissolution rate of the 5HT1B receptor agonist in less than about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in an apparatus USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0027] In some instances, promethazine or a pharmaceutically acceptable salt thereof has a dissolution rate which is about equal to or less than the dissolution rate of the 5HT13 receptor agonist in less than about 15 minutes, by for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, promethazine or a pharmaceutically acceptable salt thereof has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than about 10 minutes, for example, as measured by contact with the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some instances, promethazine or a pharmaceutically acceptable salt thereof has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than about 5 minutes, for example as measured by contact. of a pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm. In some instances, promethazine or a pharmaceutically acceptable salt thereof has a dissolution rate lower than the dissolution rate of the 5HT1B receptor agonist in less than 5 minutes, for example, as measured by contact with the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 5 150 rpm, like 100 rpm. In some cases, promethazine or a pharmaceutically acceptable salt thereof has a dissolution rate about the same as the dissolution rate of the 5HT1B receptor agonist in less than about 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 minutes, for example, as measured by contact of the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 turns / minute. In some cases, its pharmaceutically acceptable salt is promethazine hydrochloride. In some cases, the antiemetic has a dissolution rate which is about equal to or less than the dissolution rate of the triptan in less than about 15 minutes, for example, as measured by contacting the pharmaceutical composition described in US Pat. the present document with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of the triptan in less than about 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a platelet fluid. dissolution in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of the triptan in less than about 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a carrier fluid. dissolution in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some instances, the antiemetic has a dissolution rate lower than the dissolution rate of the triptan in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in the present invention. a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate about the same as the dissolution rate of the triptan in less than about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolving fluid in a USP 1 ( Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate which is about the same as or less than the dissolution rate of sumatriptan in less than about 15 minutes, for example, as measured by contact of the pharmaceutical composition described in the present document with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 rpm, like 100 rpm. In some instances, the antiemetic has a dissolution rate lower than the dissolution rate of sumatriptan in less than about 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a platelet fluid. dissolution in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of sumatriptan in less than about 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a platelet fluid. dissolution in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate lower than the dissolution rate of sumatriptan in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic has a dissolution rate about the same as the dissolution rate of sumatriptan in less than about 10, 11, 12, 13, 14, 15, 16, 17, 30, 18, 19, 21. , 22, 23, 24, 25, 26, 27, 28, 29, or 30 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart) for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the triptan is sumatriptan succinate.
[0028] In some cases, the antiemetic dissolves more rapidly than the triptan. In some cases, the antiemetic is characterized by a greater amount of dissolution after 5 minutes than the triptan after contact with a dissolution fluid, and the two active ingredients have a similarly dissolved amount after 15 minutes, for example, such that measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130 , 140 or 150 rpm, as 100 rpm. In some cases (1) about 60% of the promethazine hydrochloride dissolves within 5 minutes after contact with a dissolution fluid and about 55% of the sumatriptan succinate dissolves in 5 minutes, for example, as measured by contact with the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, like 100 rpm; and (2) about 99% of the two active ingredients dissolve in 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart), by for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, the antiemetic dissolves more slowly than the triptan. In some cases, the antiemetic is characterized by less dissolution after 5 minutes than the triptan, and the two active ingredients have a similar dissolved amount in 15 minutes, for example, as measured by contact of the pharmaceutical composition described in US Pat. The present document with a dissolution fluid in a USP 1 apparatus (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some cases, (1) about 60% or about 65% of the promethazine hydrochloride dissolves within 5 minutes after contact with a dissolution fluid and about 70% or about 75% of the sumatriptan succinate dissolves in 5 minutes, for example as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110 , 120, 130, 140 or 150 rpm, as 100 rpm; and (2) about 100% of the two active ingredients dissolve in 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart), for example , Rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the dissolution of less than all of the pharmaceutically active agent takes place in about 1 minute to about 20 minutes (for example, about 55%, about 60% about 65%, 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or 99.9% of a pharmaceutically active agent). Methods for measuring dissolution profiles are known. An exemplary method for measuring dissolution profiles is described in Example 4. In some embodiments, about 10% to about 100% of the first pharmaceutically active agent is able to dissolve from the plurality of about in 1 minute at about 60 minutes after contact with a dissolution fluid, such as the dissolution fluid described in Example 4. In some embodiments, about 100% of the first pharmaceutically active agent is able to dissolve from the plurality of first particles at about 15, 16, 17, 18, 19 or 20 minutes after contact with a dissolution fluid. In some embodiments, about 10% to about 100% of the second pharmaceutically active agent is able to dissolve from the plurality of second particles about 1 minute to about 60 minutes after contact with a dissolution fluid. In some embodiments, the pharmaceutical composition comprises a plurality of particles comprising an antiemetic and about 100% of the antiemetic dissolve after about 1 minute to about 60 minutes after contact with a dissolution fluid. In some embodiments, the antiemetic is promethazine or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic is promethazine hydrochloride. In some embodiments, the pharmaceutical composition comprises a plurality of particles comprising a triptan and about 80% of the triptan dissolves after about 15 minutes after contact with a dissolution fluid. In some embodiments, about 100% of the triptan dissolves about 15 or 16 or 17 or 18 or 19 or 20 minutes after contact with a dissolution fluid. In some embodiments, the triptan is sumatriptan or a pharmaceutically acceptable salt thereof. In some embodiments, the triptan is sumatriptan succinate. In some embodiments, the pharmaceutical composition is capable of providing an effective plasma concentration of the antiemetic about 1 minute to about 60 minutes after administration to a patient. In some embodiments, the pharmaceutical composition is capable of providing an effective plasma concentration of promethazine or a pharmaceutically acceptable salt thereof about 1 minute to about 60 minutes after administration to a patient. In certain aspects, the present disclosure provides a pharmaceutical composition comprising: a plurality of first particles comprising a therapeutically effective amount of a triptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of an antiemetic or a pharmaceutically acceptable salt thereof and one or more second pharmaceutically acceptable excipients, the antiemetic being released more rapidly than the triptan after contact of the composition pharmaceutical with a dissolution fluid. In some modes of 80%, 55% to 90% or 55% to 95% of the antiemetic are released in less than about 5 to 20 minutes, for example, about 5 to 10 minutes or about 5 to 15 minutes, after contact of the pharmaceutical composition with a dissolution fluid and about 30% to 90%, for example about 55% to 90%, 55% to 80%, 55% to 70%, 55% to 60%, 50% at 90%, 50% to 80%, 50% to 70%, 50% to 60%, 40% to 90%, 40% to 80%, 40% to 70%, 40% to 60%, 30% to 90% %, 30% to 80%, 30% to 70%, or 30% to 60% of the triptan are released in less than about 5 to 20 minutes, for example, about 5 to 10 minutes or about 5 to 15 minutes, after contact of the pharmaceutical composition with the dissolution fluid. In some embodiments, about 60%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 55%, 50%, 45% or 40% of the antiemetic are released in less than about 5 to 10 minutes, for example, about 5, 6, 7, 8, 9 or 10 minutes, after contacting the pharmaceutical composition with a dissolution fluid and about: 55%, 90%, 85% , 80%, 75%, 70%, 65%, 60%, 50%, 45%, 40%, 35% or 30% of the triptan are released in less than about 5 to 10 minutes, for example, about 5 , 6, 7, 8, 9 or 10 minutes, after contact of the pharmaceutical composition with the dissolution fluid. In some embodiments, about 90% to 95%, 90% to 100%, 85% to 95%, 80% to 95%, 75% to 95%, 70% to 95%, 65% to 95%. 60% to 95%, 50% to 95%, achievement, about 40% to 95%, for example about 60% to 95%, 60% to 90%, 60% to 80%, 60% to 70%, 40% to 95%, 40% to 90%, 40% to 80%, 40% to 70%, 50% to 95%, 50% to 90%, 50% to 80%, 50% to 70%, 55% to 65%, 55% to 70%, 55% to 3025425 71 45% to 95%, 40% to 95%, 85% to 100%, 80% to 100%, 75% to 100%, 70% to 100%, 65% to 100%, 60% to 100%, 50% to 100%, 45% to 100%, 40% to 100% of the antiemetic are released in less than about 5 to 20 minutes, for example about 10, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 minutes after contacting the pharmaceutical composition with a dissolution fluid and about: 85% to 90%, 85% to 95%, 80% to 90%, 75% to 90%, 70% to 90%, 65% to 90%, 60% to 90%, 50% to 90%, 4-5% 90%, 40% to 90% %, 35% to 90%, 30% to 90%, 80% to 95%, 75% to 95%, 70% to 95%, 65% to 95%, 60% to 95%, 50% to 95% 45% to 95%, 40% to 95%, 35% to 95% or 30% to 95% of the triptan are released in less than about 5 to 20 minutes, for example, about 10, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 minutes after contact of the pharmaceutical composition with the dissolution fluid. In some embodiments, the dissolution of an active agent described herein (e.g., triptan, antiemetic) is greater than 80% in 15 minutes. In some embodiments, the dissolution of an active agent described herein (e.g., triptan, antiemetic) is greater than 80% in 30 minutes. In some embodiments, at least about 55% of the triptan is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart ), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 60% of the triptan is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart ), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 65% of the triptan is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart ), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0029] In some embodiments, at least about 70% of the triptan is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 ( Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 75% of the triptan is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 80% to 85% of the triptan is released in less than 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 90% of the triptan is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Cart ), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 99% of the triptan is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 ( Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0030] In some embodiments, at least about 55% of the triptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 60% of the triptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 65% of the triptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolving fluid in a medium. USP apparatus 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 70% of the triptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in an apparatus. USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 75% of the triptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0031] In some embodiments, at least about 80% to 85% of the triptan succinate is released in less than 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in the present invention. a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 90% of the triptan succinate is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 99% of the triptan succinate is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0032] In some embodiments, at least about 55% of sumatriptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 60% of sumatriptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 65% of sumatriptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in an apparatus. USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 70% of the sumatriptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 75% of the sumatriptan succinate is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 80% to 85% of sumatriptan succinate is released in less than 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 90% of the sumatriptan succinate is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 99% of sumatriptan succinate is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 60% of the antiemetic is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 3025425 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 65% of the antiemetic is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 70% of the antiemetic is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket), for example, rotating at about 10: 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 90% to 95%% of the antiemetic is released in less than 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in the present invention. a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 99% of the antiemetic is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 60% of the promethazine HCl are released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 65% of the HC1 promethazine is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 70% of the promethazine HCl is released in less than 5 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP apparatus. (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm.
[0033] In some embodiments, at least about 90% to 95% of the promethazine HCl are released in less than 10 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in the present invention. a USP 1 (Basket) apparatus, for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, at least about 99% of the promethazine HCl is released in less than 15 minutes, for example, as measured by contacting the pharmaceutical composition described herein with a dissolution fluid in a USP 1 (Basket), for example, rotating at about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 rpm, as 100 rpm. In some embodiments, the pharmaceutical composition described herein is characterized in that the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1, respectively. In some embodiments, the pharmaceutical composition described herein is a capsule, comprising: a capsule layer; a plurality of first particles, characterized in that each of the first particles comprises sumatriptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients, characterized in that the plurality of first particles is surrounded by the capsule, and characterized in that the diameter of each of the first particles is from about 595 micrometers to about 1190 micrometers; and a plurality of second particles, characterized in that each of the second particles comprises promethazine or a pharmaceutically acceptable salt thereof and one or more second pharmaceutically acceptable excipients, characterized in that the plurality of second particles is surrounded by the capsule layer, and characterized in that the diameter of each of the second particles is from about 595 microns to about 1190 microns, characterized in that the weight ratio of the plurality of first particles to the plurality of second particles ranges from about 3: 1 to about 5: 1, respectively.
[0034] In some embodiments, the pharmaceutical composition described herein is stable for at least about 30 days, 60 days, 90 days, 6 months, 1 year, 18 months, 2 years, 3 years, 4 years, or 5 years. for example about 80% to 100%, as about 80%, 90%, 95% or 100% of each active pharmaceutical agent in the pharmaceutical composition are stable, for example, as measured by high performance liquid chromatography ( HPLC), as with the HPLC method of Example 5. In some embodiments, about 80% to 100% (e.g., about 90% to 100% or 95% to 100%) of the receptor agonist 5HT1B (e.g., triptan such as sumatriptan) or a pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) in the pharmaceutical composition described herein are stable for at least about 30, 60 , 90, 180, 360, 540 or 720 days, for example more than 90 days, which can be measured by HPLC, as with the method of Example 5. In some embodiments, about 80%, 85%, 90%, 95%, or 100% (e.g. 5HT1B receptor agonist (e.g., a triptan such as sumatriptan) or the pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) are stable for 30 days or more, which can be measured by HPLC As in the method of Example 5, in some embodiments, about 80% to 100% (e.g., about 90% to 100% or 95% to 100%) of the antiemetic (e.g. promethazine or a pharmaceutically acceptable salt thereof, such as promethazine hydrochloride) in the pharmaceutical composition described herein are stable for at least about 30, 60, 90, 180, 360, 540 or 720 days, for example, more than 90 days, which can be measured by HPLC, as with the method of Example 5. In some embodiments, about 80%, 85%, 90%, 95% or 100% (e.g., about 100%) of the antiemetic (e.g., promethazine or a pharmaceutically acceptable salt thereof , such as promethazine hydrochloride) are stable for 30 days or more, which can be measured by HPLC, as with the method of Example 5. Plasma concentration In some embodiments, the dosage form of the pharmaceutical composition described herein provides an effective plasma concentration of the antiemetic about 1 minute to about 20 minutes after administration, such as about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes. , 9 minutes, 10 minutes, 11 minutes, 12 minutes, 13 minutes, 14 minutes, 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 21 minutes, 22 minutes, 23 minutes, 24 minutes , 25 minutes. In some embodiments, the release occurs at substantially higher rates relative to the release rates of the triptans. Therefore, in some embodiments, after administration to a patient, the antiemetic is released or an effective plasma concentration of the antiemetic is achieved prior to release of the triptan. In some embodiments, the dosage form of the pharmaceutical composition provides an effective plasma concentration of triptan about 5 minutes to about 24 hours after administration, such as about 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1, 2 hours, 1.4 hours, 1.6 hours, 1.8 hours, 2 hours, 2.2 hours, 2.4 hours, 2.6 hours, 2.8 hours, 3 hours, 3.2 hours, 3 hours , 4 hours, 3.6 hours, 3.8 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours after administration. In some embodiments, the triptan is present at an effective plasma concentration in a patient after about 1 hour to about 24 hours or about 1 day to about 30 days, including, but not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 18, 29 or 30 days.
[0035] In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of both a triptan and an antiemetic and a polymer, wherein the pharmaceutical composition is capable of providing an effective plasma concentration of the antiemetic prior to effective plasma concentration of triptan after oral administration. In some patients, tolerance to triptans develops with continued use. In some embodiments, the amounts or release characteristics over time of one or more pharmaceutically active agents of the pharmaceutical composition are adjusted, as the pharmaceutical composition comprises a therapeutically effective amount of both a triptan and a an antiemetic. In some embodiments, the adjustments serve to relieve pain in a patient with triptan tolerance. In some embodiments, the amount of triptan is increased in the pharmaceutical composition. In some embodiments, the time release characteristics of the triptan must be adjusted by adjusting the amount of the polymer, such as a vinyl polymer or a vinyl copolymer, in the pharmaceutical composition. In some embodiments, the polymer that is fitted is a vinyl polymer, such as polyvinylpyrrolidone, or a vinyl copolymer, such as a polyvinylpyrrolidone / vinyl acetate copolymer. In some embodiments, the pain that is relieved by the adjustments is associated with a headache.
[0036] In some embodiments, the headache is a migraine or cluster headache. Therapeutic Uses In certain aspects, the present invention relates to the therapeutic use of a pharmaceutical composition, comprising a therapeutically effective amount of each of a triptan and an antiemetic, for the treatment of pain. In some embodiments, the present invention relates to the therapeutic use of a pharmaceutical composition comprising a polymer or copolymer and a therapeutically effective amount of each of a triptan and an antiemetic for the treatment of pain. In certain aspects, the present invention relates to the therapeutic use of a pharmaceutical composition which includes a plurality of first particles comprising a therapeutically effective amount of a triptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of an antiemetic or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable second excipients, the first or more pharmaceutically acceptable excipients comprising a vinyl polymer or a vinyl copolymer, for the treatment of pain. In some embodiments, the plurality of first particles and the plurality of second particles are encapsulated in separate units. In some embodiments, the separate units are capsules or sachets. In some embodiments, the capsule or sachet containing a plurality of particles is administered as described herein. In some embodiments, the capsule or pouch is opened to sprinkle the plurality of particles onto foods or soft foods and swallow them without chewing. In some embodiments, the plurality of particles is administered by an enteral feeding tube. In some embodiments, the pain is associated with headache such as chronic headache, cluster headache or migraine. In one embodiment, the migraine is accompanied by an aura. In some embodiments, migraine is accompanied by symptoms including, but not limited to, nausea, photophobia, phonophobia, or osmophobia.
[0037] In some embodiments, photophobia is characterized by light sensitivity or light hypersensitivity. In some cases, photophobia is caused by acute iritis or uveitis (internal inflammation of the eye), ocular burns, corneal abrasion, corneal ulcer, drug side effects, excessive wear of contact lenses, or mis-fitting contact lenses, eye disease, injury or infection (such as chalazion, episcleritis, glaucoma), ocular testing when the eyes have been dilated, meningitis, migraine, or recovery from the eye. In some cases, photophobia is associated with migraine. In some cases, photophobia is associated with nausea and vomiting. In some cases, photophobia is associated with nausea or vomiting. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of photophobia, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition disclosed herein is for use in the treatment of photophobia, characterized in that the treatment is preventive. In some cases, preventive treatment can reduce the frequency of migraines. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of photophobia, characterized in that the treatment is preemptive. In some cases, preemptive treatment is used when the onset of photophobia is time-limited or predictable. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of photophobia, characterized in that the treatment is acute. In some cases, the treatment makes it possible to stop or prevent the progression of photophobia. In some cases, acute treatment is initiated during an attack to relieve pain. In some cases, the pharmaceutical composition disclosed herein is for use in the preventive, acute and / or preemptive treatment of photophobia. In some embodiments, the pharmaceutical composition disclosed herein is for use in treating a headache, characterized in that the treatment is prophylactic. In some cases, the pharmaceutical composition disclosed herein is for use in treating a headache, characterized in that the treatment is preventive. In some cases, preventive treatment can reduce the frequency of migraines. In some embodiments, the pharmaceutical composition disclosed herein is for use in treating a headache, characterized in that the treatment is preemptive. In some cases, preemptive treatment is used when the onset of the headache is time-limited or predictable. In some embodiments, the pharmaceutical composition disclosed herein is for use in treating a headache, characterized in that the treatment is acute. In some cases, treatment can stop or prevent the progression of a migraine. In some cases, acute treatment is initiated during an attack to relieve pain. In some instances, the pharmaceutical composition disclosed herein is for use in the preventive, acute and / or preemptive treatment of headache. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of chronic migraine. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of migraine characterized in that the treatment is prophylactic. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of migraine characterized in that the treatment is that of acute migraine. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of migraine characterized in that the treatment is that of a chronic migraine. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of migraine with aura. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of migraine without aura. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of a cluster headache. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of nausea or vomiting. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of nausea and vomiting. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of nausea associated with headache or vomiting associated with headache. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of headache-associated nausea and headache-associated vomiting. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of nausea associated with migraine or migraine-associated vomiting. In some embodiments, the pharmaceutical composition disclosed herein is for use in the treatment of nausea associated with migraine and migraine-related vomiting. In some embodiments, the pharmaceutical composition disclosed herein (e.g., capsule) does not disintegrate completely in the mouth in the space of about 1, 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 10 minutes. In some embodiments, the pharmaceutical composition disclosed herein is not a film. In some embodiments, the pharmaceutical composition disclosed herein is not intended for oral administration. In some embodiments, the pharmaceutical composition disclosed herein (e.g., capsule) dissolves in the stomach or intestine.
[0038] In some embodiments, the subject is a mammal, i.e., a human, mouse, rat, guinea pig, dog, cat, horse, pig or primate other than a human being such as a monkey, a chimpanzee or a baboon. In some embodiments, the subject is a human being. In some embodiments, the subject being administered the pharmaceutical composition as described herein is about 55 years of age or older, about 60 years of age or older, about 65 years of age or older, or about about 70 years or older. In some embodiments, the subject to which the pharmaceutical composition described herein is administered is 18 years of age or older. In some embodiments, the subject is between 35 and 45 years old. In some embodiments, the subject to which the pharmaceutical composition described herein is administered has a history of headache. In some embodiments, the subject being administered the pharmaceutical composition described herein has a history of migraines. In some embodiments, the pharmaceutical composition described herein is administered to the patient at the time of onset of the migraine as required by the patient or as fixed and prescribed by the physician. In some embodiments, the subject to which the pharmaceutical composition described herein is administered has side effects associated with the administration of a triptan. Side effects include nausea and / or vomiting, for example, associated with migraine. In some embodiments, the pharmaceutical composition described herein reduces or avoids undesirable side effects associated with injectable or tablet triptan treatment, including flushing, sweating, vertigo, fatigue, tingling, drowsiness, dizziness, dry mouth, heartburn, abdominal pain, abdominal cramps, feeling of weakness, feeling of heat or cold, bitter taste from tablets and nasal sprays , and a local burning sensation at the injection site. In some embodiments, the pharmaceutical composition described herein is administered to a subject at a frequency of about every 12 hours to about 24 hours, about every 12 hours, or about every 24 hours. In some embodiments, the pharmaceutical composition described herein is administered to a subject at a frequency of about every 8 hours to about every 12 hours. In some embodiments, the pharmaceutical composition described herein is administered once, twice, or three times daily. In some embodiments, the pharmaceutical composition defined herein is administered no more than twice a day. In some embodiments, a second dose of the pharmaceutical composition defined herein is administered only if some response to the first dose has been observed. In some embodiments, doses after a first dose of the pharmaceutical composition defined herein are spaced at least 2 hours apart. In certain embodiments, the maximum dose of the pharmaceutical composition defined herein over a period of 24 hours does not exceed 200 mg. In certain embodiments, a maximum single dose of the pharmaceutical composition defined herein does not exceed 50 mg in patients with mild to moderate hepatic impairment. In some embodiments, the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered to a subject from about every 12 hours to about every 24 hours, about every 12 hours, or approximately every 24 hours. In some embodiments, the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered to a subject from about every 8 hours to about every 12 hours. In some embodiments, the pharmaceutical composition herein defined comprising sumatriptan succinate and promethazine hydrochloride is administered once, twice, or three times daily. In some embodiments, the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered no more than twice daily. In some embodiments, a second dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride is administered only if some response to the first dose has been observed. In some embodiments, doses after a first dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride are spaced at least 2 hours apart. In some embodiments, the maximum dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride over a period of 24 hours does not exceed 200 mg. In some embodiments, a maximum single dose of the pharmaceutical composition defined herein comprising sumatriptan succinate and promethazine hydrochloride does not exceed 50 mg in patients with mild to moderate hepatic impairment. In some embodiments, the frequency of the assay is determined or evaluated by a professional assessing the subject, the severity of the condition to be treated, and the expected duration of treatment.
[0039] In some aspects, the present invention relates to the therapeutic use of a pharmaceutical composition comprising a therapeutically effective amount of a triptan; an antiemetic; and a vinyl polymer for the treatment of pain. In some embodiments, the pain is a headache. In some embodiments, the headache is a migraine. In some embodiments, headache is a cluster headache. In some embodiments, the method is also useful for treating photophobia. In some embodiments, photophobia is associated with migraine. In some embodiments, the therapeutic use for the treatment of a headache comprises: administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt of this one ; promethazine or a pharmaceutically acceptable salt thereof; and a vinyl polymer. In some embodiments, the vinyl polymer is polyvinylpyrrolidone. In some embodiments, the vinyl polymer is polyvinylpolypyrrolidone. In some embodiments, the present invention relates to the therapeutic use of a pharmaceutical composition comprising: a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof; promethazine or a pharmaceutically acceptable salt thereof; and a vinyl copolymer, for the treatment of a headache. In one embodiment, the vinyl copolymer is a polyvinylpyrrolidone / vinyl acetate copolymer or a polyvinylpyrrolidone / polyvinyl acetate copolymer. In some embodiments the vinyl copolymer is one. copolymer of vinylpolypyrrolidone / vinyl acetate. In some embodiments, the therapeutic use for treating a headache comprises administering to a subject in need thereof a pharmaceutical composition comprising: a plurality of first particles comprising a therapeutically effective amount of a triptan and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of an antiemetic and one or more second pharmaceutically acceptable excipients; Wherein the first or more pharmaceutically acceptable excipients comprise a vinyl polymer or a vinyl copolymer. In one embodiment, the headache is a migraine. In some embodiments, the headache is a cluster headache. In some embodiments, the present invention relates to the therapeutic use of a pharmaceutical composition comprising: a plurality of first particles comprising a therapeutically effective amount of sumatriptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients; and a plurality of second particles comprising a therapeutically effective amount of promethazine or a pharmaceutically acceptable salt thereof and one or more second pharmaceutically acceptable excipients; wherein the first or more pharmaceutically acceptable excipients comprise polyvinylpyrrolidone, for the treatment of a headache. In some embodiments, the therapeutic use for the treatment of a headache comprises administering to a subject in need thereof a pharmaceutical composition comprising: a plurality of first particles comprising a therapeutically effective amount of sumatriptan succinate polyvinylpyrrolidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and talc; and a plurality of second particles comprising a therapeutically effective amount of promethazine hydrochloride, microcrystalline cellulose and croscarmellose sodium.
[0040] In certain embodiments, the therapeutic use for the treatment of a headache comprises administering to a subject in need thereof a pharmaceutical composition comprising: a plurality of first particles comprising from about 84 mg to about 126 mg of sumatriptan succinate, from about 1.05 mg to about 10.5 mg of polyvinylpyrrolidone, from about 42 mg to about 126 mg of microcrystalline cellulose, from about 1.05 mg to about 10.5 mg of croscarmellose sodium, from about 0.525 mg to about 10.5 mg of magnesium stearate, and from about 2.1 mg to about 10.5 mg of talc; and a plurality of second particles comprising from about 20 mg to about 30 mg of promethazine hydrochloride, from about 10 mg to about 30 mg of microcrystalline cellulose, and from about 0.25 mg to about 2.5 mg of croscarmellose sodium. In some embodiments, the therapeutic use for the treatment of a headache comprises administering to a subject in need thereof a pharmaceutical composition comprising: a plurality of first particles comprising about 126 mg sumatriptan succinate, about 4.2 mg of polyvinylpyrrolidone, about 72.45 mg of microcrystalline cellulose, about 4.2 mg of croscarmellose sodium, about 1.05 mg of magnesium stearate, and about 2.1 mg of talc; and a plurality of second particles comprising about 25 mg of promethazine hydrochloride, about 24 mg of microcrystalline cellulose, and about 1 mg of croscarmellose sodium.
[0041] Manufacturing Methods In some embodiments, there is provided a method of making the pharmaceutical composition as described herein. In some embodiments, the pharmaceutical composition as described herein is prepared by standard techniques and using equipment known to those skilled in the art. In some embodiments, the plurality of particles comprising a pharmaceutically active ingredient such as triptan or antiemetic is prepared by a treatment method including wet granulation, extrusion and spheronization. In some embodiments, a triptan (eg, sumatriptan or other triptans disclosed herein) or an antiemetic (eg, promethazine) and one or more pharmaceutically acceptable second excipients are sieved by means of a mesh sieves adapted and introduced into the container of a granulator. In some embodiments, the triptan or antiemetic and one or more pharmaceutically acceptable second excipients are mixed in a high shear granulator at a suitable rate for a suitable period of time. In some embodiments, a binder solution is prepared by dissolving a polymer such as polyvinylpyrrolidone in water, and then mixed for a period of time in a stirring assembly.
[0042] In some embodiments, the granulation is carried out in accordance with fixed parameters such as the speed of the stirring vanes, the chopper speed and the rate of the binder / water solution. In some embodiments, the speed of the agitator blades is 300-400 rpm, the chopper speed is 700750 rpm and the flow rate of the binder / water solution is 40 g / minute. In some embodiments, the wet mass is loaded onto a multi-granulator type extruder such as an LCI Multi-granulator MG-55 extruder equipped with a sieve of appropriate size and set at a speed appropriate, for example, 50 rpm, 60 rpm, or 70 rpm. In some embodiments, the resulting extrudates are loaded into a spheronizer such as an LCI Marumerizer QJ-230T spheronizer equipped with a 2mm cross-cutter disk or other appropriately sized disk. In some embodiments, the speed of the spheronizer is between 1100 and 1700 rpm. In some embodiments, the spheronization time is 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds, 70 seconds, 80 seconds, 90 seconds, 100 seconds, 110 seconds, or 120 seconds. In some embodiments, the particles, for example the spherules / beads, obtained are transferred to a Vector fluidized bed dryer. In some embodiments, the dryer has predefined drying parameters such as but not limited to an inlet temperature of 55 to 65 ° C or 70 ° C, an exit temperature of 20 to 30 ° C. or 30 and 40 ° C, a product temperature between 20 and 45 ° C or 21 and 42 ° C, a total time of 45 to 75 minutes, a fan at 180 to 7401pm (liters per minute). In certain embodiments, the values of the loss on drying (LOD) following the drying step are between 1.5 and 3%. In some embodiments, the particles, e.g., spherules / beads, are sieved through a set of # 16 to # 30 mesh sieves to further determine the particle size range. In some embodiments, the plurality of particles are mixed with talc or a coating material. In one example, the mixing is done by inversion or by rapid rotation. In some embodiments, the plurality of particles comprising a pharmaceutically active ingredient such as a triptan or antiemetic and a pharmaceutically acceptable excipient are weighed and combined in a separate unit at predetermined weight ratios. In some aspects, there is provided a method of making a pharmaceutical composition which comprises: producing a plurality of first particles by wet granulating a mixture of triptan or a pharmaceutically acceptable salt of it and one or more pharmaceutically acceptable excipients, adding a binder solution containing at least one polymer to the mixture at a suitable time and in an amount sufficient to form granules, forming extrudates of a mass Wet-containing mixture and binder solution, and subjecting the extrudates to spheronization parameters sufficient in disk diameter, velocity, and time to produce particles (e.g., spherules or beads) ; and producing a plurality of second particles by wet granulation on a mixture of the antiemetic or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, the formation of extrudates of a wet mass containing the mixture and a binder solution, and subjecting the extrudates to spheronization parameters sufficient in disk diameter, velocity, and time to produce particles (e.g. spherules or balls). In some embodiments, the pharmaceutical composition is provided in the form of a capsule, which capsule comprises a plurality of first particles and a plurality of second particles, wherein each particle comprises one or more pharmaceutically active agents disclosed herein. In some embodiments, the capsule comprises a plurality of first particles comprising sumatriptan succinate and a plurality of second particles comprising promethazine hydrochloride. Stability In one aspect, the pharmaceutical composition disclosed herein is stable for at least about 30 days, 60 days, 90 days, 6 months, 1 year, 18 months, 2 years, 3 years, 4 years, or 5 years. for example about 80% to 100% such that about 80%, 90%, 95%, or 100% of each active pharmaceutical agent of the pharmaceutical composition is stable, for example, from measurements made by chromatography in high performance liquid phase (HPLC) such as the HPLC method of Example 5. In some embodiments, about 80% to 100% (for example, about 90% to 100% or 95% to 100%). ) of the 5HT1B receptor agonist (e.g., triptan such as sumatriptan) or a pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) in the pharmaceutical composition disclosed herein are stable for at least about 30, 60, 90, 180, 360, 540, or 720 days, for example, for more than 90 days, which can be measured by high performance liquid chromatography (HPLC) such as the HPLC method of Example 5. In some embodiments, about 80%, 85%, 90%, 95%, or 100% (e.g., about 95%) of the 5HI'1B receptor agonist (e.g., triptan such as sumatriptan) or the pharmaceutically acceptable salt thereof (e.g., succinate sumatriptan) are stable for 30 days or more, which can be measured by high performance liquid chromatography (HPLC) such as the HPLC method of Example 5. In some embodiments, the 5HT1B receptor agonist (e.g., a triptan such as sumatriptan) or the pharmaceutically acceptable salt thereof (e.g., sumatriptan succinate) comprises a coating material. In some embodiments, about 80% to 100% (e.g., about 90% to 100% or 95% to 100%) of the antiemetic (e.g., promethazine or a pharmaceutically acceptable salt thereof such as promethazine hydrochloride) in the pharmaceutical composition disclosed herein are stable for at least about 30, 60, 90, 180, 360, 540, or 720 days, for example for more than 90 days, which can be measured by high performance liquid chromatography (HPLC) such as the HPLC method of Example 5. In some embodiments, about 80%, 85%, 90%, 95%, or 100% (e.g., about 100 %) of the antiemetic (eg, promethazine or a pharmaceutically acceptable salt thereof such as promethazine hydrochloride) are stable for 30 days or more, which can be measured by high performance liquid chromatography ( HPLC) such as the HPLC process of the Example 5. In some embodiments, the antiemetic (eg, promethazine or a pharmaceutically acceptable salt thereof such as promethazine hydrochloride) comprises a coating material. In some embodiments, the coating material of the 5HTIB receptor agonist and / or the antiemetic comprises polyvinyl alcohol, cellulose acetate phthalate, polyvinyl acetate phthalate, a copolymer of methacrylic acid, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, shellac gum, sodium alginate, zein, or mixtures thereof, e.g. polyvinyl alcohol. In some embodiments, the coating material of the 5HT1B receptor agonist and / or the antiemetic is polyvinyl alcohol. In some embodiments, the pharmaceutical composition disclosed herein is characterized in that the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1, respectively. In some embodiments, the pharmaceutical composition disclosed herein is a capsule, comprising: a capsule layer; a plurality of first particles, characterized in that each of the first particles comprises sumatriptan or a pharmaceutically acceptable salt thereof and one or more first pharmaceutically acceptable excipients, characterized in that the plurality of first particles is surrounded by the layer capsule, and characterized in that the diameter of each of the first particles is from about 595 micrometers to about 1190 micrometers; and a plurality of second particles, characterized in that each of the second particles comprises promethazine or a pharmaceutically acceptable salt thereof and one or more second pharmaceutically acceptable excipients, characterized in that the plurality of second particles is surrounded by the capsule layer, and characterized in that the diameter of each of the second particles is from about 595 microns to about 1190 microns, characterized in that the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1, respectively. In some embodiments, the pharmaceutical composition disclosed herein is a rapid release pharmaceutical composition, characterized in that at least about 80% of both sumatriptan or a pharmaceutically acceptable salt thereof and the Promethazine or a pharmaceutically acceptable salt thereof are released within about 15 minutes from the measurements made by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 apparatus (Basket ) rotating at 100 rpm. In some embodiments, the pharmaceutical composition disclosed herein is a rapid release pharmaceutical composition, comprising: a plurality of first particles, characterized in that each of the first particles comprises sumatriptan or a pharmaceutically acceptable salt thereof ; and a plurality of second particles, characterized in that each of the second particles comprises promethazine or a pharmaceutically acceptable salt thereof, characterized in that at least about 80% of both sumatriptan or a salt of pharmaceutically acceptable salt thereof and promethazine or a pharmaceutically acceptable salt thereof are released within about 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid 5 in a USP 1 apparatus (Basket) rotating at 100 rpm.
[0043] EXAMPLES The following examples are presented by way of illustration and without limitation.
[0044] Example 1. Preparation of Formulation I Sumatriptan particles and promethazine particles were generated and then encapsulated together in one capsule. The formulation of sumatriptan 90 mg particles was performed as described below. A list of ingredients is provided in Table 1. Each pharmaceutically active ingredient (API) was spheronized into separate particles and filled into a capsule in the appropriate proportions. Table 1. Sumatriptan particle formulation Ingredients Percent weight / weight mg / dose Quantity Lot (g) sumatriptan succinate equivalent to sumatriptan 90 mg 60.00 126.00 180.00 Microcrystalline Cellulose, NF, Ph. Eur., JP (Avicel PH101) 34.50 72.45 103.50 Polyvinylpyrrolidone (Plasdone K29 / 32) 2.00 4.20 6.00 Croscarmellose sodium, NF, Ph. Eur., JP (Ac-Di-Sol) 2.00 4.20 6.00 Magnesium stearate, NF Kosher Passover (Hyqual 5712) 0.50 1.05 1.50 Talc 1.00 2.10 3.00 Purified water * qs qs qs Total 210.00 300.00 sumatriptan, microcrystalline cellulose, croscarmellose sodium and magnesium stearate were passed through a # 20 mesh screen and then introduced into the bowl of the high shear mixing mixer mixer. The ingredients were mixed in the high shear granulator at 250 rpm for 5 minutes and the drying (LOD) loss of the dried mixture was measured (2.303%). A binder solution was prepared by dissolving polyvinylpyrrolidone (6 g) in purified water (24 g) and then mixing for 45 minutes using a suitable kneading assembly. Granulation was performed using the following parameters: 11 granulator bowl size, 300 rpm stirring pad speed, 700 rpm mincer speed, and binder / water solution flow rate. 40 g / minute. A total of 30 g of binder solution and 128 g of water was added to the granulation bowl and mixed for 3 min. Mixing of the wet mass was carried out for 2 minutes after the addition of water using a stirring paddle speed of 300 rpm and a chopper speed of 700 rpm. The wet mass was loaded onto the LCI Multi-granulator MG-55 extruder equipped with a 1.0 mm sieve at a speed of 65 rpm. The resulting extrudates were loaded into the LCI Marumerizer QJ-230T spheronizer equipped with a 2mm cross-cutter. The following parameters were used for spheronization: 2 mm disk, 1200 rpm speed, and 30 second spheronization time. The resulting particles were transferred to a Vector fluidized bed dryer for drying in 2 sublots. The drying parameters were as follows: inlet temperature 70 ° C, outlet temperature 20 ° C to 30 ° C, fan (%) 180 to 740 lpm, total time 45 minutes, loss on drying (LOD ) obtained after drying for sublot 1 = 1.834%, loss on drying (LOD) obtained after drying for sublot 2: 1.979%. The particles were then sieved through a set of # 16 and # 30 nested sieves to determine particle size range. The formulation of the 25 mg promethazine hydrochloride particles was carried out as described below. A list of ingredients is provided in Table 2. Table 2. Promethazine Hydrochloride Particle Formulation Ingredients Percent weight / weight mg / dose Quantity Lot (g) Promethazine Hydrochloride 50.00 25.00 150.00 Microcrystalline Cellulose, NF, Ph. Eur., JP (Avicel PU101) 48.00 24.00 144.00 3025425 94 Croscarmellose sodium, NF, Ph. Eur., JP (Ac-Di-Sol) 2.00 1.00 6.00 Purified water * qs qs qs Total 100.00 50 300 La, promethazine, microcrystalline cellulose and croscarmelose sodium were passed through a # 20 mesh screen and then introduced into the bowl of the high shear mixing mixer mixer. The ingredients were mixed in the high shear granulator at 250 rpm for 5 minutes and the loss on drying (LOD) of the dried mixture was measured (2.831%). Granulation was performed using purified water. The granulation parameters were: granulator bowl size 21, stirring paddle speed 400 rpm, chopper speed 750 rpm, and binder / water solution flow rate 40 g / min. minute.
[0045] A total of 75 g of water was added to the granulation bowl for 1 min 55 sec. Mixing of the wet mass was carried out for 15 seconds after the addition of water using a stirring paddle speed of 400 rpm and a chopper speed of 750 rpm. The wet mass was loaded onto the LCI Multi-granulator MG-55 extruder equipped with a 1.0 mm sieve at a speed of 65 rpm. The resulting extrudates were loaded into the LCI Marumerizer QJ-230T spheronizer equipped with a 2mm cross-cutter. The following parameters were used for spheronization: 2 mm disk, 1600 rpm speed, and 2 minute spheronization time. The resulting particles were transferred to a Vector 20 fluid bed dryer for drying in 2 sublots. The drying parameters were as follows: inlet temperature 555-65 ° C, outlet temperature 27-40 ° C, fan (%) 45-75 lpm, total time 50 minutes, loss on drying ( LOD) obtained after drying = 2.80434%. The particles obtained from the above steps were sieved through a set of # 16 and # 30 nested sieves to determine the particle size range. The formulation of capsules comprising sumatriptan and promethazine was performed as described in Table 3 and presented in detail below.
[0046] 3025425 Table 3 Formulation and encapsulation - 100 capsules Ingredients Manufacturer Date Exp Percent weight / weight mg / capsule Quantity Lot (g) Lot number Particles of Xcelience NA 79.81 207.90 20.79 sumatriptan N2999-43 Talc Imerys 0, 7981 2.08 0.208 H06033 Total 298.98 21.0 Promethazine particles Xcelience NA 19.20 50.00 5.00 N2999-76 Talc Imerys 0.192 0.5 0.05 H06033 Total 50.5 5.05 Capsules, Capsules ConiSnap (CS) opaque white gelatin, Size 0 Capsugel N / A 1 capsule 100 90177971 capsules Total 260.48 26.05 Sumatriptan and talc were manually mixed in a rapid inversion / rotation amber glass bottle. Promethazine and talc were manually mixed in an amber glass bottle by inversion / rapid rotation. The average weight of the 100 empty capsules obtained was 92.85 mg. 210.0 mg (200 to 220 mg) of sumatriptan particles and 50.0 mg (47.5 to 52.5 mg) of promethazine particles were weighed manually and introduced into each individual capsule. Given the static particles, a filter funnel was used to facilitate filling. The capsules were packaged in opaque high density polyethylene (HDPE) bottles. Encapsulation was carried out under yellow light. Example 2. Preparation of Formulation II Sumatriptan particles and promethazine particles were generated and then encapsulated together in a capsule. The sumatriptan 90 mg coated particle formulation was performed as described below. A list of ingredients is provided in Table 4. Each pharmaceutically active ingredient (API) was spheronized into separate particles. Table 4. Sumatriptan Particle Formulation Ingredients Percent Weight / Weight Quantity Lot (g) Sumatriptan Succinate USP 60.61 1827.2 Microcrystalline Cellulose, NF (AVICEL PH101) 34.85 1050.7 Croscarmellose Sodium, NF (AC-DI) - SOL) 2.02 60.9 Povidone (Plasdone K29 / 32) 2.02 60.9 Magnesium stearate, NF (Kosher Passover Hyqual) 0.5 15.4 Sterile water for irrigation, USP qs 1000.0 Total 100 The sumatriptan succinate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate were passed through a # 20 mesh screen and then introduced into the bowl of the high shear mixing mixer mixer. The ingredients were mixed in the high shear granulator at about 150 rpm for 5 minutes. The binder solution was prepared by dissolving povidone (2.02 g) in sterile water (246.3 g) and then mixing using a suitable mixing set. Granulation was performed using the following parameters: 300 rpm stirring pad speed, 700 rpm chopper speed, and 80 g / minute binder / water solution flow rate. The binder solution and water were added to the granulation bowl and mixed. The wet mass was loaded onto the LCI Multi-granulator MG-55 extruder equipped with a sieve of 1.0 mm size at a speed of 65 rpm. The resulting extrudates were loaded into the LCI Marumerizer QJ-230T spheronizer equipped with a 2mm cross-cutter. The following parameters were used for spheronization: 2 mm disk, 1200 rpm speed, and 30 second spheronization time. The resulting particles were transferred to a Vector fluidized bed dryer for batch drying as needed. The drying parameters were as follows: inlet temperature 60 ° C. Drying was performed to a Desiccation Loss Target Percent (LOD) of ± 1% on a Loss of Dryness Test (LOD) recorded after granulation. The particles were then sieved through a set of # 16 and # 30 nested sieves to determine particle size range.
[0047] The amounts of material for the coated particles generated are shown in Table 5. To generate the coating solution, sterile and irrigation water was mixed in a blender with a clear film coating system "OPADRY II Complete Film". 85F19250 Clear Coating System. After the entire "OPADRY II Complete Film Coating System 85F19250 Clear" clear film coating system was mixed, the speed of the mixer was reduced and mixing was continued for 45 minutes. A spray nozzle calibrated at a spray rate of 1.0 g / min / kg was used to spray the coating solution onto the particles. The air pressure in the nozzle was set to a target value of 0.7 bar. Suction and extraction fans were used with an inlet air temperature of 60 to 80 ° C. The coating criterion was a sufficient application to give the particles a weight gain of 2.0%. Table 5. Formulation of Coated Particles - Target Weight Gain 2.0% Ingredients Concentration (Percent weight / weight) Amount / Coated Particle (mg) Amount / Lot (g) Sumatriptan 90 mg, Particles 98.04 207.90 3014 , 9 "OPADRY II Complete Film Coating System 85F19250 Clear" Clear Film System 1.96 4.158 60.3 Sterile Water for Irrigation, USP N / AN / A 1447.2 Total 100.0 212.06 3014.9 3025425 98 Particulate Matter The formulation of promethazine hydrochloride coated particles 25 mg was performed as described below. A list of ingredients is provided in Table 6. Table 6. Formulation of Promethazine Particles Ingredients% w / w Quantity Lot (g) Promethazine Hydrochloride 50.0 1516.8 Microcrystalline Cellulose, NF (AVICEL PH101) 48.0 1456.1 Croscarmellose sodium, NF (AC-DISOL) 2.0 60.7 Sterile water for irrigation, USP qs 1000.0 Total 100.00 3033.6 Promethazine hydrochloride, microcrystalline cellulose and croscarmellose sodium were passed in a # 20 mesh screen and then introduced into the bowl of the high shear mixer granulator mixer. The ingredients were mixed in the high shear granulator at about 150 rpm for 5 minutes. 707.8 g of sterile water for irrigation were prepared. Granulation was performed using the following parameters: 400 rpm stirring pad speed, 750 rpm chopper speed, and 70 g / minute binder / water solution rate. Sterile water was added to the granulation bowl and mixed. The wet mass was loaded onto the LCI Multi-granulator MG-55 extruder equipped with a 1.0 mm sieve at a speed of 65 rpm. The resulting extrudates were loaded into the LCI Marumerizer QJ-230T spheronizer equipped with a 2mm cross-cutter. The following parameters were used for spheronization: 2 mm disk, 1600 rpm speed, and 2 minute spheronization time. The resulting particles were transferred to a Vector fluidized bed dryer for batch drying as needed. The drying parameters were as follows: inlet temperature 60 ° C. Drying was performed to a Desiccation Loss Target Percent (LOD) of ± 1% on a Loss of Dryness Test (LOD) recorded after granulation. The particles were then sieved through a set of # 16 and # 30 nested sieves to determine the particle size range. The amounts of material for the coated particles generated are shown in Table 7. To generate the coating solution, sterile and irrigation water was mixed in a blender with a clear film coating system "OPADRY II Complete Film Coating System 85F19250 Clear ". After the entire "OPADRY II Complete Film Coating System 85F19250 Clear" clear film coating system was mixed, the speed of the mixer was reduced and mixing was continued for 45 minutes. A spray nozzle calibrated at a spray rate of 1.7 g / min was used to spray the coating solution onto the particles. The air pressure in the nozzle was set to a target value of 0.7 bar. Suction and extraction fans were used with an inlet air temperature of 60 to 80 ° C. The coating criterion was a sufficient application to give the particles a weight gain of 2.0%. Table 7. Formulation of Coated Particles - Target Weight Gain 2.0% Ingredients Concentration (wt / wt%) Qty / Coated Particle (mg) Qty / Lot (g) Promethazine Hydrochloride 25 mg, Particles 98.04 50, 0 3033.6 Clear Film System OPADRY II Complete Film Coating 85F19250 Clear 1.96 1.00 60.7 Sterile Water for Irrigation, USP N / AN / A 1456.1 Total 100.0 51.0 3094.3 20 The formulation of capsules comprising sumatriptan and promethazine was performed as described in Table 8 and presented in detail below.
[0048] 3025425 Table 8 Formulation and Encapsulation - 100 Capsules Ingredients Manufacturer% w / w mg / capsule Qty Lot (g) Lot Number Particles of Xcelience sumatriptan 80.6% 212.06 556.7 IP00048 Xcelience Promethazine Particles 19.4% 51 , 0 133.9 1P00047 Total 263.06 Capsules, Gelatin capsules 264.9 Capsugel 96.0 white N / A (2500 opaque Con-RM00895 (1 capsule) capsules} Snap (CS), Size 0 Total 359.06 955.5 Table 8. The batch weights for sumatriptan and promethazine particles showed an approximate excess of 5% to yield 2500 acceptable capsules based on a theoretical lot size of 2625 capsules. 9 g of capsules showed an approximate excess of 5% to cover potential losses during manufacture 212.06 mg sumatriptan-coated particles 90 mg (range 201.5 to 222.6 mg ± 5% ) were introduced in size 0 capsules. 25 mg (with a range of 48.5 to 53.5 mg ± 5%) were introduced into size 0 capsules. 51.0 mg of 25 mg promethazine hydrochloride coated particles were coated. opaque high density polyethylene (HDPE) bottles. EXAMPLE 3 Dissolution measurements by the USP method in a basket apparatus Dissolution studies were carried out to measure the dissolution rates of the active substances. Dissolution tests were performed using a USP 1 (Basket Maker) apparatus with a dissolving fluid of 900 ml of 0.01 N hydrochloric acid deaerated at 37.0 ± 0.5 ° C. Dissolution samples were analyzed by high performance liquid chromatography (HPLC). The chromatographs for the dissolution medium, standard samples, and test sample are as shown in Figures 1, 2A-2B, and 3A-3B, respectively. The dissolution results for Formulation I and Formulation II are shown in Figure 4 and Figure 5, respectively. The dissolution medium of 0.01N HCl was prepared by mixing well of the order of 5 ml of concentrated hydrochloric acid (12N) with 6 L of water. The standard promethazine hydrochloride stock solution was prepared by adding approximately 30 ml of dissolution medium to 14.0 mg of promethazine hydrochloride (USP reference standard) in a 50 ml volumetric flask, diluted to volume with medium. of dissolution, and well mixed. The standard working solution was prepared by first mixing 14.0 mg of sumatriptan succinate (USP reference standard) with approximately 60 ml of dissolution medium and then pipetting 10.0 ml of hydrochloride stock solution. promethazine in the sumatriptan succinate solution prepared. The resulting solution was diluted to volume with the dissolution medium and mixed well. The nominal concentration of sumatriptan was 0.10 mg / mL (free base form) and that of promethazine hydrochloride was 0.028 mg / mL in sumatriptan succinate and promethazine hydrochloride A and B working standards. Since the wording of the sumatriptan label mentions a free base, the standard final concentration has therefore been converted accordingly with a multiplication by the conversion factor of a salt to a base: (295.40 / 413.49). The dissolution apparatus used was a USP I (Basket) apparatus with a speed of 100 rpm at 37.0 ° C ± 0.5 ° C. The dissolution medium (900 ml) was sparged with helium for at least 10 minutes. N = 6 samples were tested, one per ballast system and one per tank. At each time point of 5, 15, 30, and 45 minutes, a 5 ml aliquot from each dissolution vessel was filtered through a 0.45 innon nylon membrane syringe filter prior to analysis. high performance liquid chromatography (HPLC). Conditions for High Performance Liquid Chromatography (HPLC): Flow Rate: 1.0 ml / min; Injection volume: 5 Ill; Column temperature: 40 ° C; Wavelengths: 254 nm; Transit time: 7 minutes; Mobile phase A consisted of a mixture of 0.2% TFA in water, which was prepared by mixing well 2.0 ml of trifluoroacetic acid with 11 ml of water. Mobile phase B: 0.2% TFA in acetonitrile, which was prepared by mixing well 2.0 ml of trifluoroacetic acid with 11 of acetonitrile; and the gradient used was as shown below in Table 9. Table 9 Time (minutes)% A% B (ACN) (Buffer) Initial 90 10 4.0 40 60 4.1 90 10 7.0 90 The approximate retention time for sumatriptan and promethazine was 2.8 minutes and 4.8 minutes respectively. Calculations Percent release calculations were performed using the following formulas. Percent release of promethazine (Profile):% released =, R r x100 (R x Cstd X Vd L t X Cstd X Vi i = 1 , Rs Where: Ru = Area of promethazine peak in sample preparation RS = Mean area of promethazine peak in all working standard injections A Cstd = Working standard A - Promethazine hydrochloride concentration, adjusted for purity (mg / m1) Vd = Volume of dissolution medium at the time of rise (ml) R, = Area of the promethazine peak obtained from the sample preparation at the different rise points V, = Volume of the sample taken from the tank at the point of rise (ml) LC = Label of the sample (25 mg or 25000 mg) 100 = Percent conversion Sumatriptan percent release (Profile): 3025425 103% released = (R n (R, 1 xCstaxVd -E x C std X Vi XX 1 00. ' .Jt.,, I = l Rs) LC Where: Ru = Area of Sumatriptan Peak in Sample Preparation RS = Mean Area of Suma Peak triptan in all working standard injections A Cstd = Working standard A - Concentration of sumatriptan, adjusted succinate for purity and conversion to free base (μg / ml) Vd = Volume of dissolution medium at the time of rise (ml ) Ri = Area of sumatriptan peak obtained from the sample preparation at different rise points Vi = Volume of the sample taken from the tank at the point of rise (ml) LC = Labeling of the label (90 mg or 90000 mg) 100 = Percentage conversion Table 10. Formulation I dissolution measurements performed with a USP 1 (Cart) apparatus at a speed of 100 rpm. See also Figure 4. Minutes 5 10 15 20 45 60% dissolution of sumatriptan succinate 56 88 99 99 100 100% dissolution of promethazine hydrochloride 61 93 99 99 99 99 Tables 11 and 12. Dissolution measures of formulation II performed with a USP 1 (Basket) apparatus at a speed of 100 rpm. See also Figure 5.
[0049] Table 11. Percent Dissolving Compound: Promethazine Column: A1100 DAD Au Chl Bath Vat Injection 5.0 min 15.0 min 30.0 min 45.0 min 1 A 1 1 64.14 101.57 102.40 102.26 2 A 2 1 68.86 103.65 104.21 104.06 3 A 3 1 51.79 100.02 101.14 101.14 3025425 104 4 A 4 1 57.94 100.55 101.85 101.66 5 A 5 1 72.94 98.05 98.39 98.27 6 A 6 1 63.54 101.20 102.40 102.15 Average A 63.20 100.84 101.73 101.59 Difference - Relative type in% 11.961 1.831 1.893 1.873 Table 12. Percent Dissolving Compound: Sumatriptan Column: A1100 DAD Au Chl Bath Tank Injection 5.0 min 15.0 min 30.0 min 45.0 min 1 A 1 1 75 , 96 98.80 99.05 98.84 2 A 2 1 76.01 98.52 98.74 98.62 3 A 3 1 62.76 99.76 100.89 100.99 4 A 4 1 70.64 102.00 102.54 102.11 5 A 5 1 82.71 98.89 99.17 98.97 6 A 6 1 70.25 100.15 101.36 100.97 Average A 73.06 99.69 100 , 29 100.08 Relative standard deviation in% 9.284 1.294 1.531 1.460 Example 4. Capsules Appropriate capsule designs for containing compositions The pharmaceutical compositions disclosed herein are shown in Figures 6 and 7. For the capsule shown in Figure 7, each capsule weighs approximately 96 ± 6 mg. The characteristics of this capsule are presented in detail in Table 13.
[0050] Table 13. Approximate capacity of each capsule Volume of capsule: 0.68 ml Density of powder: Amount in capsule: 3025425 0.6 g / ml 408 mg 0.8 g / ml 544 mg 1.0 g / ml m1 680 mg 1.2 g / m1 816 mg In the case of the capsule of Figure 6, the approximate lengths of the parts of the capsule are as follows: body: 0.726 ± 0.018 inches or 18.44 ± 0.46 mm; and cuff: 0.422 ± 0.018 inches or 10.72 ± 0.46 mm. The approximate outer diameter of the body is: 0.289 ± 0.002 inches or 7.34 ± 0.06 mm; and for the cap: 0.300 ± 0.002 inches or 7.61 ± 0.06 mm. The approximate total length of the closed capsule is 0.854 ± 0.012 inches or 21.7 ± 0.3 mm. Example 5. Stability Study 10 Formulation I and Formulation II were examined for stability over time ( T), at initial reading and at one month, under two different environmental conditions: 40 ° C and 75% ambient humidity (RH) or 25 ° C and 60% ambient humidity (RH). The samples were then analyzed by high performance liquid chromatography (HPLC) under the following conditions: HPLC system 15 (Agilent or Waters) equipped with a diode array detector (DAD) or photodiode array (PDA) with an analytical column Phenomenex Luna C18 (2), 51am, 4.6 x 250 mm; Mobile phase A: 24 mM sodium phosphate buffer solution, pH 4.0 - (11); Mobile phase B: 100% acetonitrile - (11); Flow rate: 0.8 ml / min; Injection volume: 5; Column temperature: 45 ° C; Sample temperature: 5 ° C; Wavelength: 228 nm (for sumatriptan and its related substances); 254 nm (for promethazine and its related substances); Time of passage: 50 minutes; Needle wash: 50/50 Water / Acetonitrile (1 cycle). The elution conditions are shown in Table 14. Table 14. Elution gradient Time (minutes)% A% B Initial 95 5 20 60 40 28 10 90 3025425 106 42 10 90 43 95 5 50 95 5 Calculations Test - Percentage by label label: A sample x DX 100 C STD X% Label Label = A STD LC x N 1 5 Where: Asampie = Peak Promethazine or Sumatriptan Area in Sample Preparation AsTD = Mean peak area of promethazine or sumatriptan in all working standard injections A CSTD = Concentration of standard A of promethazine hydrochloride and sumatriptan (mg / m1), including purity and conversion to free base (Sumatriptan only ) Nc = Number of capsules used LC = Label name: 90 mg (Sumatriptan) or 25 mg (Promethazine hydrochloride) D = Dilution factor 100 = Percentage conversion% Range for related substances: A RI% Aire = A Main + A Sum RS Where: ARS Area of the related substance peak AMai n = Area of promethazine peak or sumatriptan in sample preparation ASum RI = Sum of all associated substance areas lower bound of quantification (LOQ) in sample prep * 100 = Percentage conversion X100 3025425 107 * Peaks between 0 and 17 minutes were considered associated with sumatriptan. Peaks between 17 and 40 minutes were considered associated with promethazine.
[0051] Test Results The results of the stability studies of Formulation I and Formulation II are shown in Table 15, below. Table 15. Concentrations of sumatriptan and promethazine hydrochloride measured in a high-performance liquid chromatography (HPLC) test against their respective standards. Initial time point T = 1M T = 1M Condition T = 0 40 ° C / 75% RH 25 ° C / 60% RH Formulation I Sumatriptan 102.4 92.0 90.4 Promethazine Hydrochloride 98.7 93.5 90.0 Formulation II Sumatriptan 101.1 95.4 100.4 Promethazine Hydrochloride 102 Example 6. Clinical Study of Formulation II A clinical study will be conducted to evaluate the pharmacokinetics of Formulation II. In order to obtain controlled results, the study will compare data from subjects treated with formulation II to data obtained in subjects treated with control products. As treatment progresses, additional observations, in addition to pharmacokinetic analysis, should be considered. Additional categories of observations to be considered include, but are not limited to, safety of use, correlations with predispositions (genetic or otherwise) of patients, and results in terms of efficacy. The study will be a crossover study of three, single-dose, open-label, randomized, three-period, regimens in which healthy adult subjects receive a single dose of Formulation II (sumatriptan 90 mg succinate capsule / promethazine hydrochloride). 25 mg) over a period of time, a single single dose in the form of 100 mg tablet of IMITREX (sumatriptan succinate) over a period, and a single single dose in the form of a hydrochloride tablet. Promethazine 25 mg over a period, on an empty stomach. More specifically, subjects will receive each of the treatments listed below at random during the three treatment periods: Treatment A: Study Formulation Treatment B: Formulation II (Sumatriptan Succinate / Treatment C Hydrochloride: Promethazine) 90 mg / 25 mg capsule Dose = 1 x 90 mg / 25 mg capsule Control product IMITREX (sumatriptan succinate) tablet, 100 mg Dose = 1 x 100 mg tablet GlaxoSmithKline Control product Promethazine hydrochloride tablet, 25 mg mg Dose = 1 x 25 mg tablet Zydus Pharmaceuticals Each drug administration will be separated by a weaning period of at least 7 days. Each dose will be administered orally with approximately 240 ml (8 fluid ounces) of water at room temperature after a 10-hour fasting night. After administration of the treatment dose, no food will be allowed for 4 hours. In addition to the 240 ml of room-temperature water supplied with the dose, no water consumption will be permitted for 1 hour until 1 hour after dosing. Meals will be identical and scheduled at approximately the same times as the drug dose administration for each period of the study. During each study period, 4 ml blood samples will be collected prior to dose administration and after each dose at selected time points within 48 hours of dosing. Pharmacokinetic analyzes of plasma samples will be performed for promethazine and sumatriptan using validated assay methods. Appropriate pharmacokinetic parameters will be calculated for each formulation using non-compartmental methods. In addition, blood and urine samples will be collected for clinical bioassays during the subject selection period and at the end of the study. Each subject treated in this study will receive a treatment sequence that will be assigned to him according to a randomization scheme prepared by the clinical investigation center. Subjects will be randomized to receive either treatment A, treatment B or treatment C during the first study period. After weaning for at least 7 days, each subject will be switched to receive another treatment. After another weaning of at least 7 days, the subjects will be switched in order to receive the last treatment. At the end of the study, each subject will have received a single dose of treatment A, a single dose of treatment B, and a single dose of treatment C. Plasma samples will be analyzed for sumatriptan and promethazine using methods validated analyzes. Samples from all evaluable subjects having completed at least one study period will be analyzed. The pharmacokinetic parameters of sumatriptan and promethazine will be calculated using a non-compartmental analysis with a 10% adjustment for the 10 mg difference in sumatriptan doses. The pharmacokinetic parameters below will be determined.
[0052] The maximum plasma concentration (Cmax) and the time to reach C ',' (Tmax) will be taken directly from the data. The rate of elimination constant, kz, will be calculated as the negative of the slope of the terminal log-linear segment of the plasma concentration curve versus time; the range of data to be used will be determined by visual inspection of a semi-logarithmic plot of concentration versus time. The elimination half-life (T'A) will be calculated according to the following equation: P / 2 =: T1 = 0.693 / kz. The area under the curve of the final sample with a concentration greater than the limit of quantification (LOQ), (AUCiast), will be calculated according to the linear trapezoidal method and extrapolated to infinity using: AUCIllf = AUCiast + Clast / Xz where Ciast is the final concentration> at the limit of quantification (LOQ). In addition, the following partial AUCs will be calculated for promethazine and sumatriptan: AUC (o-0.25), AUC (0-0.5), AUC (0-0.75), AUC (0-1.0) ), AUC (0-1.5), AUC (0-2.0), AUC (0-3.0) and AUC (0-4.0) - The logarithmic comparison of pharmacokinetic parameters Cmax, AUCiast, and AUCinf sumatriptan and promethazine for all 3025425 treatments will be performed using a variance model analysis (ANOVA) and procedure with two unilateral t-tests. Partial AUCs [AUC (o_0,25), AUC (oo, 5), AUC (oo, 75), AUC (04,0), AUC (0-1,5), AUC (0-2, o), AUC (0_3.0) and AUC (0_4.0)] for sumatriptan and promethazine will be included in the analysis to establish comparisons of early systemic exposure for all treatments. The ANOVA model will include sequence factors, subject within a sequence, treatment and period. The ratios of geometric means (test versus reference) and 90% confidence intervals will be reported. Statistical analyzes will be performed using appropriate software, for example, PHOENIX WINNONLIN 10 (Version 6.3, Pharsight Corporation) and / or SAS (Version 9.3, SAS Institute Inc.). EXAMPLE 7 Dissolution measurement by USP paddle method A dissolution study must be carried out to measure the dissolution rates of the active substances. This study will utilize a rotary paddle USP 2 with an automated sampling station (e.g., VK-8000 or equivalent). A dissolving fluid of 900 ml of deaerated 0.01 N HCl maintained at 37.0 ± 0.5 ° C will be used during the dissolution procedure. The fluid will be prepared by diluting 5 ml of concentrated HCl in 6000 ml of deaerated water and mixing. To measure peaks, a dual wavelength detector (eg, Hitachi L-2420) will be used, or alternatively, two separate chromatographic systems will be used to measure peaks at two different wavelengths. To prepare standard solutions, each ingredient will be weighed into a 50 ml volumetric flask and diluted with the dissolution medium until the mark is reached. The resulting solution will be mixed to form a stock solution. Different ingredients will be similarly prepared to provide stock solutions (e.g., promethazine hydrochloride, triptan). 2 ml of each standard stock solution will be diluted with the dissolving fluid and mixed to produce a final standard solution. Dissolution test solutions will be prepared in 900 ml of 0.01 N HCl using the 50 m.M. rotating paddle USP apparatus. An aliquot of the solution solution will be filtered and a 50 μl aliquot is chromatographed on a Waters sunFire C18 column, 50 mm x 4.6 mm (id), particle size 3.5 μm using a gradient HPLC method. . The mobile phase A will consist of a mixture of water / acetonitrile / TFA, 950/50/2 (v / v / v) and the mobile phase B will consist of a mixture of water / acetonitrile / TFA , 50/950 / 1.5 (v / v / v). The flow rate will be 2.0 ml / minute. The amount of triptan released will be determined at 300 nm by comparing the area obtained for the peak due to the triptan in the chromatogram of the dissolution test solution to that obtained for the corresponding peak in a chromatogram of a standard solution. The amount of promethazine hydrochloride released will be determined at 230 nm by comparing the resulting area for the promethazine hydrochloride peak in the chromatogram of the dissolution test solution to that obtained for the corresponding peak in a chromatogram of a solution. standard.
[0053] The speed of the pallet will be 50 rpm and the elution volume will be 10 ml. Rise points at 5, 10, 15, 20, 25, 30, 45 and 60 minutes will be used. The amount of each compound dissolved in the dissolution medium will be determined by HPLC. This protocol will use a bound C18 stationary phase of high purity, and a binary mobile phase consisting of a suitable buffer and an organic modifier.
[0054] To begin the dissolution procedure, 900 ml of dissolution fluid will be preheated to 37 ° C and placed in each tank. A pharmaceutically active agent as described herein will be weighed and placed in tanks, respectively. At prescribed time intervals, 5 ml aliquot of the dissolving fluid will be removed using the automatic sampling station equipped with a full-bore 35-Jim filter connected to a sampling probe. The filtrate will be allowed to cool to room temperature to produce a final sample solution. The fluid removed will not be replaced. Samples will be injected into the HPLC for analysis after a baseline has been established. The responses in the form of peak areas will be measured for the pharmaceutically active agent. The resolution between each peak will be calculated as well as the asymmetry factor. The five repeated injections will not exceed 2.0% RSD. 50 μl aliquots of standard solutions and sample solutions will be subjected to liquid chromatography. The amount of a pharmaceutically active agent in a particle or capsule will be determined by comparing the area obtained for the peak due to the agent in a chromatogram of the dissolution test solution to that obtained for the corresponding peak. in a chromatogram of a standard solution. Example 8. Pharmaceutical Compositions The pharmaceutical compositions will be designed to include a combination of one or more molecules of triptan and one or more antiemetics. The pharmaceutical compositions formed include combinations of the active substances listed in Table 16, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions, such as those listed in Table 16, will be investigated for their effectiveness in the treatment of pain. Table 16. Pharmaceutical Drug Compositions No. of composition Triptan Antiemetic 1 Sumatriptan Promethazine 2 Sumatriptan Aprepitant 3 Sumatriptan Dronabinol 4 Sumatriptan Perphenazine 5 Sumatriptan Palonosetron 6 Sumatriptan Trirnthyobenzamide 7 Sumatriptan Metoclopromide 8 Sumatriptan Dperidone 9 Sumatriptan Prochlorperazine 10 Sumatriptan Chlorpromazine 11 Sumatriptan Trimethobenz amide 12 Sumatriptan Ondansetron 13 Sumatriptan Granisetron 14 Sumatriptan Hydroxyzine 15 Sumatriptan Acetylleucin Monoethanolamine 16 Sumatriptan Alizapride 17 Sumatriptan Azasetron 18 Sumatriptan Benzquinarnide 19 Sumatriptan Bietanautin 20 Sumatriptan Bromopride 21 Sumatriptan Buclizine 22 Sumatriptan Clebopride 23 Sumatriptan _Cyclizine 24 Sumatriptan Dimenhydrinate 25 Sumatriptan Diphenidol 26 Sumatriptan Dol asetron 3025425 113 Item No. composition Triptan Antiemetic 27 Sumatriptan Meclizine 28 Sumatriptan Methallatal 29 Sumatriptan Metopimazine 30 S umatriptan Nabilone 31 Sumatriptan Oxyperndyl 32 Sumatriptan Pipamazine 33 Sumatriptan Scopolamine 34 Sumatriptan Sulpiride 35 Sumatriptan Tetrahydrocannabinol 36 Sumatriptan Thiethylperazine 37 Sumatriptan thioproperazine 38 Sumatriptan tropisetron 39 Sumatriptan Droperidol 40 Sumatriptan Haloperidol 41 Sumatriptan Prochlopérazine 42 Sumatriptan Metoclopramide 43 Sumatriptan Diphenhydramine Cannabis 44 Sumatriptan 45 Sumatriptan Midazolam 46 Sumatriptan Lorazepam 47 Sumatriptan Hyoscine 48 Sumatriptan Dexamethasone 49 Sumatriptan Emetrol 50 Sumatriptan Propofol 51 Almotriptan Promethazine 52 Almotriptan Aprepitant 53 Almotriptan Dronabinol 54 Almotriptan Perphenazine 55 Almotriptan Palonosetron 56 Almotriptan Trimethylobenz amide 57 Almotriptan Metoclopromide 58 Almotriptan Dperidone 59 Almotriptan Prochlorperazine Chlorpromazine 60 Almotriptan 3025425 114 No. of composition Triptan Antiemetic 61 Almotriptan Trimethobenzamide 62 Almotriptan Ondansetron 63 Almotriptan Granisetron 64 almotriptan Hydroxyzine 65 almotriptan acetylleucine monoethanolamine 66 almotriptan alizapride 67 almotriptan azasetron 68 almotriptan benzquinamide 69 almotriptan Biétanautine 70 almotriptan Bromopride 71 almotriptan buclizine 72 almotriptan clebopride 73 almotriptan Cyclizine 74 almotriptan Dimenhydrinate 75 almotriptan diphenidol 76 almotriptan Dolasetron 77 almotriptan Meclizine 78 almotriptan Méthallatal 79 almotriptan metopimazine 80 Almotriptan Nabilone 81 Almotriptan Oxyperndyl 82 Almotriptan Pipamazine 83 Almotriptan Scopolamine 84 Almotriptan Sulpiride 85 Almotriptan Tetrahydrocannabinol 86 Almotriptan Thiethylperazine thioproperazine tropisetron 87 Almotriptan 88 Almotriptan 89 Almotriptan Droperidol 90 Almotriptan Haloperidol 91 Almotriptan Prochlopérazine 92 Almotriptan Metoclopramide 93 Almotriptan Diphenhydramine 94 Almotriptan Cannabis 3,025,425 No. the composition Triptan Antiemetic 95 Almotriptan Midazolam 96 Almot riptan Lorazepam 97 Almotriptan Hyoscine 98 Almotriptan Dexamethasone 99 Almotriptan Emetrol 100 Almotriptan Propofol 101 Forvatriptan Promethazine 102 Forvatriptan Aprepitant 103 Forvatriptan Dronabinol 104 Forvatriptan Perphenazine 105 Forvatriptan Palonosetron 106 Forvatriptan Triméthyobenzamide metoclopromide 107 Forvatriptan 108 Forvatriptan Domperidone 109 Forvatriptan Prochlorperazine 110 Forvatriptan Chlorpromazine trimethobenzamide 111 Forvatriptan 112 Forvatriptan Ondansetron 113 Forvatriptan Granisetron 114 Forvatriptan Hydroxyzine 115 Forvatriptan acetylleucine monoethanolamine 116 Forvatriptan alizapride 117 Forvatriptan azasetron 118 Forvatriptan benzquinamide Bietanautine 119 Forvatriptan Forvatriptan Bromopride 121 Forvatriptan buclizine 122 Forvatriptan clebopride 123 Forvatriptan Cyclizine 124 Forvatriptan dimenhydrinate Forvatriptan diphenidol 126 Forvatriptan Dolasetron 127 Forvatriptan Meclizine 128 Forvatriptan Méthallatal 3025425 116 N ° of a composition triptan Antiemetic 129 Forvatriptan metopimazine Forvatriptan Nabilone 131 Forvatriptan Oxyperndyl 132 Forvatriptan Pipamazine 133 Forvatriptan Scopolamine 134 Forvatriptan Sulpiride Forvatriptan Forvatriptan Tetrahydrocannabinol Thiethylperazine 136 137 Forvatriptan thioproperazine tropisetron 138 Forvatriptan 139 Forvatriptan Droperidol Forvatriptan Haloperidol 141 Forvatriptan Prochlopérazine Metoclopramide Diphenhydramine 142 Forvatriptan 143 Forvatriptan 144 Forvatriptan Cannabis Forvatriptan midazolam 146 Forvatriptan Lorazepam 147 Forvatriptan Hyoscine 148 Forvatriptan dexamethasone 149 Forvatriptan Emetrol Forvatriptan Propofol 151 152 Promethazine Rizatriptan Rizatriptan Aprepitant 153 Rizatriptan Dronabinol 154 Perphenazine Rizatriptan Rizatriptan Palonosetron 156 Rizatriptan Triméthyobenzamide metoclopromide 157 158 Rizatriptan Rizatriptan Domperidone 159 Prochlorperazine Rizatriptan Rizatriptan Chlorpromazine 161 Rizatriptan Trimétho benzamide 162 Rizatriptan Ondansetron 3025425 117 No composition triptan Antiemetic 163 Rizatriptan Granisetron 164 Rizatriptan Hydroxyzine Rizatriptan acetylleucine monoethanolamine 166 Rizatriptan alizapride 167 Rizatriptan azasetron 168 Rizatriptan benzquinamide 169 Rizatriptan Biétanautine Rizatriptan Bromopride 171 Rizatriptan buclizine 172 Rizatriptan clebopride 173 Rizatriptan Cyclizine 174 Rizatriptan DIMENHYDRINATE Rizatriptan diphenidol 176 Rizatriptan dolasetron 177 Rizatriptan Meclizine 178 Rizatriptan Méthallatal 179 Rizatriptan metopimazine Rizatriptan nabilone 181 Rizatriptan Oxyperndyl 182 Rizatriptan Pipamazine 183 Rizatriptan Scopolamine 184 Rizatriptan Sulpiride Rizatriptan Tetrahydrocannabinol 186 Rizatriptan Thiethylperazine 187 Rizatriptan thioproperazine 188 Rizatriptan tropisetron 189 Rizatriptan Droperidol Rizatriptan Haloperidol 191 Rizatriptan Prochlopérazine 192 Rizatriptan Metoclopramide 193 Rizatriptan Diphenhydramine 194 R izatriptan Cannabis Rizatriptan Midazolam 196 Rizatriptan Lorazepam 3,025,425 118 No of composition triptan Antiemetic 197 Rizatriptan Hyoscine 198 Rizatriptan Dexamethasone 199 Rizatriptan Emetrol Rizatriptan Propofol 201 Zolmitriptan Promethazine 202 Zolmitriptan Aprepitant 203 Zolmitriptan Dronabinol 204 Zolmitriptan Perphenazine Zolmitriptan Palonosetron 206 Zolmitriptan Zolmitriptan Triméthyobenzamide metoclopromide 207 208 Zolmitriptan Domperidone 209 Zolmitriptan Prochlorperazine Zolmitriptan Zolmitriptan Chlorpromazine trimethobenzamide 211 212 Zolmitriptan Ondansetron 213 Zolmitriptan Granisetron 214 Zolmitriptan Hydroxyzine Zolmitriptan acetylleucine monoethanolamine 216 Zolmitriptan alizapride 217 Zolmitriptan azasetron 218 Zolmitriptan benzquinamide 219 Zolmitriptan Biétanautine Zolmitriptan Bromopride 221 Zolmitriptan buclizine 222 Zolmitriptan clebopride 223 Zolmitriptan Cyclizine 224 Zolmitriptan dimenhydrinate Zolmitriptan diphenidol 226 Zolmit riptan Dolasetron 227 Zolmitriptan Meclizine 228 Zolmitriptan Méthallatal 229 Zolmitriptan metopimazine Zolmitriptan Nabilone 3,025,425 119 No of composition triptan Antiemetic 231 Zolmitriptan Oxyperndyl 232 Zolmitriptan Pipamazine 233 Zolmitriptan Scopolamine 234 Zolmitriptan Sulpiride Zolmitriptan Tetrahydrocannabinol thiethylperazine 236 Zolmitriptan 237 Zolmitriptan thioproperazine 238 Zolmitriptan tropisetron 239 Zolmitriptan Droperidol Zolmitriptan Haloperidol 241 Zolmitriptan Prochlopérazine 242 Zolmitriptan Metoclopramide 243 Zolmitriptan Diphenhydramine Cannabis 244 Zolmitriptan Zolmitriptan Midazolam 246 Zolmitriptan Lorazepam 247 Zolmitriptan Hyoscine 248 Zolmitriptan Dexamethasone 249 Zolmitriptan Emetrol Zolmitriptan Propofol 251 Eletriptan Promethazine 252 Eletriptan Aprepitant 253 Eletriptan Dronabinol 254 Eletriptan Perphenazine Eletriptan Palonosetron 256 Eletriptan Triméthyobenzamide 257 Eletriptan metoclopromide 258 Eletriptan Domperidone 2 59 Eletriptan Prochlorperazine Eletriptan Chlorpromazine 261 Eletriptan trimethobenzamide 262 Eletriptan Ondansetron 263 Eletriptan Granisetron 264 Eletriptan Hydroxyzine 3,025,425 120 No of composition triptan Antiemetic Eletriptan acetylleucine monoethanolamine 266 Eletriptan alizapride 267 Eletriptan azasetron 268 Eletriptan benzquinamide 269 Eletriptan Biétanautine Eletriptan Bromopride 271 Eletriptan buclizine 272 Eletriptan clebopride 273 eletriptan Cyclizine 274 eletriptan dimenhydrinate eletriptan diphenidol 276 eletriptan Dolasetron 277 eletriptan Meclizine 278 eletriptan Méthallatal 279 eletriptan metopimazine eletriptan Nabilone 281 eletriptan Oxyperndyl 282 eletriptan Pipamazine 283 eletriptan Scopolamine 284 eletriptan Sulpiride eletriptan Tetrahydrocannabinol Thiethylperazine 286 eletriptan 287 eletriptan thioproperazine 288 eletriptan tropisetron 289 eletriptan Droperidol eletriptan Haloperidol 291 Eletriptan Prochloperazine Metoclopramide 29 2 Eletriptan 293 Eletriptan Diphenhydramine Cannabis 294 Eletriptan Eletriptan Midazolam 296 Eletriptan Lorazepam 297 Eletriptan Hyoscine 298 Eletriptan Dexamethasone 3025425 121 No composition triptan Antiemetic 299 Eletriptan Emetrol Eletriptan Propofol 301 Naratriptan Promethazine 302 Naratriptan Aprepitant 303 Naratriptan Dronabinol 304 Naratriptan Perphenazine Naratriptan Palonosetron 306 Naratriptan Triméthyobenzamide 307 Naratriptan metoclopromide 308 Naratriptan Domperidone 309 Naratriptan Prochlorperazine Naratriptan Chlorpromazine 311 Naratriptan Trirnéthobenzamide 312 Naratriptan Ondansetron 313 Naratriptan Granisetron 314 Naratriptan Hydroxyzine Naratriptan acetylleucine monoethanolamine 316 Naratriptan alizapride 317 Naratriptan azasetron 318 Naratriptan benzquinamide Biétanautine 319 Naratriptan Naratriptan Bromopride 321 Naratriptan buclizine 322 Naratriptan clebopride 323 Naratriptan Cyclizine 324 Naratriptan Dirnenhydrinate Naratriptan Di phénidol 326 Naratriptan Dolasetron 327 Naratriptan Meclizine 328 Naratriptan Méthallatal 329 Naratriptan metopimazine Naratriptan Nabilone 331 Naratriptan Oxyperndyl 332 Naratriptan Pipamazine 3,025,425 122 No of composition triptan Antiemetic 333 Naratriptan Scopolamine 334 Naratriptan Sulpiride Naratriptan Tetrahydrocannabinol 336 Naratriptan Thiethylperazine 337 Naratriptan thioproperazine 338 Naratriptan tropisetron 339 Naratriptan Droperidol Naratriptan Haloperidol 341 Naratriptan Prochloperazine 342 Naratriptan Metoclopramide 343 Naratriptan Diphenhydramine 344 Naratriptan Cannabis Naratriptan Midazolam 346 Naratriptan Lorazepam 347 Naratriptan Hyoscine 348 Naratriptan Dexamethasone 349 Naratriptan Emetrol Naratriptan Propofol For any of the pharmaceutically active agents listed in Table 16 above, it should be noted that any pharmaceutically acceptable salt of the listed pharmaceutically active agent is contemplated for use in the present invention. In addition, non-limiting examples of such pharmaceutically acceptable salts are disclosed herein. While particular embodiments have been presented and described herein, such embodiments are provided by way of example only. Many variations, modifications, and substitutions may now be made by those skilled in the art without departing from the scope of the invention. It should be understood that various variations of the embodiments of the invention that are described herein may be used in the practice of the invention. It is intended that the following claims define the scope of the invention and that methods and structures falling within the scope of these claims, as well as their equivalents, are thereby covered.

权利要求:
Claims (58)
[0001]
REVENDICATIONS1. A pharmaceutical composition comprising: a plurality of first particles comprising a 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof; and a plurality of second particles comprising an antiemetic or a pharmaceutically acceptable salt thereof, characterized in that the pharmaceutical composition comprises one or more of i) a weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5: 1; ii) at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic or a pharmaceutically acceptable salt thereof are released in less than approximately 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm; or iii) from about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof are stable for at least 30 days as measured by high performance liquid chromatography (HPLC) and about 90% to about 100% of the antiemetic or a pharmaceutically acceptable salt thereof are stable for at least 30 days as measured by HPLC.
[0002]
Pharmaceutical composition according to claim 1, characterized in that the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof is 25. from about 9: 2 to about 11: 2.
[0003]
Pharmaceutical composition according to claim 2, characterized in that the weight ratio of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof to the antiemetic or a pharmaceutically acceptable salt thereof is about 5: 1. 3025425 124
[0004]
The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the weight ratio of the plurality of first particles to the plurality of second particles is about 4: 1.
[0005]
Pharmaceutical composition according to any one of claims 1 to 4, characterized in that the weight ratio of the 5HT1B receptor agonist or the pharmaceutically acceptable salt thereof to the total weight of the plurality of first particles is about 2: 5 to about 7:10.
[0006]
Pharmaceutical composition according to claim 5, characterized in that the 5HT1B receptor agonist is present in an amount of about 61% by weight of the plurality of first particles.
[0007]
7. The pharmaceutical composition according to any one of claims 1 to 6, characterized in that the weight ratio of the antiemetic or a pharmaceutically acceptable salt thereof to the total weight of the plurality of second particles is about 2: 5 to about 3: 5.
[0008]
8. The pharmaceutical composition according to claim 7, characterized in that the antiemetic or a pharmaceutically acceptable salt thereof is present in an amount of about 50% by weight of the plurality of second particles.
[0009]
The pharmaceutical composition according to any one of claims 1 to 8, characterized in that the plurality of first particles comprises one or more first pharmaceutically acceptable excipients and the weight ratio of the total amount of the 5HT1B receptor agonist or of a pharmaceutically acceptable salt thereof to the total amount of said one or more first pharmaceutically acceptable excipients is about 3: 2. 30
[0010]
10. Pharmaceutical composition according to any one of claims 1 to 9, characterized in that the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, and the ratio by weight of the total amount of the antiemetic or a A pharmaceutically acceptable salt thereof to the total amount of said one or more pharmaceutically acceptable second excipients is about 1: 1.
[0011]
The pharmaceutical composition according to any one of claims 1 to 10, characterized in that at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the Antiemetic agents are released within about 30 minutes as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm. 10
[0012]
12. Pharmaceutical composition according to any one of claims 1 to 11, characterized in that the antiemetic or a pharmaceutically acceptable salt thereof has about the same release rate as that of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof.
[0013]
13. Pharmaceutical composition according to any one of claims 1 to 11, characterized in that the antiemetic or a pharmaceutically acceptable salt thereof has a release rate slower than the release rate of the 5HT1B receptor agonist. or a pharmaceutically acceptable salt thereof.
[0014]
14. Pharmaceutical composition according to claim 13, characterized in that the antiemetic or a pharmaceutically acceptable salt thereof has a slower release rate than the release rate of the 5HT1B receptor agonist or a pharmaceutically acceptable salt. It was acceptable within about 5 minutes as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm.
[0015]
15. Pharmaceutical composition according to claim 14, characterized in that about 60% to about 65% of the antiemetic or a pharmaceutically acceptable salt thereof are released in about 5 minutes and about 70%. about 75% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof are released within about 5 minutes as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 apparatus (Basket) rotating at 100 rpm. 3025425 126
[0016]
16. Pharmaceutical composition according to any one of claims 1 to 15, characterized in that the pharmaceutical composition is a fast-release pharmaceutical composition.
[0017]
The pharmaceutical composition according to any one of claims 1 to 16, characterized in that about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof is stable for at least 90%. days.
[0018]
18. Pharmaceutical composition according to any one of claims 1 to 17, characterized in that about 95% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof are stable for at least 30 days. 15
[0019]
19. The pharmaceutical composition according to any one of claims 1 to 18, characterized in that about 90% to about 100% of the antiemetic or a pharmaceutically acceptable salt thereof are stable for at least 90 days.
[0020]
20. The pharmaceutical composition according to claim 19, characterized in that about 95% of the antiemetic or a pharmaceutically acceptable salt thereof is stable for at least 30 days.
[0021]
21. The pharmaceutical composition according to any one of claims 1 to 20, characterized in that the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof comprises a triptan or a pharmaceutically acceptable salt thereof.
[0022]
22. Pharmaceutical composition according to claim 21, characterized in that the triptan or a pharmaceutically acceptable salt thereof comprises sumatriptan, almotriptan, frovatriptan, eletriptan, rizatriptan, naratriptan, or their derivatives. mixtures. 5 10 3025425 127
[0023]
23. Pharmaceutical composition according to claim 22, characterized in that sumatriptan or a pharmaceutically acceptable salt thereof is present in a therapeutically equivalent amount to about 90 mg of sumatriptan. 5
[0024]
24. Pharmaceutical composition according to claim 22 or 23, characterized in that the pharmaceutically acceptable salt of sumatriptan comprises sumatriptan succinate.
[0025]
25. The pharmaceutical composition according to claim 24, characterized in that sumatriptan succinate is present in an amount of from about 35 mg to about 140 mg.
[0026]
26. Pharmaceutical composition according to claim 25, characterized in that sumatriptan succinate is present in an amount of about 126 mg. 15
[0027]
27. Pharmaceutical composition according to any one of claims 1 to 26, characterized in that the antiemetic comprises promethazine, aprepitant, dronabinol, perphenazine, palonosetron, trimethylobenzamide, metoclopromide, domperidone, prochlorperazine chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine , dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, droperidol , haloperidol, prochloperazine, metoclopramide, diphenhydramine, cannabis, midazolam, lorazepam, hyoscine, dexamethasone, emetrol, ropofol or mixtures thereof.
[0028]
28. The pharmaceutical composition according to claim 27, characterized in that the promethazine or a pharmaceutically acceptable salt thereof is present in a therapeutically equivalent amount to about 22 mg of promethazine. 3025425 128
[0029]
29. Pharmaceutical composition according to claim 27 or 28, characterized in that the pharmaceutically acceptable salt of promethazine comprises promethazine hydrochloride. 5
[0030]
30. Pharmaceutical composition according to claim 29, characterized in that the promethazine hydrochloride is present in an amount of about 25 mg.
[0031]
31. The pharmaceutical composition as claimed in any one of claims 1 to 30, characterized in that the plurality of first particles comprises one or more first pharmaceutically acceptable excipients, characterized in that the first or more pharmaceutically acceptable excipients comprise a diluent, a binder, a disintegrant, a lubricant, or mixtures thereof.
[0032]
32. The pharmaceutical composition according to claim 31, characterized in that: the diluent comprises microcrystalline cellulose; the binder comprises polyvinylpyrrolidone; the disintegrating agent comprises croscarmellose sodium; or the lubricant comprises magnesium stearate or talc. 20
[0033]
33. Pharmaceutical composition according to any one of claims 1 to 32, characterized in that the plurality of second particles comprises one or more second pharmaceutically acceptable excipients, characterized in that the one or more second pharmaceutically acceptable excipients comprise a diluent, a disintegrant, or mixtures thereof. 25
[0034]
34. Pharmaceutical composition according to claim 33, characterized in that the diluent comprises microcrystalline cellulose; or the disintegrating agent comprises croscarmellose sodium. 30
[0035]
35. Pharmaceutical composition according to any one of claims 1 to 34, characterized in that: the plurality of first particles comprises: approximately 50 to 150 mg of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof ; About 1 to 10 mg of polyvinylpyrrolidone; about 50 to 100 mg of microcrystalline cellulose; about 1 to 10 mg of croscarmellose sodium; about 0.1 to 5 mg of magnesium stearate; and a coating material; and the plurality of second particles comprises: about 10 to 50 mg of the antiemetic or a pharmaceutically acceptable salt thereof; about 10 to 50 mg of microcrystalline cellulose; About 0.1 to 5 mg of croscarmellose sodium; and a coating material.
[0036]
36. The pharmaceutical composition according to claim 35, characterized in that: the plurality of first particles comprises: about 90 mg of sumatriptan or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof; about 4 mg of polyvinylpyrrolidone; about 69 mg of microcrystalline cellulose; about 4 mg of croscarmellose sodium; About 1 mg of magnesium stearate; and a coating material, characterized in that the coating material comprises a polyvinyl alcohol; and the plurality of second particles comprises: about 22 mg of promethazine or a therapeutically equivalent amount of a pharmaceutically acceptable salt thereof; about 24 mg of microcrystalline cellulose; about 1 mg of croscarmellose sodium; and a coating material, characterized in that the coating material comprises a polyvinyl alcohol. 30
[0037]
37. Pharmaceutical composition according to any one of claims 1 to 36, characterized in that the first particles comprise a coating material. 3025425 130
[0038]
38. Pharmaceutical composition according to any one of claims 1 to 37, characterized in that the second particles comprise a coating material.
[0039]
39. The pharmaceutical composition according to claim 37 or 38, characterized in that the coating material is applied to the plurality of first particles or to the plurality of second particles by imparting to them a weight gain of about 2%.
[0040]
40. Pharmaceutical composition according to claim 37 or 38, characterized in that the first particles and the second particles comprise the same coating material.
[0041]
41. Pharmaceutical composition according to claim 37 or 38, characterized in that the coating material comprises polyvinyl alcohol, cellulose acetate phthalate, polyvinyl acetate phthalate, a methacrylic acid copolymer, acetate Cellulose trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, shellac gum, sodium alginate, zein or mixtures thereof.
[0042]
42. Pharmaceutical composition according to claim 41, characterized in that the coating material comprises polyvinyl alcohol.
[0043]
43. Pharmaceutical composition according to claim 42, characterized in that the coating material is polyvinyl alcohol. 25
[0044]
44. Pharmaceutical composition according to any one of claims 1 to 43, characterized in that the pharmaceutical composition is in a dosage form for oral administration.
[0045]
45. The pharmaceutical composition according to claim 44, characterized in that the galenic fauna for oral administration comprises a capsule.
[0046]
46. The pharmaceutical composition according to any one of claims 1 to 45, characterized in that: i) the weight ratio of the plurality of first particles to the plurality of second particles is from about 3: 1 to about 5; : 1; ii) at least about 80% of both the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof and the antiemetic or a pharmaceutically acceptable salt thereof are released in less than approximately 15 minutes, as measured by contacting the pharmaceutical composition with a dissolution fluid in a USP 1 (Basket) apparatus rotating at 100 rpm; and iii) from about 90% to about 100% of the 5HT1B receptor agonist or a pharmaceutically acceptable salt thereof are stable for at least 30 days, as measured by HPLC, and about 90% to about 100%. % of the antiemetic or a pharmaceutically acceptable salt thereof are stable for at least 30 days, as measured by HPLC. 15
[0047]
47. A pharmaceutical composition for use in the treatment of a headache in a subject in need, characterized in that the pharmaceutical composition is as defined in one of claims 1 to 46.
[0048]
48. Pharmaceutical composition for use according to claim 47, characterized in that the treatment of the headache is acute or prophylactic.
[0049]
49. Pharmaceutical composition for its use according to claim 47 or 48, characterized in that the headache is a migraine. 25
[0050]
50. Pharmaceutical composition for use according to claim 49, characterized in that the headache is acute migraine or chronic migraine.
[0051]
51. Pharmaceutical composition for use according to claim 49 or 50, characterized in that the headache is a migraine with or without aura. 30
[0052]
52. Pharmaceutical composition for use according to any one of claims 47 to 51, characterized in that the headache is a cluster headache. 3025425 132
[0053]
53. Pharmaceutical composition for its use in the treatment of photophobia in a subject in need characterized in that the pharmaceutical composition is as defined in any one of claims 1 to 46.
[0054]
54. Pharmaceutical composition for its use according to claim 53, characterized in that the treatment of photophobia is acute or prophylactic.
[0055]
55. A pharmaceutical composition for use according to claim 53 or 54, characterized in that the pharmaceutical composition is used in the treatment of light sensitivity.
[0056]
56. Pharmaceutical composition for use according to any one of claims 47 to 55, characterized in that the pharmaceutical composition is used in the treatment of nausea or vomiting. 15
[0057]
57. Pharmaceutical composition for its use according to claim 56, characterized in that the pharmaceutical composition is used in the treatment of nausea associated with headache or vomiting associated with a headache. 20
[0058]
58. Pharmaceutical composition for its use according to claim 56, characterized in that the pharmaceutical composition is used in the treatment of nausea associated with headache and vomiting associated with a headache.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2399898T3|2013-04-04|Pharmaceutical compositions of masked flavor prepared by coacervation

---

JP6014044B2|2016-10-25|Rapidly dispersible granules, orally disintegrating tablets, and methods

---

JP5845172B2|2016-01-20|Orally disintegrating tablet composition comprising a combination of high and low dose drugs

---

JP5808670B2|2015-11-10|Composition containing weakly basic drug and sustained release dosage form

---

JP2010512317A|2010-04-22|pH sensitive matrix formulation

---

EP1646379B1|2013-09-18|Novel solid pharmaceutical composition comprising amisulpride

---

KR100660072B1|2006-12-22|Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

---

US20200179395A1|2020-06-11|Pharmaceutical compositions

---

JP2007509155A|2007-04-12|Drugs containing quetiapine

---

JP5948648B2|2016-07-06|Sustained release formulation containing stabilized eperisone

---

US20100047343A1|2010-02-25|Multiparticulate formulation having tramadol in immediate and controlled release form

---

US20210145756A1|2021-05-20|Pharmaceutical compositions

---

KR20150043497A|2015-04-22|Medicament-containing hollow particle

---

WO2001051033A1|2001-07-19|Solid pharmaceutical compositions for controlled release of active substances

---

JP6061516B2|2017-01-18|Domperidone orally disintegrating tablets

---

US20200338010A1|2020-10-29|Novel fine particle coating |

同族专利:

---

公开号 | 公开日

---

JP2021176907A|2021-11-11|

---

EP3191093A1|2017-07-19|

---

CA2960116A1|2016-03-17|

---

WO2016040358A1|2016-03-17|

---

US20170173037A1|2017-06-22|

---

BR112017004552A2|2017-12-05|

---

JP2017527581A|2017-09-21|

---

RU2017111887A|2018-10-11|

---

GB201515866D0|2015-10-21|

---

KR20170054446A|2017-05-17|

---

EP3191093A4|2018-04-25|

---

IL250817D0|2017-04-30|

---

GB2535257A|2016-08-17|

---

US20200179395A1|2020-06-11|

---

RU2017111887A3|2019-04-04|

---

CN107072961A|2017-08-18|

---

DE202015006313U1|2016-02-02|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US20060240105A1|1998-11-02|2006-10-26|Elan Corporation, Plc|Multiparticulate modified release composition|

---

GB0018968D0|2000-08-02|2000-09-20|Pfizer Ltd|Particulate composition|

---

GB0104554D0|2001-02-23|2001-04-11|Glaxo Group Ltd|New uses|

---

JP2008534562A|2005-03-28|2008-08-28|オレクソ・アクチエボラゲット|New pharmaceutical compositions useful for the treatment of migraine|

---

US20080026053A1|2006-07-28|2008-01-31|Sovereign Pharmaceuticals, Ltd.|Capsule containing granular pharmaceutical compositions|

---

CA2682872A1|2007-04-04|2008-10-16|Teva Pharmaceutical Industries Ltd.|Rapid dissolution of combination products|

---

EP2219449A4|2007-11-16|2010-10-27|Univ Arizona State|Methods for treating visceral pain|

---

JP5714910B2|2008-01-09|2015-05-07|チャールストン ラボラトリーズ，インコーポレイテッド|Pharmaceutical composition|

---

US20090311335A1|2008-06-12|2009-12-17|Scott Jenkins|Combination of a triptan and an nsaid|

---

US20140073678A1|2012-09-12|2014-03-13|Monosol Rx, Llc|Anti-pain and anti-nausea and/or vomiting combinatorial compositions|JP5714910B2|2008-01-09|2015-05-07|チャールストン ラボラトリーズ，インコーポレイテッド|Pharmaceutical composition|

---

WO2017152130A1|2016-03-04|2017-09-08|Charleston Laboratories, Inc.|Pharmaceutical compositions|

---

US11071739B1|2020-09-29|2021-07-27|Genus Lifesciences Inc.|Oral liquid compositions including chlorpromazine|

法律状态:
2016-09-26| PLFP| Fee payment|Year of fee payment: 2 |

---

2017-09-25| PLFP| Fee payment|Year of fee payment: 3 |

---

2018-09-25| PLFP| Fee payment|Year of fee payment: 4 |

---

2020-05-08| RX| Complete rejection|Effective date: 20200327 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201462047882P| true| 2014-09-09|2014-09-09|

---

US201562168334P| true| 2015-05-29|2015-05-29|

---